[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cardinal Health Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":416},{"warningLetters":4,"total":415},[5,31,51,72,98,118,138,157,181,201,218,237,259,273,294,314,335,355,374,395],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1507,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-04-25T16:50:00Z\">04\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-24T04:00:00Z\">04\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcardinal-health-679404-04242024\">Cardinal Health\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FPMA\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Steve Mason\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cardinal Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7000 Dublin Place\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dublin\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 679404\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mason:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm Cardinal Health 200, LLC., located at 3651 Birchwood Dr., Waukegan, Illinois 60085 on December 11-20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is an importer \u002Fown label distributor of the Monoject™ Luer-lock tip syringes, intended to inject fluids into or withdraw fluids from the body, and the Monoject™ Enteral Feeding Syringes, intended for use to deliver fluid, feeding, or medications to a patient’s feeding tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>We received responses from you dated January 12, 2024, and April 10, 2024, concerning our investigators observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to the noted violations and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. The United States Food and Drug Administration (FDA) has learned that your firm is marketing convenience kits that include certain piston syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. These devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Specifically, the convenience kits your firm markets in the United States include 3 mL, 10 mL, and 20 mL piston syringes and control syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. The only Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe cleared under K103830 is their 5cc Luer Lock, and no other size piston syringes were included under K103830. Based on FDA's evaluation of K103830 and your firm's activities, there is evidence that your firm is engaged in the distribution of Jiangsu Shenli syringes for use within the United States, included as part of convenience kits, with substantially different technological characteristics. In particular, FDA’s evaluation revealed that these kits include Jiangsu Shenli syringes in sizes other than 5 mL and also include control syringes. The inclusion of these syringes whose specifications were not included or otherwise reviewed under the conditions of clearance in K103830, constitutes a significant change or modification in design that could significantly alter the safety or effectiveness of the finished kit product. Specifically, changing the volume of the syringe and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing and a leaking device.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Quality System Regulation Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection found that your Procedure “QS00015426, Manufacturing Concept Sample Inspection” Rev. 4 employed by your firm to outline product requirements, confirm purchased products have met these requirements, and conduct supplier qualification activities, has not been adequately established. Your firm’s procedure does not require that data to demonstrate product requirements are met is reviewed and evaluated during supplier qualification activities. Per your product requirements document “Needle and Syringe PRD” the product requirements for these devices included, but were not limited to, those in ISO Standard 7886-1:2017 “\u003Cem>Sterile hypodermic syringes for single use - Part 1: Syringes for Manual Use\u003C\u002Fem>”. The ISO Standard 7886-1 relates specifically to the manual use of the syringes and includes product specifications such as limits for acidity and alkalinity, extractable metals, and dimensions. The review of your supplier qualification activities disclosed that specific product requirements required under the standard such as dimensions, limits for acidity and alkalinity, and extractable metals were not established in the product requirements document. Furthermore, no data was received from the supplier and\u002For evaluated at the time of supplier qualification to ensure that other product requirements included in the PRD document were met. In addition, you were not able to produce data to support the use of your Monoject Syringes for compatible use with infusion pumps. In particular, on September 20, 2023 and December 28, 2023, your firm initiated recalls for the Cardinal Health Monoject sterile Syringe Luer-Lock Tip Soft Packs (1, 3, 6, 12, 20, 35 and 60 mL) and Cardinal Health Monoject sterile Enteral Syringes with ENFit connection (1, 3, 6, 12, 35, and 60 mL) due to a change in manufacturing that resulted in different product dimensions, which can lead to recognition and compatibility issues when used with syringe pumps, patient-controlled analgesia (PCA) pumps, and enteral syringe feeding pumps.\u003C\u002Fp>\n\n\u003Cp>Your responses dated January 12, 2024, and April 10, 2024, indicated that you have opened CAPA-CRP-03163 (also referenced as CAPA QE-00303) to address this observation and that the process will be revised to demonstrate product requirements are met, reviewed, and evaluated during supplier qualification activities. Your response indicates you will revise and update your procedure QS00015441, Private Brand Procedure, and revise your Technical Guide template adding detail and greater focus on customer needs and clinical requirements. You will perform a product audit prior to initial release to verify requirements are met, validations meet requirements, and product lot testing and release acceptance process are statistically based and meets requirements. You will repurpose and revise your procedure QS00015426, Manufacturing Concept Sample Inspection Process, and revise the Q00014202, Private Brand Supplier Quality Agreement Template. Training will be conducted. In addition, you will conduct a systemic review of in-process and completed Private Brand Conversions, from the past three (3) years.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. FDA acknowledges that your responses to date state that your firm has conducted a variety of updates to its internal processes and associated trainings, including, but not limited to, those related to QS00015441 (Private Brand Technical Procedure), QS00015426 (Manufacturing Concept Sample Review), and QS00014202 (Private Brand Supplier Quality Agreement (SQA) Template). However, your corrective actions have not yet been evaluated for effectiveness. A follow-up inspection will need to verify the implementation and the effectiveness of your planned corrective actions.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>During our inspection, FDA determined that your firm was engaged in the self-manufacturing of 3, 6, 20, 35, and 60mL Monoject Standard Luer Lock Syringes based on specifications cleared under K945715. Your firm then switched to overseas manufacturing with Jiangsu Caina Medical Co. Ltd. to produce the same size range of syringes branded as Cardinal Health Monject Syringes and based on specifications cleared under K113091. FDA is aware that your firm’s self-manufactured syringes were validated by infusion pump manufacturers for use with their devices, that as of December 2023 your firm’s syringes were collectively marketed and advertised as compatible for use with infusion pumps, and that since switching to overseas manufacturing there have been increases in reported syringe safety issues regarding syringe\u002Finfusion pump compatibility resulting in your firm’s ongoing syringe recalls. Further, during our inspection, you were unable to provide documented rationales, assessments or evaluations during the inspection concerning any impact of pump compatibility claims on regulatory submissions for the Cardinal Health Monoject Syringe product family. You also stated during the inspection that existing procedures at the time failed to ensure that this assessment was conducted and documented. No evidence was produced during the inspection describing evaluation of infusion pump compatibility intended use claims for the Cardinal Health Monoject Syringes by you or Jiangsu Caina Medical Co. Ltd, that you conducted any product testing related to the use of Monoject syringes with infusion pumps, or that you informed infusion pump manufacturers of the specification changes to the 3, 6, 20, 35 and 60 ml Monoject Standard Luer Lock Syringes. FDA acknowledges that your firm has ceased using marketing materials regarding compatibility with infusion pumps, and that your firm has taken several actions to revise and review its internal policies regarding device marketing. However, to date FDA has not received information regarding the effectiveness of these actions or what additional actions your firm is taking or plans to take regarding the use of these syringes with infusion pumps, especially in light of known patient safety risks regarding syringe incompatibility with infusion pumps. Accordingly, we request that you provide to us in writing what actions your firm has taken and plans to take regarding these products with respect to their use with infusion pumps.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. \u003Cstrong>Refer to CMS # 679404\u003C\u002Fstrong> when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at 612-758-7210 or Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nJames Hildreth\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health Operations (OMDRHO)\u003Cbr>\nDivision 2 Central\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003Cbr>\nKellie B. Kelm, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT 3: Office of Gastrorenal, ObGyn, General Hospital, and Urology\u003Cbr>\nDevices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nSteve Mason\n\nRecipient Title\n\nPresident\u002FCEO\n\nCardinal Health\n\n7000 Dublin Place\n\nDublin, OH 43017\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 679404\n\nApril 24, 2024\n\nDear Mr. Mason:\n\nDuring an inspection of your firm Cardinal Health 200, LLC., located at 3651 Birchwood Dr., Waukegan, Illinois 60085 on December 11-20, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is an importer \u002Fown label distributor of the Monoject™ Luer-lock tip syringes, intended to inject fluids into or withdraw fluids from the body, and the Monoject™ Enteral Feeding Syringes, intended for use to deliver fluid, feeding, or medications to a patient’s feeding tube. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), each of these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nWe received responses from you dated January 12, 2024, and April 10, 2024, concerning our investigators observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address these responses below, in relation to the noted violations and any additional responses will be reviewed as part of your warning letter response.\n\nUnapproved Device Violations\n\n1. The United States Food and Drug Administration (FDA) has learned that your firm is marketing convenience kits that include certain piston syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. These devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because you do not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that you need to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that you submit and decide whether the product may be legally marketed.\n\nSpecifically, the convenience kits your firm markets in the United States include 3 mL, 10 mL, and 20 mL piston syringes and control syringes manufactured by Jiangsu Shenli Medical Production Co. Ltd under K103830. The only Jiangsu Shenli Medical Production Co. Ltd. Piston Syringe cleared under K103830 is their 5cc Luer Lock, and no other size piston syringes were included under K103830. Based on FDA's evaluation of K103830 and your firm's activities, there is evidence that your firm is engaged in the distribution of Jiangsu Shenli syringes for use within the United States, included as part of convenience kits, with substantially different technological characteristics. In particular, FDA’s evaluation revealed that these kits include Jiangsu Shenli syringes in sizes other than 5 mL and also include control syringes. The inclusion of these syringes whose specifications were not included or otherwise reviewed under the conditions of clearance in K103830, constitutes a significant change or modification in design that could significantly alter the safety or effectiveness of the finished kit product. Specifically, changing the volume of the syringe and changing from a traditional syringe to a control syringe could result in the risk of patient harm such as inaccurate dosing and a leaking device.\n\nYour firm’s failure to ensure the syringes you are including in convenience kits, importing, and commercially distributing in the United States have 510(k) clearance has prevented FDA from evaluating the risks posed by these substantially different technological characteristics or from determining that there is reasonable assurance of the safety and effectiveness of these modified devices such that they may be legally marketed syringes.\n\nQuality System Regulation Violations\n\nThis inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.\n\nSpecifically, our inspection found that your Procedure “QS00015426, Manufacturing Concept Sample Inspection” Rev. 4 employed by your firm to outline product requirements, confirm purchased products have met these requirements, and conduct supplier qualification activities, has not been adequately established. Your firm’s procedure does not require that data to demonstrate product requirements are met is reviewed and evaluated during supplier qualification activities. Per your product requirements document “Needle and Syringe PRD” the product requirements for these devices included, but were not limited to, those in ISO Standard 7886-1:2017 “Sterile hypodermic syringes for single use - Part 1: Syringes for Manual Use”. The ISO Standard 7886-1 relates specifically to the manual use of the syringes and includes product specifications such as limits for acidity and alkalinity, extractable metals, and dimensions. The review of your supplier qualification activities disclosed that specific product requirements required under the standard such as dimensions, limits for acidity and alkalinity, and extractable metals were not established in the product requirements document. Furthermore, no data was received from the supplier and\u002For evaluated at the time of supplier qualification to ensure that other product requirements included in the PRD document were met. In addition, you were not able to produce data to support the use of your Monoject Syringes for compatible use with infusion pumps. In particular, on September 20, 2023 and December 28, 2023, your firm initiated recalls for the Cardinal Health Monoject sterile Syringe Luer-Lock Tip Soft Packs (1, 3, 6, 12, 20, 35 and 60 mL) and Cardinal Health Monoject sterile Enteral Syringes with ENFit connection (1, 3, 6, 12, 35, and 60 mL) due to a change in manufacturing that resulted in different product dimensions, which can lead to recognition and compatibility issues when used with syringe pumps, patient-controlled analgesia (PCA) pumps, and enteral syringe feeding pumps.\n\nYour responses dated January 12, 2024, and April 10, 2024, indicated that you have opened CAPA-CRP-03163 (also referenced as CAPA QE-00303) to address this observation and that the process will be revised to demonstrate product requirements are met, reviewed, and evaluated during supplier qualification activities. Your response indicates you will revise and update your procedure QS00015441, Private Brand Procedure, and revise your Technical Guide template adding detail and greater focus on customer needs and clinical requirements. You will perform a product audit prior to initial release to verify requirements are met, validations meet requirements, and product lot testing and release acceptance process are statistically based and meets requirements. You will repurpose and revise your procedure QS00015426, Manufacturing Concept Sample Inspection Process, and revise the Q00014202, Private Brand Supplier Quality Agreement Template. Training will be conducted. In addition, you will conduct a systemic review of in-process and completed Private Brand Conversions, from the past three (3) years.\n\nThe adequacy of your firm’s response cannot be determined at this time. FDA acknowledges that your responses to date state that your firm has conducted a variety of updates to its internal processes and associated trainings, including, but not limited to, those related to QS00015441 (Private Brand Technical Procedure), QS00015426 (Manufacturing Concept Sample Review), and QS00014202 (Private Brand Supplier Quality Agreement (SQA) Template). However, your corrective actions have not yet been evaluated for effectiveness. A follow-up inspection will need to verify the implementation and the effectiveness of your planned corrective actions.\n\nIn addition, we offer the following comment:\n\nDuring our inspection, FDA determined that your firm was engaged in the self-manufacturing of 3, 6, 20, 35, and 60mL Monoject Standard Luer Lock Syringes based on specifications cleared under K945715. Your firm then switched to overseas manufacturing with Jiangsu Caina Medical Co. Ltd. to produce the same size range of syringes branded as Cardinal Health Monject Syringes and based on specifications cleared under K113091. FDA is aware that your firm’s self-manufactured syringes were validated by infusion pump manufacturers for use with their devices, that as of December 2023 your firm’s syringes were collectively marketed and advertised as compatible for use with infusion pumps, and that since switching to overseas manufacturing there have been increases in reported syringe safety issues regarding syringe\u002Finfusion pump compatibility resulting in your firm’s ongoing syringe recalls. Further, during our inspection, you were unable to provide documented rationales, assessments or evaluations during the inspection concerning any impact of pump compatibility claims on regulatory submissions for the Cardinal Health Monoject Syringe product family. You also stated during the inspection that existing procedures at the time failed to ensure that this assessment was conducted and documented. No evidence was produced during the inspection describing evaluation of infusion pump compatibility intended use claims for the Cardinal Health Monoject Syringes by you or Jiangsu Caina Medical Co. Ltd, that you conducted any product testing related to the use of Monoject syringes with infusion pumps, or that you informed infusion pump manufacturers of the specification changes to the 3, 6, 20, 35 and 60 ml Monoject Standard Luer Lock Syringes. FDA acknowledges that your firm has ceased using marketing materials regarding compatibility with infusion pumps, and that your firm has taken several actions to revise and review its internal policies regarding device marketing. However, to date FDA has not received information regarding the effectiveness of these actions or what additional actions your firm is taking or plans to take regarding the use of these syringes with infusion pumps, especially in light of known patient safety risks regarding syringe incompatibility with infusion pumps. Accordingly, we request that you provide to us in writing what actions your firm has taken and plans to take regarding these products with respect to their use with infusion pumps.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Melissa Michurski, Director of Compliance Branch, at oradevices2firmresponse@fda.hhs.gov. Refer to CMS # 679404 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at 612-758-7210 or Demetria.Lueneburg@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nJames Hildreth\n\nActing Program Division Director\n\nOffice of Medical Device and Radiological Health Operations (OMDRHO)\n\nDivision 2 Central\n\n\u002FS\u002F\n\nKellie B. Kelm, Ph.D.\n\nActing Office Director\n\nOHT 3: Office of Gastrorenal, ObGyn, General Hospital, and Urology\n\nDevices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Cardinal Health","cardinal-health-679404-04242024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcardinal-health-679404-04242024","2026-10-26T08:08:11.196227+00:00","Warning Letter","Issued","2024-04-25","679404","Medical Devices","Steve Mason","2026-08-20T00:09:49.056+00:00","VIA UNITED PARCEL SERVICE","2024-04-24",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":48,"body_fetched_at":49,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1472,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-05-13T13:20:00Z\">05\u002F13\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-09T04:00:00Z\">05\u002F09\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcue-health-inc-675673-05092024\">Cue Health, Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Clint Sever\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cue Health, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4980 Carroll Canyon Rd Ste 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121-1736\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS# 675673\u003C\u002Fp>\n\n\u003Cp>May 9, 2024\u003Cbr>\n\u003Cbr>\nDear Mr. Sever:\u003C\u002Fp>\n\n\u003Cp>The Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Cue Health, Inc. (“Cue Health”, “you”, or “your firm”) located at 4980 Carroll Canyon Rd Ste 100, San Diego, CA 92121-1736 on 10 dates between October 17, 2023 and November 3, 2023. During this inspection, the investigator determined that your firm markets and distributes the Cue Health COVID-19 Test and the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>FDA authorized the Cue Health COVID-19 Test under EUA200248 on June 10, 2020, granted revisions to the authorized labeling on August 20, 2020, and subsequently re-issued the emergency use authorization (EUA) in its entirety on March 26, 2021. The COVID-19 Test is authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in direct anterior nasal swabs or in previously collected anterior nasal specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. Emergency use of this test is limited to authorized laboratories.\u003C\u002Fp>\n\n\u003Cp>FDA also authorized the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use under EUA210180 on March 5, 2021. The COVID-19 Test for Home and Over The Counter (OTC) Use is a molecular diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal (nasal) swab specimens collected with the Cue Sample Wand. The test is intended for use in adults (self-swabbing) or children ≥2 years of age (swabbed by an adult) with or without symptoms or other epidemiological reasons to suspect COVID-19 and is authorized for non-prescription home use.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that you are not complying with the following Conditions of Authorization in the Letters of Authorization for EUA200248 and EUA210180. For example:\u003C\u002Fp>\n\n\u003Cp>1. Evidence obtained during the inspection demonstrated that your firm implemented several changes to your EUA-authorized devices and implemented those changes without authorization from FDA pursuant to the Conditions of Authorization. For example, documentation showed that on October 23, 2023, your firm implemented change order CP-4166 to both EUA-authorized COVID-19 devices. As part of this change order, it appears that you implemented changes in the formulation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which serves as a substrate for the reaction and is responsible for generating the signal to detect the presence of the target, modified the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and updated the device firmware to add functionality to detect failure of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and added a \u003Cstrong>(b)(4)\u003C\u002Fstrong> to modify the raw electrochemical signal from the reaction to correct for observed temperature-based signal differences, and that these changes were implemented after your firm received an EUA-authorization for your devices and in the absence of notification or FDA concurrence. These modifications may negatively impact the stability of the devices, resulting in failure earlier than the 9 months claimed on the product labeling, as documents TS0496 and TS0555 observed during our inspection indicated that these modifications were implemented with the intent to affect overall device performance and in particular device stability.\u003C\u002Fp>\n\n\u003Cp>Pursuant to Condition K (EUA200248) and Condition L (EUA210180), “You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling and shall not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)\u002FOffice of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)\u002FOffice of Product Evaluation and Quality (OPEQ)\u002FCenter for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation”. CDRH has reviewed the information collected during the inspection and has determined that your firm has failed to submit a request for the changes identified above to your devices for FDA review and obtain FDA authorization prior to implementation. CDRH has determined that these are significant modifications, as they have a strong likelihood to impact the performance of the device due to significant changes to reagent formulations and device design of these devices. Therefore, you are not permitted to distribute the modified Cue Health COVID-19 Test or Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until you receive authorization.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> We request that you take immediate action to cease the sale and distribution of your Cue Health COVID-19 Test and your Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until such time that you have received FDA concurrence for the modifications you have made to your tests pursuant to your respective conditions of authorization.\u003C\u002Fp>\n\n\u003Cp>2. Pursuant to Condition M (EUA200248) and Condition N (EUA210180), your firm is required to have lot release activities to ensure that the product released meets the clinical and analytical performance claimed in the authorized labeling. CDRH has reviewed the information collected during the inspection and has determined that you are not in compliance with Conditions M and N of the respective EUAs. For example, inspection of your firm’s document “QC2900005 Cartridge Assembly, COVID-19, Pouched” (Revision 12) effective since August 31, 2022, has identified that your firm is using an Acceptable Quality Level (AQL) for functional testing of the COVID-19 cartridges when testing against negative panels which would allow for a failure rate for commercially released product to be higher than the stated Negative Percent Agreement (NPA) clinical performance claims for the EUA devices. Your EUA-authorized devices have a claimed performance of 99.1% Negative Percent Agreement (NPA). However, your lot release activities indicate that you are using an AQL of \u003Cstrong>(b)(4)\u003C\u002Fstrong>% which is not sufficient to ensure that tests released for distribution have the analytical and clinical performance claimed in the authorized labeling. The release of products that fail to meet their claimed performance could lead to an increase in false positive results.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov and CDRHWarningLetterResponse@fda.hhs.gov. Refer to CMS #675673 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer, at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nShari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that a device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), if it does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). A device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), if a firm does not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA [21 CFR 807.81(b)].\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Clint Sever\n\nRecipient Title\n\nChief Executive Officer\n\nCue Health, Inc.\n\n4980 Carroll Canyon Rd Ste 100\n\nSan Diego, CA 92121-1736\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS# 675673\n\nMay 9, 2024\n\nDear Mr. Sever:\n\nThe Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at Cue Health, Inc. (“Cue Health”, “you”, or “your firm”) located at 4980 Carroll Canyon Rd Ste 100, San Diego, CA 92121-1736 on 10 dates between October 17, 2023 and November 3, 2023. During this inspection, the investigator determined that your firm markets and distributes the Cue Health COVID-19 Test and the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nFDA authorized the Cue Health COVID-19 Test under EUA200248 on June 10, 2020, granted revisions to the authorized labeling on August 20, 2020, and subsequently re-issued the emergency use authorization (EUA) in its entirety on March 26, 2021. The COVID-19 Test is authorized for the qualitative detection of nucleic acid from SARS-CoV-2 in direct anterior nasal swabs or in previously collected anterior nasal specimens in viral transport media from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19. Emergency use of this test is limited to authorized laboratories.\n\nFDA also authorized the Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use under EUA210180 on March 5, 2021. The COVID-19 Test for Home and Over The Counter (OTC) Use is a molecular diagnostic test for the qualitative detection of nucleic acid from SARS-CoV-2 in anterior nasal (nasal) swab specimens collected with the Cue Sample Wand. The test is intended for use in adults (self-swabbing) or children ≥2 years of age (swabbed by an adult) with or without symptoms or other epidemiological reasons to suspect COVID-19 and is authorized for non-prescription home use.\n\nOur inspection revealed that you are not complying with the following Conditions of Authorization in the Letters of Authorization for EUA200248 and EUA210180. For example:\n\n1. Evidence obtained during the inspection demonstrated that your firm implemented several changes to your EUA-authorized devices and implemented those changes without authorization from FDA pursuant to the Conditions of Authorization. For example, documentation showed that on October 23, 2023, your firm implemented change order CP-4166 to both EUA-authorized COVID-19 devices. As part of this change order, it appears that you implemented changes in the formulation of your (b)(4), which serves as a substrate for the reaction and is responsible for generating the signal to detect the presence of the target, modified the (b)(4) and updated the device firmware to add functionality to detect failure of (b)(4), and added a (b)(4) to modify the raw electrochemical signal from the reaction to correct for observed temperature-based signal differences, and that these changes were implemented after your firm received an EUA-authorization for your devices and in the absence of notification or FDA concurrence. These modifications may negatively impact the stability of the devices, resulting in failure earlier than the 9 months claimed on the product labeling, as documents TS0496 and TS0555 observed during our inspection indicated that these modifications were implemented with the intent to affect overall device performance and in particular device stability.\n\nPursuant to Condition K (EUA200248) and Condition L (EUA210180), “You may request changes to this EUA for your product, including to the Scope of Authorization (Section II in this letter) or to the authorized labeling, including requests to make available additional authorized labeling specific to an authorized distributor. Such additional labeling may use another name for the product but otherwise must be consistent with the authorized labeling and shall not exceed the terms of authorization of this letter. Any request for changes to this EUA should be submitted to the Division of Microbiology (DMD)\u002FOffice of Health Technology 7 (OHT7)-Office of In Vitro Diagnostics and Radiological Health (OIR)\u002FOffice of Product Evaluation and Quality (OPEQ)\u002FCenter for Devices and Radiological Health (CDRH) and require appropriate authorization from FDA prior to implementation”. CDRH has reviewed the information collected during the inspection and has determined that your firm has failed to submit a request for the changes identified above to your devices for FDA review and obtain FDA authorization prior to implementation. CDRH has determined that these are significant modifications, as they have a strong likelihood to impact the performance of the device due to significant changes to reagent formulations and device design of these devices. Therefore, you are not permitted to distribute the modified Cue Health COVID-19 Test or Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until you receive authorization.1 We request that you take immediate action to cease the sale and distribution of your Cue Health COVID-19 Test and your Cue Health COVID-19 Test for Home and Over The Counter (OTC) Use until such time that you have received FDA concurrence for the modifications you have made to your tests pursuant to your respective conditions of authorization.\n\n2. Pursuant to Condition M (EUA200248) and Condition N (EUA210180), your firm is required to have lot release activities to ensure that the product released meets the clinical and analytical performance claimed in the authorized labeling. CDRH has reviewed the information collected during the inspection and has determined that you are not in compliance with Conditions M and N of the respective EUAs. For example, inspection of your firm’s document “QC2900005 Cartridge Assembly, COVID-19, Pouched” (Revision 12) effective since August 31, 2022, has identified that your firm is using an Acceptable Quality Level (AQL) for functional testing of the COVID-19 cartridges when testing against negative panels which would allow for a failure rate for commercially released product to be higher than the stated Negative Percent Agreement (NPA) clinical performance claims for the EUA devices. Your EUA-authorized devices have a claimed performance of 99.1% Negative Percent Agreement (NPA). However, your lot release activities indicate that you are using an AQL of (b)(4)% which is not sufficient to ensure that tests released for distribution have the analytical and clinical performance claimed in the authorized labeling. The release of products that fail to meet their claimed performance could lead to an increase in false positive results.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed.\n\nYour firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch, at ORADevices3FirmResponse@fda.hhs.gov and CDRHWarningLetterResponse@fda.hhs.gov. Refer to CMS #675673 when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Y. Perkins, Compliance Officer, at (619) 941-3763 or shaquenta.perkins@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\n\nOffice of Regulatory Affairs\n\n\u002FS\u002F\n\nCourtney Lias\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n__________________________\n\n1 We note that a device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), if it does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). A device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), if a firm does not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3)(i). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the FDA [21 CFR 807.81(b)].","Cue Health, Inc.","cue-health-inc-675673-05092024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcue-health-inc-675673-05092024","2026-10-26T08:08:19.781607+00:00","2024-05-13","675673","Mr. Clint Sever","2026-08-20T00:06:27.848+00:00","2024-05-09",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":18,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":57,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1870,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2023-09-12T13:00:00Z\">09\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-11T04:00:00Z\">09\u002F11\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcvs-health-663246-09112023\">CVS Health\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Karen S. Lynch\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CVS Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>One CVS Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Woonsocket\u003C\u002Fspan>, \u003Cspan>RI\u003C\u002Fspan> \u003Cspan>02895\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Karen.Lynch@cvshealth.com\"> Karen.Lynch@cvshealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 11, 2023\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: 663246\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Karen S. Lynch:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.cvs.com in July 2023. The FDA has observed that your website offers “CVS Health Pink Eye Relief Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>Your “CVS Health Pink Eye Relief Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your product labeling, including on your website, your “CVS Health Pink Eye Relief Drops” is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including on your website www.cvs.com, that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On the product webpage for “CVS Health Pink Eye Relief Drops,” https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fcvs-health-pink-eye-relief-drops-0-33-oz-prodid-1010883:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\"Relieves •Redness •Burning •Watery discharge •Gritty sensation”\u003C\u002Fli>\n\t\u003Cli>“[T]emporarily relieve minor eye symptoms: •excessive watery (clear) discharge •sensation of grittiness •redness and burning”\u003C\u002Fli>\n\t\u003Cli>“CVS Health Pink Eye Drops is a homeopathic formula that stimulates the body’s ability to relieve redness, burning, watery discharge, and sensations of grittiness.”\u003C\u002Fli>\n\t\u003Cli>“When your eyes are dry, itching, or burning, it can be a big problem that you want relief from right away. These Irritated Eye Drops from CVS Health can provide you with the rapid relief you need . . . They are very helpful for relieving irritation, redness, burning, and dryness. The homeopathic formula is safe for use in the eyes and easy to apply . . . These drops are gentle enough for frequent use and even for use on children.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your “CVS Health Pink Eye Relief Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for “CVS Health Pink Eye Relief Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that your “CVS Health Pink Eye Relief Drops” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\n\n\u003Cp>Additionally, CVS is responsible for ensuring that the drug products it distributes are not adulterated. We understand that your “CVS Health Pink Eye Relief Drops” product is produced for CVS by a contract manufacturer, i.e., \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The significant violations of Current Good Manufacturing Practice (CGMP) requirements observed at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, with respect to its manufacture of homeopathic ophthalmic products, are documented in the Agency’s \u003Cstrong>(b)(4)\u003C\u002Fstrong> warning letter to \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Under section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), drugs are deemed adulterated if they are not manufactured in conformance with CGMPs. The CGMP violations identified at \u003Cstrong>(b)(4)\u003C\u002Fstrong> caused all drug products manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> to be adulterated. The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of an adulterated drug is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). Further, the receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&amp;C Act, 21 U.S.C. 331(c).\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jill Furman\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>cc:&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note that your ophthalmic drug products utilize silver sulfate as a preservative. The Agency has significant concerns regarding the safety of silver sulfate for use as an ophthalmic preservative. Long term use of medicinal compounds containing silver may cause argyria, which is a blueish-gray discoloration of the skin and eyes that is irreversible. Additionally, granular deposits of silver in the conjunctiva and cornea may cause decreased night vision. Accordingly, we are concerned that your use of silver sulfate as a preservative in your ophthalmic products is inconsistent with 21 C.F.R. 200.50(b)(1), under which ophthalmic preservatives should be “suitable and harmless.”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKaren S. Lynch\n\nRecipient Title\n\nPresident & CEO\n\nCVS Health\n\nOne CVS Drive\n\nWoonsocket, RI 02895\n\nUnited States\n\nKaren.Lynch@cvshealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nSeptember 11, 2023\n\nRE: 663246\n\nDear Karen S. Lynch:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address www.cvs.com in July 2023. The FDA has observed that your website offers “CVS Health Pink Eye Relief Drops” for sale in the United States. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nYour “CVS Health Pink Eye Relief Drops” product is especially concerning from a public health perspective. Ophthalmic drug products, which are intended for administration into the eyes, in general pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses.1\n\nBased on a review of your product labeling, including on your website, your “CVS Health Pink Eye Relief Drops” is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples of claims from your product labeling, including on your website www.cvs.com, that provide evidence of the intended use of this product as a drug include, but may not be limited to, the following:\n\nOn the product webpage for “CVS Health Pink Eye Relief Drops,” https:\u002F\u002Fwww.cvs.com\u002Fshop\u002Fcvs-health-pink-eye-relief-drops-0-33-oz-prodid-1010883:\n\n\"Relieves •Redness •Burning •Watery discharge •Gritty sensation”\n\n“[T]emporarily relieve minor eye symptoms: •excessive watery (clear) discharge •sensation of grittiness •redness and burning”\n\n“CVS Health Pink Eye Drops is a homeopathic formula that stimulates the body’s ability to relieve redness, burning, watery discharge, and sensations of grittiness.”\n\n“When your eyes are dry, itching, or burning, it can be a big problem that you want relief from right away. These Irritated Eye Drops from CVS Health can provide you with the rapid relief you need . . . They are very helpful for relieving irritation, redness, burning, and dryness. The homeopathic formula is safe for use in the eyes and easy to apply . . . These drops are gentle enough for frequent use and even for use on children.”\n\nYour “CVS Health Pink Eye Relief Drops” is not generally recognized as safe and effective (GRASE) for its above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for “CVS Health Pink Eye Relief Drops.” Accordingly, the introduction or delivery for introduction into interstate commerce of this product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that your “CVS Health Pink Eye Relief Drops” is labeled as a homeopathic drug with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\n\nAdditionally, CVS is responsible for ensuring that the drug products it distributes are not adulterated. We understand that your “CVS Health Pink Eye Relief Drops” product is produced for CVS by a contract manufacturer, i.e., (b)(4). The significant violations of Current Good Manufacturing Practice (CGMP) requirements observed at (b)(4), with respect to its manufacture of homeopathic ophthalmic products, are documented in the Agency’s (b)(4) warning letter to (b)(4). Under section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), drugs are deemed adulterated if they are not manufactured in conformance with CGMPs. The CGMP violations identified at (b)(4) caused all drug products manufactured by (b)(4) to be adulterated. The introduction, delivery for introduction, or causing the introduction or delivery for introduction into interstate commerce of an adulterated drug is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). Further, the receipt in interstate commerce of adulterated drugs, and the delivery or proffered delivery thereof, is a violation of section 301(c) of the FD&C Act, 21 U.S.C. 331(c).\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. In addition, please note that unapproved new drugs are subject to refusal of admission into the United States, and such products may be subject to detention without physical examination. For more information about detention without physical examination, see Import Alert 66-41.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\ncc: (b)(4)\n\n___________________________\n\n1 We note that your ophthalmic drug products utilize silver sulfate as a preservative. The Agency has significant concerns regarding the safety of silver sulfate for use as an ophthalmic preservative. Long term use of medicinal compounds containing silver may cause argyria, which is a blueish-gray discoloration of the skin and eyes that is irreversible. Additionally, granular deposits of silver in the conjunctiva and cornea may cause decreased night vision. Accordingly, we are concerned that your use of silver sulfate as a preservative in your ophthalmic products is inconsistent with 21 C.F.R. 200.50(b)(1), under which ophthalmic preservatives should be “suitable and harmless.”","CVS Health","cvs-health-663246-09112023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcvs-health-663246-09112023","2026-10-26T08:08:20.505694+00:00","2023-09-12","663246","Drugs","Karen S. Lynch","2026-08-20T00:41:46.185+00:00","Via Email","2023-09-11",{"id":73,"raw":74,"subject":79,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":88,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":92,"issuing_office":78,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":96,"action_taken_date":97,"medical_device_id":19,"response_letter_date":19},256,[75,76,77,78,79,13,80,13],"\u003Ctime datetime=\"2026-03-24T04:00:00Z\">03\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-17T04:00:00Z\">03\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-03172026\">4U Health\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Premarket Approval\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-06162026\">\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-720527\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Alfred Caminos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Founder and Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>4U Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>71 Lighthouse Road, Suite 220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hilton Head Island\u003C\u002Fspan>, \u003Cspan>SC\u003C\u002Fspan> \u003Cspan>29928\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@4uhealth.com\"> help@4uhealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>March 17, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-720527\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Alfred Caminos:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA or the Agency) has learned that your firm, 4U Health, is offering for sale in the United States a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit (hereinafter, your “HIV DBS card self-collection kit”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Under section 201(h)(1) of the FD&amp;C Act, 21 U.S.C. 321(h)(1), your HIV DBS card self-collection kit is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed your company’s website at www.4uhealth.com (last visited March 2026) and your firm’s responses to previous FDA correspondence. Based on our review of these materials, your firm offers its HIV DBS card self-collection kit for delivery to individuals and intends for these individuals to use the kit to self-collect DBS samples and ship those samples to laboratories for HIV testing. FDA has determined that your HIV DBS card self-collection kit is adulterated under section 501(f)(1)(B) of the FD&amp;C Act, 21 U.S.C. 351(f)(1)(B) because it does not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&amp;C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&amp;C Act, 21 U.S.C. 360j(g). Your HIV DBS card self-collection kit is also misbranded under section 502(o) the FD&amp;C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the agency, as required by section 510(k) of the FD&amp;C Act, 21 U.S.C. 360(k).\u003C\u002Fp>\u003Cp>FDA has not authorized your firm’s HIV DBS card self-collection kit for use in HIV serological diagnostic testing.\u003C\u002Fp>\u003Cp>In a letter dated March 31, 2025, FDA informed you that you appeared to be offering for sale and distributing your HIV serological diagnostic self-collection kits in a manner that may violate the FD&amp;C Act. In your response dated April 30, 2025, you assert that 4U Health “do[es] not sell self-collection testing kits,” and that 4U Health instead “facilitates access to professional medical services, including HIV testing.” You indicate that “[y]our physician consultants order” tests and “oversee the entire testing process.” And you state that the “service” you offer is “not intended to diagnose, treat, or cure any disease on its own,” as “[p]ositive results require confirmation and diagnosis by a licensed medical provider not affiliated with 4U Health.”\u003C\u002Fp>\u003Cp>Express statements on your firm’s website and in your April 30, 2025 response make clear that your firm is selling and distributing HIV serological diagnostic self-collection kits. For example, your website states that the kit “will arrive in plain packaging” and “contains everything you need to collect your home sample.” And your April 30, 2025 response acknowledges that your “at-home testing collection supplies” are “provided to [y]our clients for sample collection.” As explained above, because your firm’s HIV DBS card self-collection kit is a device that has not received FDA marketing authorization, the kit is adulterated and misbranded.\u003C\u002Fp>\u003Cp>Notably, this letter and the March 31, 2025 letter sent to your firm focus on your HIV serological diagnostic self-collection kits and are not intended to be a comprehensive list of potential issues with your firm’s products. Even if, as you say, any testing you conduct on samples is intended to provide only preliminary results, the kits you “source[] from independent distributors” and ship to customers for the purpose of sample collection by customers “at-home” (as stated in your April 30, 2025 response) are devices. Nor does the involvement of “physician consultants” in ordering any testing or interpreting any results mean that the collection kits you are shipping are not devices.\u003C\u002Fp>\u003Cp>Without appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your HIV DBS card self-collection kit. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We also note that there are FDA-approved over-the-counter HIV tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your HIV DBS card self-collection kit. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality&nbsp;&nbsp;\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-720527\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAlfred Caminos\n\nRecipient Title\n\nCo-Founder and Managing Director\n\n4U Health\n\n71 Lighthouse Road, Suite 220\n\nHilton Head Island, SC 29928\n\nUnited States\n\nhelp@4uhealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nMarch 17, 2026\nCBER 26-720527\nDear Alfred Caminos:\nThe United States Food and Drug Administration (FDA or the Agency) has learned that your firm, 4U Health, is offering for sale in the United States a human immunodeficiency virus (HIV) serological diagnostic dried blood spot (DBS) card self-collection kit (hereinafter, your “HIV DBS card self-collection kit”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under section 201(h)(1) of the FD&C Act, 21 U.S.C. 321(h)(1), your HIV DBS card self-collection kit is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed your company’s website at www.4uhealth.com (last visited March 2026) and your firm’s responses to previous FDA correspondence. Based on our review of these materials, your firm offers its HIV DBS card self-collection kit for delivery to individuals and intends for these individuals to use the kit to self-collect DBS samples and ship those samples to laboratories for HIV testing. FDA has determined that your HIV DBS card self-collection kit is adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B) because it does not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g). Your HIV DBS card self-collection kit is also misbranded under section 502(o) the FD&C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the agency, as required by section 510(k) of the FD&C Act, 21 U.S.C. 360(k).\nFDA has not authorized your firm’s HIV DBS card self-collection kit for use in HIV serological diagnostic testing.\nIn a letter dated March 31, 2025, FDA informed you that you appeared to be offering for sale and distributing your HIV serological diagnostic self-collection kits in a manner that may violate the FD&C Act. In your response dated April 30, 2025, you assert that 4U Health “do[es] not sell self-collection testing kits,” and that 4U Health instead “facilitates access to professional medical services, including HIV testing.” You indicate that “[y]our physician consultants order” tests and “oversee the entire testing process.” And you state that the “service” you offer is “not intended to diagnose, treat, or cure any disease on its own,” as “[p]ositive results require confirmation and diagnosis by a licensed medical provider not affiliated with 4U Health.”\nExpress statements on your firm’s website and in your April 30, 2025 response make clear that your firm is selling and distributing HIV serological diagnostic self-collection kits. For example, your website states that the kit “will arrive in plain packaging” and “contains everything you need to collect your home sample.” And your April 30, 2025 response acknowledges that your “at-home testing collection supplies” are “provided to [y]our clients for sample collection.” As explained above, because your firm’s HIV DBS card self-collection kit is a device that has not received FDA marketing authorization, the kit is adulterated and misbranded.\nNotably, this letter and the March 31, 2025 letter sent to your firm focus on your HIV serological diagnostic self-collection kits and are not intended to be a comprehensive list of potential issues with your firm’s products. Even if, as you say, any testing you conduct on samples is intended to provide only preliminary results, the kits you “source[] from independent distributors” and ship to customers for the purpose of sample collection by customers “at-home” (as stated in your April 30, 2025 response) are devices. Nor does the involvement of “physician consultants” in ordering any testing or interpreting any results mean that the collection kits you are shipping are not devices.\nWithout appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your HIV DBS card self-collection kit. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We also note that there are FDA-approved over-the-counter HIV tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your HIV DBS card self-collection kit. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research","4U Health","4u-health-720527-03172026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F4u-health-720527-03172026","2026-10-26T08:07:47.869397+00:00","Closed Out","2026-03-24","720527","Biologics","2026-06-23","Alfred Caminos","2026-08-19T04:50:02.803+00:00","Via UPS and EMAIL","CBER 26-720527","2026-03-17",{"id":99,"raw":100,"subject":105,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":43,"fei_number":19,"letter_url":110,"updated_at":111,"action_type":22,"case_status":23,"posted_date":112,"marcs_cms_no":113,"product_type":67,"closeout_date":19,"issuing_office":104,"recipient_name":114,"body_fetched_at":115,"delivery_method":116,"recipient_title":19,"reference_number":19,"action_taken_date":117,"medical_device_id":19,"response_letter_date":19},1251,[101,102,103,104,105,13,13,13],"\u003Ctime datetime=\"2024-09-17T13:20:00Z\">09\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-17T04:00:00Z\">07\u002F17\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftja-health-llc-678539-07172024\">TJA Health, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Behnam (Ben) Vaziri\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Operating Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>TJA Health, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2501 Reeves Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Joliet\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60436-9523\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Bvaziri@plaquehd.com\"> Bvaziri@plaquehd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 17, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCASE #678539\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Vaziri:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, TJA Health LLC, FEI 3010203410, located at 2501 &amp; 2505 Reeves Road, Joliet, IL 60436, from January 25 to 29, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your response dated February 8, 2024, to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to adequately test incoming raw materials used for the manufacture of your drug products, including active pharmaceutical ingredients (API) and other high-risk components. Instead, your firm released API and other materials for use in drug product manufacturing based on your supplier’s certificate of analysis (COA) without performing at least one specific identity test on each component.\u003C\u002Fp>\n\n\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Products Contain High Risk Components\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to adequately test each shipment of each lot of incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. This includes, but is not limited to, testing of the glycerin and sorbitol you used in manufacturing of Plaque HD Toothpaste and Plaque Remineralizing Mouth Rinse drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP), to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Water\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm produced \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that was used as a component in the production of your drug products. Your firm has not demonstrated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water was suitable for manufacturing of your aqueous-based OTC drug products due to lack of routine monitoring for \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex (BCC).\u003C\u002Fp>\n\n\u003Cp>BCC poses a risk of contamination in non-sterile, water-based drug products. For more information regarding the significance of BCC contamination in drug products, see the FDA’s July 7, 2021, advisory for drug manufacturers.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Because water is used as a component in your non-sterile drug products, the lack of data regarding the state of control of your water system poses a potential risk of introducing objectionable microbial contamination into your products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> identity test summary reports of components, including glycerin and sorbitol, and commit to perform at least one identity test for the components used in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>You also include your updated procedure for water system maintenance and testing that requires all \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples to be routinely tested per USP Chapters &lt;60&gt;, &lt;61&gt; and &lt;62&gt;. You indicate that you have started testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> water as per USP Chapter &lt;60&gt; since February 1, 2024.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not perform a limit test for DEG and EG for glycerin and sorbitol as required by USP to ensure that the component meets the relevant safety limits for the levels. Additionally, you do not provide a comprehensive assessment of your water system describing whether all ports are free of objectionable microorganisms and the frequency of water testing, including sampling from all ports. You also do not include supporting documentation of microorganism identification testing.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of components including high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, sorbitol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a reserve of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labeling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should refer to Case # 678539. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Sneha Patel, Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003Cbr>\n\u003Cbr>\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Sneha Patel at (313) 393-8254.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Rebecca E. Dowd\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operation III\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>L. Hier\u003Cbr>\nChief Executive Officer\u003Cbr>\nTJA Health, LLC\u003Cbr>\n2501 Reeves Road\u003Cbr>\nJoliet, IL 60436-9523\u003C\u002Fp>\n\n\u003Cp>_______________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Behnam (Ben) Vaziri\n\nRecipient Title\n\nChief Operating Officer\n\nTJA Health, LLC\n\n2501 Reeves Road\n\nJoliet, IL 60436-9523\n\nUnited States\n\nBvaziri@plaquehd.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nJuly 17, 2024\n\nWARNING LETTER\n\nCASE #678539\n\nDear Mr. Vaziri:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, TJA Health LLC, FEI 3010203410, located at 2501 & 2505 Reeves Road, Joliet, IL 60436, from January 25 to 29, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your response dated February 8, 2024, to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm failed to adequately test incoming raw materials used for the manufacture of your drug products, including active pharmaceutical ingredients (API) and other high-risk components. Instead, your firm released API and other materials for use in drug product manufacturing based on your supplier’s certificate of analysis (COA) without performing at least one specific identity test on each component.\n\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before use in the manufacture of your drug products.\n\nProducts Contain High Risk Components\n\nYou failed to adequately test each shipment of each lot of incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. This includes, but is not limited to, testing of the glycerin and sorbitol you used in manufacturing of Plaque HD Toothpaste and Plaque Remineralizing Mouth Rinse drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components include a limit test in the United States Pharmacopeia (USP), to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\n(b)(4) Water\n\nYour firm produced (b)(4) water that was used as a component in the production of your drug products. Your firm has not demonstrated that the (b)(4) water was suitable for manufacturing of your aqueous-based OTC drug products due to lack of routine monitoring for Burkholderia cepacia complex (BCC).\n\nBCC poses a risk of contamination in non-sterile, water-based drug products. For more information regarding the significance of BCC contamination in drug products, see the FDA’s July 7, 2021, advisory for drug manufacturers.1\n\nBecause water is used as a component in your non-sterile drug products, the lack of data regarding the state of control of your water system poses a potential risk of introducing objectionable microbial contamination into your products. Pharmaceutical water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nIn your response, you provide (b)(4) identity test summary reports of components, including glycerin and sorbitol, and commit to perform at least one identity test for the components used in the manufacture of your drug products.\n\nYou also include your updated procedure for water system maintenance and testing that requires all (b)(4) water samples to be routinely tested per USP Chapters \u003C60>, \u003C61> and \u003C62>. You indicate that you have started testing (b)(4) water as per USP Chapter \u003C60> since February 1, 2024.\n\nYour response is inadequate. You did not perform a limit test for DEG and EG for glycerin and sorbitol as required by USP to ensure that the component meets the relevant safety limits for the levels. Additionally, you do not provide a comprehensive assessment of your water system describing whether all ports are free of objectionable microorganisms and the frequency of water testing, including sampling from all ports. You also do not include supporting documentation of microorganism identification testing.\n\nIn response to this letter, provide the following:\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of components including high-risk drug components to determine acceptability for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, sorbitol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the United States Pharmacopeia (USP) monograph.\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing reserve samples for all lots of high-risk drug components used in the manufacture of your drug products. Alternatively, if a reserve of a component lot is unavailable, perform reserve sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination (including, but not limited to, glycerin). Take prompt and appropriate actions to determine the safety of all lots of the ingredient(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective actions and preventive actions (CAPA) that secure supply chains in the future, including but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nYour quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labeling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour response should refer to Case # 678539. Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Sneha Patel, Compliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Sneha Patel at (313) 393-8254.\n\nSincerely,\n\n\u002FS\u002F\n\nRebecca E. Dowd\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operation III\n\nOffice of Regulatory Affairs\n\nCc:\n\nL. Hier\n\nChief Executive Officer\n\nTJA Health, LLC\n\n2501 Reeves Road\n\nJoliet, IL 60436-9523\n\n_______________\n\n1 https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-advises-drug-manufacturers-burkholderia-cepacia-complex-poses-contamination-risk-non-sterile","TJA Health, LLC","tja-health-llc-678539-07172024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftja-health-llc-678539-07172024","2026-10-26T08:10:12.762431+00:00","2024-09-17","678539","Mr. Behnam (Ben) Vaziri","2026-08-19T23:48:02.59+00:00","UPS","2024-07-17",{"id":119,"raw":120,"subject":125,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":43,"fei_number":19,"letter_url":130,"updated_at":131,"action_type":22,"case_status":23,"posted_date":132,"marcs_cms_no":133,"product_type":134,"closeout_date":19,"issuing_office":124,"recipient_name":135,"body_fetched_at":136,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":137,"medical_device_id":19,"response_letter_date":19},1178,[121,122,123,124,125,13,13,13],"\u003Ctime datetime=\"2024-11-05T14:20:00Z\">11\u002F05\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-22T04:00:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fardent-animal-health-llc-662394-10222024\">Ardent Animal Health, LLC\u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rachel Bahr\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President, CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ardent Animal Health, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>220 Bellaire Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nicholasville\u003C\u002Fspan>, \u003Cspan>KY\u003C\u002Fspan> \u003Cspan>40356\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@ardentanimalhealth.com\"> info@ardentanimalhealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 22, 2024\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Re: 662394\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Rachel Bahr,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility located at 220 Bellaire Drive, Nicholasville, KY 40356 from September 10, 2024, through September 13, 2024. After a review of the inspection report, and a subsequent review of information provided on your website www.ardentanimalhealth.com, your social media webpages www.facebook.com\u002FArdentanimalhealth and www.instagram.com\u002Fardentanimalhealth, and your Ardent Animal Health phone application, we have determined that you are marketing unapproved new animal drugs. The claims on your website establish that your cell and tissue-based, regenerative therapy products Acti-Stem Therapy and PureVet PRP are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (The FD&amp;C Act) [21 U.S.C. § 321(g)(1)(B)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, your products are unapproved new animal drugs. Acti-Stem Therapy consists of stromal vascular fraction with platelet-rich plasma for autologous use in dogs and cats. PureVet PRP consists of platelet-rich plasma for autologous use in dogs and cats. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov. You can find specific information about how FDA regulates cell and tissue products for animals at https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fbiotechnology-products-cvm-animals-and-animal-food\u002Fcell-and-tissue-products-animals.\u003C\u002Fp>\n\n\u003Cp>Examples of claims FDA observed on your website, www.ardentanimalhealth.com, your social media webpages, www.facebook.com\u002FArdentanimalhealth and www.instagram.com\u002Fardentanimalhealth, and your Ardent Animal Health phone application that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>Acti-Stem Therapy\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o “How Does it Work? This ability arises from repair cells that are found throughout our body. In the case of injury or disease repair cells are mobilized to damaged areas to attempt to fix the problem.\u003Cbr>\nDue to injury and\u002For age sometimes our own repair abilities can use a jump-start. By using the pet’s own repair cells isolated from fat tissue in the body, this repair ability can be applied to areas of need.”\u003C\u002Fp>\n\n\u003Cp>o At the :41 second mark to the 1:22 minute mark of the “What is ActiStem? Ardent Animal Health” video posted on your https:\u002F\u002Fardentanimalhealth.com\u002Factistem-therapy\u002F webpage, it states: “As we age, our stem cells response to injury and ability to repair can decrease or be overwhelmed due to disease. Degenerative disease such as Osteoarthritis can overwhelm your pet’s own natural repair process, leading to pain, inflammation, and limited mobility. Osteoarthritis has a long-term impact on the patient by causing loss of cartilage and accelerated lameness. Acti-Stem Therapy provides an all-natural solution to rebuild and regenerate cartilage as well as repair tissues and processes the way the body intended. This provides a solution to the underlying cause of the disease as opposed to just suppressing the symptoms.”\u003C\u002Fp>\n\n\u003Cp>o “\u003Cstrong>(b)(6)\u003C\u002Fstrong> Actistem Story… She went from paralyzed to the wheelchair, to dragging herself out of the chair and trying to stand on her own. In the last 3 years, she progressed to walking which was still ataxic, but she has not regained the ability to urinate on her own… She has received 2 doses of stem cells now on July 2, 2019 and August 10, 2019. She is running, wagging her tail and can support herself on her hind legs. She has much more conscious control of her hind legs. She still is unable to urinate on her own and has to be expressed, but we will see what happens with that as time goes on.”\u003C\u002Fp>\n\n\u003Cp>o “\u003Cstrong>(b)(6)\u003C\u002Fstrong> is our rescue boxer mix who was diagnosed with patellar luxation in both back legs and hip dysplasia in both hips. She’s had several knee surgeries (including a torn ACL) …This April, she could no longer stand up from a sitting position or walk. Dr. \u003Cstrong>(b)(6)\u003C\u002Fstrong> (and his awesome staff) wanted \u003Cstrong>(b)(6)\u003C\u002Fstrong> to be their first stem cell patient… I went to pick her up after her surgery — and she walked to me…”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>PureVet PRP\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>o “PRP or Platelet Rich Plasma is a convenient same day treatment that harnesses the healing abilities of the patient’s blood platelets. Veterinarians utilize the treatment in conjunction with common surgeries or as a part of treatment plans to combat injury and disease.”\u003C\u002Fp>\n\n\u003Cp>o “Ardent’s PRP Kit can be used to treat injured joints, tendons, or used in its gel form.”\u003C\u002Fp>\n\n\u003Cp>o “PRP can be used to aid in the treatment of many ailments as seen in the illustration below… canine degenerative joint disease, hip dysplasia, soft tissue injuries… feline degenerative joint disease, wound healing, soft tissue injuries”\u003C\u002Fp>\n\n\u003Cp>o “…I HAVE USED PRP THERAPY IN THE TREATMENT OF OSTEOARTHRITIS, BICEPS TENOSYNOVITIS, AS WELL AS NONSURGICAL MANAGEMENT OF CHRONIC ACHILLES MECHANISM INJURIES…”\u003C\u002Fp>\n\n\u003Cp>o “Case Study… These radiographs were taken from the left hock of a 7 year old FS Mix breed dog that was chronically lame in both hind legs. The ankles were swollen and painful, not responding to any anti-inflammatory medication. The pronounced dystrophic mineralization was present in both hocks, but the response to regenerative medicine was striking on the left side. The owner consented to injections of PRP, or platelet rich plasma, into the gastrocnemius tendon as well as an intravenous application of the autologous fluid. As you can see after a few weeks, the mineralization is less pronounced. There is less soft tissue swelling, and there is a greater degree of joint mobility. Most importantly, the dog is more comfortable and does not require NSAIDs.”\u003C\u002Fp>\n\n\u003Cp>o “Ardent’s PRP Kit can be introduced topically in or around an injured joint, tendon, or used in its gel form to treat large burns or wounds. Ardent’s PRP is not limited to acute injuries, it can also be used for chronic conditions. Here are some of the most common uses for PRP therapy in pets:\u003C\u002Fp>\n\n\u003Cp> Complimentary to your pet’s next surgery\u003Cbr>\n Osteoarthritis\u003Cbr>\n Tenosynovitis\u003Cbr>\n Wound Care\u003Cbr>\n General Inflammation\u003Cbr>\n Corneal Ulcers\u003Cbr>\n Post Surgical Healing”\u003C\u002Fp>\n\n\u003Cp>o On your September 24, 2024 Facebook and Instagram posts:\u003C\u002Fp>\n\n\u003Cp> “5 Things Every Pet Owner Should Know About PUREVET PRP Therapy! Did you know PRP therapy can help pets heal naturally? Here’s why you should consider it:\u003Cbr>\n&nbsp; &nbsp; 1. PRP utilizes your pet’s own healing factors. 2. PRP is a nonsurgical form of regenerative medicine therapy. 3. PRP is a same-day procedure. 4. PRP can be a standalone treatment or in conjunction with surgeries. 5. PUREVET PRP can be utilized for a variety of conditions and injuries.”\u003C\u002Fp>\n\n\u003Cp>Because your Acti-Stem Therapy and PureVet PRP products are intended to diagnose, cure, mitigate, treat, or prevent disease in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&amp;C Act, [21 U.S.C. § 321 (g)(1)(B)]. Moreover, these products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1].\u003C\u002Fp>\n\n\u003Cp>These products are not approved or index listed by FDA, and therefore these products are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. § 351(a)(5). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 662394” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003C\u002Fp>\n\n\u003Cp>Cc: Matt Yeich, Operations Manager\u003Cbr>\nmatt@ardentanimalhealth.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRachel Bahr\n\nRecipient Title\n\nPresident, CEO\n\nArdent Animal Health, LLC\n\n220 Bellaire Drive\n\nNicholasville, KY 40356\n\nUnited States\n\ninfo@ardentanimalhealth.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nOctober 22, 2024\n\nRe: 662394\n\nDear Rachel Bahr,\n\nThe U.S. Food and Drug Administration (FDA) inspected your facility located at 220 Bellaire Drive, Nicholasville, KY 40356 from September 10, 2024, through September 13, 2024. After a review of the inspection report, and a subsequent review of information provided on your website www.ardentanimalhealth.com, your social media webpages www.facebook.com\u002FArdentanimalhealth and www.instagram.com\u002Fardentanimalhealth, and your Ardent Animal Health phone application, we have determined that you are marketing unapproved new animal drugs. The claims on your website establish that your cell and tissue-based, regenerative therapy products Acti-Stem Therapy and PureVet PRP are drugs under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (The FD&C Act) [21 U.S.C. § 321(g)(1)(B)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, your products are unapproved new animal drugs. Acti-Stem Therapy consists of stromal vascular fraction with platelet-rich plasma for autologous use in dogs and cats. PureVet PRP consists of platelet-rich plasma for autologous use in dogs and cats. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov. You can find specific information about how FDA regulates cell and tissue products for animals at https:\u002F\u002Fwww.fda.gov\u002Fanimal-veterinary\u002Fbiotechnology-products-cvm-animals-and-animal-food\u002Fcell-and-tissue-products-animals.\n\nExamples of claims FDA observed on your website, www.ardentanimalhealth.com, your social media webpages, www.facebook.com\u002FArdentanimalhealth and www.instagram.com\u002Fardentanimalhealth, and your Ardent Animal Health phone application that show the intended use of your products as drugs include, but are not limited to, the following:\n\nActi-Stem Therapy\n\no “How Does it Work? This ability arises from repair cells that are found throughout our body. In the case of injury or disease repair cells are mobilized to damaged areas to attempt to fix the problem.\n\nDue to injury and\u002For age sometimes our own repair abilities can use a jump-start. By using the pet’s own repair cells isolated from fat tissue in the body, this repair ability can be applied to areas of need.”\n\no At the :41 second mark to the 1:22 minute mark of the “What is ActiStem? Ardent Animal Health” video posted on your https:\u002F\u002Fardentanimalhealth.com\u002Factistem-therapy\u002F webpage, it states: “As we age, our stem cells response to injury and ability to repair can decrease or be overwhelmed due to disease. Degenerative disease such as Osteoarthritis can overwhelm your pet’s own natural repair process, leading to pain, inflammation, and limited mobility. Osteoarthritis has a long-term impact on the patient by causing loss of cartilage and accelerated lameness. Acti-Stem Therapy provides an all-natural solution to rebuild and regenerate cartilage as well as repair tissues and processes the way the body intended. This provides a solution to the underlying cause of the disease as opposed to just suppressing the symptoms.”\n\no “(b)(6) Actistem Story… She went from paralyzed to the wheelchair, to dragging herself out of the chair and trying to stand on her own. In the last 3 years, she progressed to walking which was still ataxic, but she has not regained the ability to urinate on her own… She has received 2 doses of stem cells now on July 2, 2019 and August 10, 2019. She is running, wagging her tail and can support herself on her hind legs. She has much more conscious control of her hind legs. She still is unable to urinate on her own and has to be expressed, but we will see what happens with that as time goes on.”\n\no “(b)(6) is our rescue boxer mix who was diagnosed with patellar luxation in both back legs and hip dysplasia in both hips. She’s had several knee surgeries (including a torn ACL) …This April, she could no longer stand up from a sitting position or walk. Dr. (b)(6) (and his awesome staff) wanted (b)(6) to be their first stem cell patient… I went to pick her up after her surgery — and she walked to me…”\n\nPureVet PRP\n\no “PRP or Platelet Rich Plasma is a convenient same day treatment that harnesses the healing abilities of the patient’s blood platelets. Veterinarians utilize the treatment in conjunction with common surgeries or as a part of treatment plans to combat injury and disease.”\n\no “Ardent’s PRP Kit can be used to treat injured joints, tendons, or used in its gel form.”\n\no “PRP can be used to aid in the treatment of many ailments as seen in the illustration below… canine degenerative joint disease, hip dysplasia, soft tissue injuries… feline degenerative joint disease, wound healing, soft tissue injuries”\n\no “…I HAVE USED PRP THERAPY IN THE TREATMENT OF OSTEOARTHRITIS, BICEPS TENOSYNOVITIS, AS WELL AS NONSURGICAL MANAGEMENT OF CHRONIC ACHILLES MECHANISM INJURIES…”\n\no “Case Study… These radiographs were taken from the left hock of a 7 year old FS Mix breed dog that was chronically lame in both hind legs. The ankles were swollen and painful, not responding to any anti-inflammatory medication. The pronounced dystrophic mineralization was present in both hocks, but the response to regenerative medicine was striking on the left side. The owner consented to injections of PRP, or platelet rich plasma, into the gastrocnemius tendon as well as an intravenous application of the autologous fluid. As you can see after a few weeks, the mineralization is less pronounced. There is less soft tissue swelling, and there is a greater degree of joint mobility. Most importantly, the dog is more comfortable and does not require NSAIDs.”\n\no “Ardent’s PRP Kit can be introduced topically in or around an injured joint, tendon, or used in its gel form to treat large burns or wounds. Ardent’s PRP is not limited to acute injuries, it can also be used for chronic conditions. Here are some of the most common uses for PRP therapy in pets:\n\n Complimentary to your pet’s next surgery\n\n Osteoarthritis\n\n Tenosynovitis\n\n Wound Care\n\n General Inflammation\n\n Corneal Ulcers\n\n Post Surgical Healing”\n\no On your September 24, 2024 Facebook and Instagram posts:\n\n “5 Things Every Pet Owner Should Know About PUREVET PRP Therapy! Did you know PRP therapy can help pets heal naturally? Here’s why you should consider it:\n\n1. PRP utilizes your pet’s own healing factors. 2. PRP is a nonsurgical form of regenerative medicine therapy. 3. PRP is a same-day procedure. 4. PRP can be a standalone treatment or in conjunction with surgeries. 5. PUREVET PRP can be utilized for a variety of conditions and injuries.”\n\nBecause your Acti-Stem Therapy and PureVet PRP products are intended to diagnose, cure, mitigate, treat, or prevent disease in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&C Act, [21 U.S.C. § 321 (g)(1)(B)]. Moreover, these products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1].\n\nThese products are not approved or index listed by FDA, and therefore these products are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. § 351(a)(5). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&C Act, [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 662394” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nCc: Matt Yeich, Operations Manager\n\nmatt@ardentanimalhealth.com","Ardent Animal Health, LLC","ardent-animal-health-llc-662394-10222024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fardent-animal-health-llc-662394-10222024","2026-10-26T08:07:57.218353+00:00","2024-11-05","662394","Animal & VeterinaryDrugs","Rachel Bahr","2026-08-19T19:14:56.797+00:00","2024-10-22",{"id":139,"raw":140,"subject":105,"body_html":145,"body_text":146,"firm_name":147,"letter_id":148,"created_at":149,"fei_number":19,"letter_url":150,"updated_at":151,"action_type":22,"case_status":23,"posted_date":152,"marcs_cms_no":153,"product_type":67,"closeout_date":19,"issuing_office":144,"recipient_name":154,"body_fetched_at":155,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":156,"medical_device_id":19,"response_letter_date":19},2905,[141,142,143,144,105,13,13,13],"\u003Ctime datetime=\"2022-01-25T14:20:00Z\">01\u002F25\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-29T05:00:00Z\">12\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealth-plus-inc-616877-12292021\">Health Plus Inc.\u003C\u002Fa>","Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Rita Mediratta\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Health Plus Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13837 Magnolia Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chino\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91710\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ritam@healthplusinc.com\"> ritam@healthplusinc.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 29, 2021\u003Cbr>\n\u003Cbr>\nDear Ms. Mediratta:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Health Plus Inc., FEI 2027164, at 13837 Magnolia Avenue, Chino, California, from June 23 to July 1, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your July 20, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to ensure that returned drugs meet appropriate standards of safety, identity, strength, quality and purity prior to redistributing (21 CFR 211.204).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s handling of returned drug product before its redistribution is inadequate. For example, during the inspection, you were not able to provide documentation of adequate inspection and investigation of the returned product confirming the label conditions under which the returned drug product was held, stored, or shipped before its return and before redistributing. Furthermore, you failed to perform adequate testing to ensure the safety, identity, strength, quality, and purity of the returned product. Organoleptic examination alone is not sufficient to ensure that a product maintains its safety, identity, strength, purity, and quality after it has been in a situation where it may have been exposed to improper storage conditions.\u003C\u002Fp>\n\n\u003Cp>Before redistribution, you combined returned capsules from various lots into new batches with new lot numbers. These new lots did not have uniform character and quality, including capsules that would expire in less than three years. However, you then assigned these comingled batches new lot numbers and granted them an additional three-year shelf life. The new expiration dates are not supported by stability data and, in some instances, exceeded the expiration date of the returned product by up to 18 months. Your batch production records did not indicate you performed testing on these comingled batches before their redistribution.\u003C\u002Fp>\n\n\u003Cp>Your practices of conducting organoleptic examination on the returned product that was subjected to unknown conditions before return, making comingled batches by combining returned drug product with various lot numbers and expiration dates, and assigning a new product shelf life disregarding the expiration dates of the returned product are unacceptable.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and remediation plan to ensure the adequacy of your returned drug product handling and processing for redistribution. Provide a detailed action plan and associated procedures that should include, but not be limited to, the following:\u003Cbr>\n&nbsp; o Documentation of the conditions under which returned drug products have been held, stored, or shipped before, during and after return, reason for the return, quantity returned, date of disposition, and ultimate disposition, including procedures for destruction if doubt exists as to drug quality.\u003Cbr>\n&nbsp; o A procedure for ensuring the conditions under which returned drug products were held, stored, or shipped did not adversely affect the safety, identity, strength, quality or purity of the drug products.\u003C\u002Fp>\n\n\u003Cp>• Provide your action plan to address any product quality risks associated with the redistributed batches in the United States, including potential customer notifications and recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not adequately validate the process used to manufacture your over-the-counter drug product Super Colon Cleanse Stimulant Laxative. Your firm changed the formulation of your Super Colon Cleanse Stimulant Laxative in December 2017, including the removal of multiple components. You did not issue a process validation protocol and associated analytical testing report until November and December 2018, respectively, a year after your reformulation. Additionally, the only data supporting your November 2018 validation protocol, dated October 21, 2014, was from a test of the previous formulation and does not reflect the current drug product formulation. Since the December 2017 formulation change, your firm has manufactured and released at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches of the drug product which you distributed to the U.S. market with inadequate process validation data.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you would create a new standard operating procedure (SOP) for process validation and would document and review the results of the process validation study. Additionally, you indicated that you would commence manufacturing the first process validation batch in August 2021.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because failure to conduct process validation studies can result in product quality attribute failures. You also failed to address your justification for continuing to manufacture the drug product when you have not adequately demonstrated that your manufacturing processes are reproducible and controlled to yield a drug product of uniform character and quality.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fp>\n\n\u003Cp>• A timeline for performing appropriate process performance qualification for your marketed drug product.\u003C\u002Fp>\n\n\u003Cp>• Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fp>\n\n\u003Cp>• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit (QU). Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately validate the method for assay used for your Super Colon Cleanse laxative drug product release specification. Specifically, per your specifications, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Spectrophotometer method for assay is to be conducted at the wavelength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;as indicated in your finished drug product specifications. However, according to the data in the validation report you used the wavelength of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, the method validation report did not include system suitability, nor did it demonstrate that your modified method is fit for purpose.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that the method validation for assay was conducted at the correct wavelength. Your response is inadequate as follows.\u003C\u002Fp>\n\n\u003Cp>• It lacked supporting documentation to support your claim that the method validation for assay was conducted at the correct wavelength.\u003C\u002Fp>\n\n\u003Cp>• It did not provide a risk assessment for the drug product released using the assay method that was not adequately validated nor a justification for continuation of the drug product currently on the market.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of all test methods to ensure that they are adequately validated and suitable for their intended purposes.\u003C\u002Fp>\n\n\u003Cp>• A retrospective assessment of reserve samples for all finished drug products that are currently on the market, using an adequately validated test method, to ensure that your drug products conform to the drug product specification.\u003C\u002Fp>\n\n\u003Cp>• A review of the completeness, consistency, accuracy of data from your use of uncontrolled documents (e.g., legal pads) to document the data.\u003C\u002Fp>\n\n\u003Cp>• A review of applicable compendial methods for your product.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance documents \u003Cem>Q2(R1) Validation of Analytical Procedures and Analytical Procedures and Methods Validation for Drugs and Biologics\u003C\u002Fem> for general principles and approaches for method validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry\u003C\u002Fa> and \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics\u003C\u002Fa>, respectively.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>4. Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s stability program is inadequate. Specifically, you only placed \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;of your Super Colon Cleanse Stimulant Laxative drug product on stability and failed to perform any stability testing since at least September 2017. Furthermore, you did not have any stability data for drug product manufactured using the new formulation. Therefore, you lack sufficient stability data to substantiate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration of this drug product.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that the delay in conducting a stability study was because of restrained resources for the QU. You stated that you will initiate long-term stability testing for ongoing \u003Cstrong>(b)(4)\u003C\u002Fstrong> stability testing and accelerated stability testing for the determination of the expiration dating period of the drug product.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because your firm has been aware of the inadequacy of your stability program since the 2013 inspection. Subsequent inspections in 2015, 2018, and 2021, all had identical or similar observations in your stability program. Your response lacked information on what you did between 2013 and the current inspection to remediate your stability program.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your CAPA plan should include, but not be limited to:\u003Cbr>\n&nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf life claim remains valid\u003Cbr>\n&nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003C\u002Fp>\n\n\u003Cp>• All procedures that describe these and other elements of your remediated stability program.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> for general principles and approaches for stability testing at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm’s quality control unit failed to approve or reject all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product (21 CFR 211.22(c)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to establish, review, and approve all procedures, including those which may impact the safety, identity, strength, quality, and purity of your drug product. Specifically, your QU failed to implement SOPs that are critical to ensure the quality of the drug product, such as the SOPs for operating the equipment used to manufacture the drug product.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will create and revise corresponding SOPs. Your response is inadequate because you failed to provide supporting documentation (e.g., draft SOPs, training). Additionally, you provided similar responses to repeat or similar observations in the 2012, 2013, and 2018 inspections. Therefore, we have no assurance that your corrective actions will be implemented.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>• Your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recall.\u003C\u002Fp>\n\n\u003Cp>Refer to FDA’s guidance document: \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for general principles and approaches at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your inspectional history and significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Repeat Observations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In a previous inspection conducted in 2018, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your response with unique identifier \u003Cstrong>616877\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven E. Porter, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Rita Mediratta\n\nRecipient Title\n\nPresident\n\nHealth Plus Inc.\n\n13837 Magnolia Avenue\n\nChino, CA 91710\n\nUnited States\n\nritam@healthplusinc.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nDecember 29, 2021\n\nDear Ms. Mediratta:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Health Plus Inc., FEI 2027164, at 13837 Magnolia Avenue, Chino, California, from June 23 to July 1, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your July 20, 2021 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to ensure that returned drugs meet appropriate standards of safety, identity, strength, quality and purity prior to redistributing (21 CFR 211.204).\n\nYour firm’s handling of returned drug product before its redistribution is inadequate. For example, during the inspection, you were not able to provide documentation of adequate inspection and investigation of the returned product confirming the label conditions under which the returned drug product was held, stored, or shipped before its return and before redistributing. Furthermore, you failed to perform adequate testing to ensure the safety, identity, strength, quality, and purity of the returned product. Organoleptic examination alone is not sufficient to ensure that a product maintains its safety, identity, strength, purity, and quality after it has been in a situation where it may have been exposed to improper storage conditions.\n\nBefore redistribution, you combined returned capsules from various lots into new batches with new lot numbers. These new lots did not have uniform character and quality, including capsules that would expire in less than three years. However, you then assigned these comingled batches new lot numbers and granted them an additional three-year shelf life. The new expiration dates are not supported by stability data and, in some instances, exceeded the expiration date of the returned product by up to 18 months. Your batch production records did not indicate you performed testing on these comingled batches before their redistribution.\n\nYour practices of conducting organoleptic examination on the returned product that was subjected to unknown conditions before return, making comingled batches by combining returned drug product with various lot numbers and expiration dates, and assigning a new product shelf life disregarding the expiration dates of the returned product are unacceptable.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment and remediation plan to ensure the adequacy of your returned drug product handling and processing for redistribution. Provide a detailed action plan and associated procedures that should include, but not be limited to, the following:\n\no Documentation of the conditions under which returned drug products have been held, stored, or shipped before, during and after return, reason for the return, quantity returned, date of disposition, and ultimate disposition, including procedures for destruction if doubt exists as to drug quality.\n\no A procedure for ensuring the conditions under which returned drug products were held, stored, or shipped did not adversely affect the safety, identity, strength, quality or purity of the drug products.\n\n• Provide your action plan to address any product quality risks associated with the redistributed batches in the United States, including potential customer notifications and recalls.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and your firm’s quality control unit did not review and approve those procedures, including any changes (21 CFR 211.100(a)).\n\nYour firm did not adequately validate the process used to manufacture your over-the-counter drug product Super Colon Cleanse Stimulant Laxative. Your firm changed the formulation of your Super Colon Cleanse Stimulant Laxative in December 2017, including the removal of multiple components. You did not issue a process validation protocol and associated analytical testing report until November and December 2018, respectively, a year after your reformulation. Additionally, the only data supporting your November 2018 validation protocol, dated October 21, 2014, was from a test of the previous formulation and does not reflect the current drug product formulation. Since the December 2017 formulation change, your firm has manufactured and released at least (b)(4) batches of the drug product which you distributed to the U.S. market with inadequate process validation data.\n\nIn your response, you stated that you would create a new standard operating procedure (SOP) for process validation and would document and review the results of the process validation study. Additionally, you indicated that you would commence manufacturing the first process validation batch in August 2021.\n\nYour response is inadequate because failure to conduct process validation studies can result in product quality attribute failures. You also failed to address your justification for continuing to manufacture the drug product when you have not adequately demonstrated that your manufacturing processes are reproducible and controlled to yield a drug product of uniform character and quality.\n\nIn response to this letter, provide the following:\n\n• A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\n• A timeline for performing appropriate process performance qualification for your marketed drug product.\n\n• Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\n• An assessment of each drug product process to ensure that there is a data-driven and scientifically sound program that identifies and controls all sources of variability, such that your production processes, and will consistently meet appropriate specifications and manufacturing standards. This includes, but is not limited to, evaluating suitability of equipment for its intended use, sufficiency of detectability in your monitoring and testing systems, quality of input materials, and reliability of each manufacturing process step and control.\n\n• A comprehensive, independent assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your quality unit (QU). Your change management program should also include provisions for determining change effectiveness.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fprocess-validation-general-principles-and-practices.\n\n3. Your firm failed to establish and document the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not adequately validate the method for assay used for your Super Colon Cleanse laxative drug product release specification. Specifically, per your specifications, the (b)(4) Spectrophotometer method for assay is to be conducted at the wavelength of (b)(4) as indicated in your finished drug product specifications. However, according to the data in the validation report you used the wavelength of (b)(4). In addition, the method validation report did not include system suitability, nor did it demonstrate that your modified method is fit for purpose.\n\nIn your response, you stated that the method validation for assay was conducted at the correct wavelength. Your response is inadequate as follows.\n\n• It lacked supporting documentation to support your claim that the method validation for assay was conducted at the correct wavelength.\n\n• It did not provide a risk assessment for the drug product released using the assay method that was not adequately validated nor a justification for continuation of the drug product currently on the market.\n\nIn response to this letter, provide the following:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A comprehensive, independent assessment of all test methods to ensure that they are adequately validated and suitable for their intended purposes.\n\n• A retrospective assessment of reserve samples for all finished drug products that are currently on the market, using an adequately validated test method, to ensure that your drug products conform to the drug product specification.\n\n• A review of the completeness, consistency, accuracy of data from your use of uncontrolled documents (e.g., legal pads) to document the data.\n\n• A review of applicable compendial methods for your product.\n\nRefer to FDA’s guidance documents Q2(R1) Validation of Analytical Procedures and Analytical Procedures and Methods Validation for Drugs and Biologics for general principles and approaches for method validation at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq2r1-validation-analytical-procedures-text-and-methodology-guidance-industry and https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fanalytical-procedures-and-methods-validation-drugs-and-biologics, respectively.\n\n4. Your firm failed to follow a written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nYour firm’s stability program is inadequate. Specifically, you only placed (b)(4) of your Super Colon Cleanse Stimulant Laxative drug product on stability and failed to perform any stability testing since at least September 2017. Furthermore, you did not have any stability data for drug product manufactured using the new formulation. Therefore, you lack sufficient stability data to substantiate the (b)(4) expiration of this drug product.\n\nIn your response, you stated that the delay in conducting a stability study was because of restrained resources for the QU. You stated that you will initiate long-term stability testing for ongoing (b)(4) stability testing and accelerated stability testing for the determination of the expiration dating period of the drug product.\n\nYour response is inadequate because your firm has been aware of the inadequacy of your stability program since the 2013 inspection. Subsequent inspections in 2015, 2018, and 2021, all had identical or similar observations in your stability program. Your response lacked information on what you did between 2013 and the current inspection to remediate your stability program.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and corrective action and preventive action (CAPA) plan to ensure the adequacy of your stability program. Your CAPA plan should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\n• All procedures that describe these and other elements of your remediated stability program.\n\nRefer to FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products for general principles and approaches for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fq1ar2-stability-testing-new-drug-substances-and-products.\n\n5. Your firm’s quality control unit failed to approve or reject all procedures or specifications impacting on the identity, strength, quality, and purity of the drug product (21 CFR 211.22(c)).\n\nYou failed to establish, review, and approve all procedures, including those which may impact the safety, identity, strength, quality, and purity of your drug product. Specifically, your QU failed to implement SOPs that are critical to ensure the quality of the drug product, such as the SOPs for operating the equipment used to manufacture the drug product.\n\nIn your response, you stated that you will create and revise corresponding SOPs. Your response is inadequate because you failed to provide supporting documentation (e.g., draft SOPs, training). Additionally, you provided similar responses to repeat or similar observations in the 2012, 2013, and 2018 inspections. Therefore, we have no assurance that your corrective actions will be implemented.\n\nIn response to this letter, provide the following:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n• Your action plan to address any product quality or patient safety risks for your drug product in U.S. distribution, including potential customer notifications and recall.\n\nRefer to FDA’s guidance document: Quality Systems Approach to Pharmaceutical CGMP Regulations for general principles and approaches at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fquality-systems-approach-pharmaceutical-current-good-manufacturing-practice-regulations.\n\nQuality Unit Authority\n\nYour inspectional history and significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\n\nRepeat Observations at Facility\n\nIn a previous inspection conducted in 2018, FDA cited similar CGMP observations. You proposed specific remediation for these observations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance, and that the consultant evaluates the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your response with unique identifier 616877.\n\nIf you have any further questions, please contact Nayan Patel, Compliance Officer, by email at Nayan.Patel1@fda.hhs.gov or by phone at (303) 236-3010.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven E. Porter, Jr.\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations IV","Health Plus Inc.","health-plus-inc-616877-12292021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealth-plus-inc-616877-12292021","2026-10-26T08:08:53.613916+00:00","2022-01-25","616877","Ms. Rita Mediratta","2026-08-20T02:14:46.143+00:00","2021-12-29",{"id":158,"raw":159,"subject":164,"body_html":166,"body_text":167,"firm_name":168,"letter_id":169,"created_at":170,"fei_number":19,"letter_url":171,"updated_at":172,"action_type":22,"case_status":88,"posted_date":173,"marcs_cms_no":174,"product_type":175,"closeout_date":176,"issuing_office":163,"recipient_name":177,"body_fetched_at":178,"delivery_method":179,"recipient_title":19,"reference_number":19,"action_taken_date":180,"medical_device_id":19,"response_letter_date":19},3431,[160,161,162,163,164,13,165,13],"\u003Ctime datetime=\"2021-03-30T13:20:00Z\">03\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-16T04:00:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-03162021\">Anna Health, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations East IV","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-04042022\">\u003Ctime datetime=\"2022-04-08T04:00:00Z\">04\u002F08\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tin Huynh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Registered Agent\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Anna Health, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9724 N. Armenia Ave. Suite 400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tampa\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33612-7550\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:TinHuynh@gmail.com\"> TinHuynh@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>21-HAFE4-WL-03 \u002F CMS No. 613294\u003Cbr>\n\u003Cbr>\nDear Mr. Huynh:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that from October 2020 to March 2021, the United States Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.annahealth.com, and has determined that you take orders there for the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health. In addition, we observed that the product Immune Health is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. The claims on your website establish that the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are drugs under section 201 (g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), [21 U.S.C 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's homepage at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On the website www.annahealth.com:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Fucoidan product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Fucoidan is a powerful anticancerous supplement from the Sea.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan…triggers the natural immune system to attack and kill cancer cells.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan suppresses the generation of new blood vessels around cancer cells, cutting off their nutrient supply. This also prevents the cancer cells from spreading.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan provides an anticancer effect by way of inducing apoptosis.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan reduces side effects of chemotherapy and radiation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Prostate Health product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Improves…urinary flow.”\u003C\u002Fli>\n\t\u003Cli>“Relieves symptoms of BPH (Enlarged Prostate).”\u003C\u002Fli>\n\t\u003Cli>“Protects against prostate cancer.”\u003C\u002Fli>\n\t\u003Cli>“Reduces urinary urgency.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Under the tab “Main Ingredients”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Fritillaria Bulb (Zhe bei mu) …dissipates nodules…antitussive…reduces blood pressure”\u003C\u002Fli>\n\t\u003Cli>“Serenoa Repens (Saw palmetto) …treatment of benign prostatic hyperplasia (BPH)…reduces urinary problems…useful with prostate cancer”\u003C\u002Fli>\n\t\u003Cli>“Rhizoma Chuanxiong (Chuan xiong) …relieves headache…”\u003C\u002Fli>\n\t\u003Cli>“Angelica Sinensis (Dang gui) …treats painful obstructive syndromes…treats headache”\u003C\u002Fli>\n\t\u003Cli>“Cinnamonum Zeylanicum (Gui zhi) …reduces cholesterol level…antimicrobial…regulates blood sugar…reduces arthritis pain, joints [sic] pain”\u003C\u002Fli>\n\t\u003Cli>“Amur Corktree (Huang bai) …prevents prostate enlargement…reduces inflammation…anti-cancer”\u003C\u002Fli>\n\t\u003Cli>“Panax Quinquefolius (Xi yang shen) …repairs internal damage due to prolong stress…”\u003C\u002Fli>\n\t\u003Cli>“Radix Glycyrrhizae Uralensis (Gan cao) …reduces cough…relieves fever…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Children Liquid Vitamins product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Eliminates children symptoms of anemia, anorexia…”\u003C\u002Fli>\n\t\u003Cli>“[R]educes anxiety and attention deficit.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Under the tab “Main Ingredients”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Dipsacus Asper Radix (Xu duan)…relieves back pain”\u003C\u002Fli>\n\t\u003Cli>“Radix Rehmanniae Preparata (Sheng di) …treats anemic symptoms…antiinflammation… reduces hypertension, hyperlipidemia”\u003C\u002Fli>\n\t\u003Cli>“Radix Polygoni Multiflori (He shou wu) … treats anemia…calms hyperactive, treats insomnia…”\u003C\u002Fli>\n\t\u003Cli>“Ganoderma Lucidum (Fruit bodies with Opened Spores, Ling zhi) …antiviral…anticancer”\u003C\u002Fli>\n\t\u003Cli>“Fresh Royal Jelly (non-freeze dried) …anti-depression”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Immune Health product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“COVID-19 Influenza”\u003C\u002Fli>\n\t\u003Cli>“Helps Boost Your Immune System Against: Coronavirus…Influenza…Bronchitis…Dyspnea…Common Cold”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be directed to Mr. Ramon A. Hernandez, District Director\u002FProgram Division Director, Food and Drug Administration, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact LCDR Laura Kennedy, Compliance Officer, at \u003Cspan>(813) 915-7948\u003Cspan>\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan> or Laura.Kennedy@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director, San Juan District\u003Cbr>\nProgram Division Director,\u003Cbr>\nOffice of Human and Animal Food Operations,\u003Cbr>\nEast Division IV\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Tin Huynh\n\nRecipient Title\n\nRegistered Agent\n\nAnna Health, LLC\n\n9724 N. Armenia Ave. Suite 400\n\nTampa, FL 33612-7550\n\nUnited States\n\nTinHuynh@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nWARNING LETTER\n\n21-HAFE4-WL-03 \u002F CMS No. 613294\n\nDear Mr. Huynh:\n\nThis is to advise you that from October 2020 to March 2021, the United States Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.annahealth.com, and has determined that you take orders there for the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health. In addition, we observed that the product Immune Health is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. The claims on your website establish that the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are drugs under section 201 (g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), [21 U.S.C 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's homepage at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn the website www.annahealth.com:\n\nFucoidan product:\n\n“Fucoidan is a powerful anticancerous supplement from the Sea.”\n\n“Fucoidan…triggers the natural immune system to attack and kill cancer cells.”\n\n“Fucoidan suppresses the generation of new blood vessels around cancer cells, cutting off their nutrient supply. This also prevents the cancer cells from spreading.”\n\n“Fucoidan provides an anticancer effect by way of inducing apoptosis.”\n\n“Fucoidan reduces side effects of chemotherapy and radiation.”\n\nProstate Health product:\n\n“Improves…urinary flow.”\n\n“Relieves symptoms of BPH (Enlarged Prostate).”\n\n“Protects against prostate cancer.”\n\n“Reduces urinary urgency.”\n\nUnder the tab “Main Ingredients”:\n\n“Fritillaria Bulb (Zhe bei mu) …dissipates nodules…antitussive…reduces blood pressure”\n\n“Serenoa Repens (Saw palmetto) …treatment of benign prostatic hyperplasia (BPH)…reduces urinary problems…useful with prostate cancer”\n\n“Rhizoma Chuanxiong (Chuan xiong) …relieves headache…”\n\n“Angelica Sinensis (Dang gui) …treats painful obstructive syndromes…treats headache”\n\n“Cinnamonum Zeylanicum (Gui zhi) …reduces cholesterol level…antimicrobial…regulates blood sugar…reduces arthritis pain, joints [sic] pain”\n\n“Amur Corktree (Huang bai) …prevents prostate enlargement…reduces inflammation…anti-cancer”\n\n“Panax Quinquefolius (Xi yang shen) …repairs internal damage due to prolong stress…”\n\n“Radix Glycyrrhizae Uralensis (Gan cao) …reduces cough…relieves fever…”\n\nChildren Liquid Vitamins product:\n\n“Eliminates children symptoms of anemia, anorexia…”\n\n“[R]educes anxiety and attention deficit.”\n\nUnder the tab “Main Ingredients”:\n\n“Dipsacus Asper Radix (Xu duan)…relieves back pain”\n\n“Radix Rehmanniae Preparata (Sheng di) …treats anemic symptoms…antiinflammation… reduces hypertension, hyperlipidemia”\n\n“Radix Polygoni Multiflori (He shou wu) … treats anemia…calms hyperactive, treats insomnia…”\n\n“Ganoderma Lucidum (Fruit bodies with Opened Spores, Ling zhi) …antiviral…anticancer”\n\n“Fresh Royal Jelly (non-freeze dried) …anti-depression”\n\nImmune Health product:\n\n“COVID-19 Influenza”\n\n“Helps Boost Your Immune System Against: Coronavirus…Influenza…Bronchitis…Dyspnea…Common Cold”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be directed to Mr. Ramon A. Hernandez, District Director\u002FProgram Division Director, Food and Drug Administration, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact LCDR Laura Kennedy, Compliance Officer, at (813) 915-7948 or Laura.Kennedy@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director, San Juan District\n\nProgram Division Director,\n\nOffice of Human and Animal Food Operations,\n\nEast Division IV\n\n__________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.","Anna Health, LLC","anna-health-llc-613294-03162021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-03162021","2026-10-26T08:07:56.035163+00:00","2021-03-30","613294","Dietary SupplementsDrugs","2022-04-08","Mr. Tin Huynh","2026-08-20T03:14:19.258+00:00","VIA Electronic Mail","2021-03-16",{"id":182,"raw":183,"subject":188,"body_html":189,"body_text":190,"firm_name":191,"letter_id":192,"created_at":193,"fei_number":19,"letter_url":194,"updated_at":195,"action_type":22,"case_status":23,"posted_date":196,"marcs_cms_no":197,"product_type":67,"closeout_date":19,"issuing_office":187,"recipient_name":19,"body_fetched_at":198,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},608,[184,185,186,187,188,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025\">Las Villas Health Care LLC dba Villas Health\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Las Villas Health Care LLC dba Villas Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 Coral Way Suite 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coral Gables\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33134\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:office@villashealth.com\"> office@villashealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Villas Health:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.\u003Ca id=\"footnoteref1_f0fiwhc\" href=\"#footnote1_f0fiwhc\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and sildenafil products appear on your website:\u003Cbr>• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\u003Cbr>• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_f907p23\" href=\"#footnote2_f907p23\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_f0fiwhc\">\u003Ca href=\"#footnoteref1_f0fiwhc\">1\u003C\u002Fa>The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_f907p23\">\u003Ca href=\"#footnoteref2_f907p23\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nLas Villas Health Care LLC dba Villas Health\n\n401 Coral Way Suite 201\n\nCoral Gables, FL 33134\n\nUnited States\n\noffice@villashealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nVillas Health:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.1 As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and sildenafil products appear on your website:\n• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\n• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Las Villas Health Care LLC dba Villas Health","las-villas-health-care-llc-dba-villas-health-716504-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025","2026-10-26T08:09:12.523015+00:00","2025-09-16","716504","2026-08-19T16:23:04.859+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2025-09-09",{"id":202,"raw":203,"subject":206,"body_html":207,"body_text":208,"firm_name":209,"letter_id":210,"created_at":85,"fei_number":19,"letter_url":211,"updated_at":212,"action_type":22,"case_status":23,"posted_date":213,"marcs_cms_no":214,"product_type":91,"closeout_date":19,"issuing_office":78,"recipient_name":215,"body_fetched_at":216,"delivery_method":95,"recipient_title":19,"reference_number":217,"action_taken_date":213,"medical_device_id":19,"response_letter_date":19},345,[204,204,205,78,206,13,13,13],"\u003Ctime datetime=\"2026-02-10T05:00:00Z\">02\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026\">ProDx Health\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via UPS and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-720762\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Andreas Kogelnik, MD, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder &amp; Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ProDx Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1190 O'Brien Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Menlo Park\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94025\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@prodxhealth.com\"> support@prodxhealth.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 10, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>CBER 26-720762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Andreas Kogelnik:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act).\u003Ca id=\"footnoteref1_ygaot82\" href=\"#footnote1_ygaot82\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp; &nbsp;Under section 201(h)(1) of the FD&amp;C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>FDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. &nbsp;Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&amp;C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&amp;C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&amp;C Act, 21 U.S.C. 360j(g). &nbsp;Your sample self-collection kits are also misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&amp;C Act, 21 U.S.C. 360(k). &nbsp;\u003C\u002Fp>\u003Cp>FDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\u003C\u002Fp>\u003Cp>Without appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\u003C\u002Fp>\u003Cp>The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. &nbsp;Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. &nbsp;If you believe that your firm’s sample self-collection kits are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. &nbsp;Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002Fs\u002F\u003Cbr>Melissa J. Mendoza\u003Cbr>Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_ygaot82\">\u003Ca href=\"#footnoteref1_ygaot82\">1\u003C\u002Fa>The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia UPS and EMAIL\n\nReference #:\n\nCBER 26-720762\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nAndreas Kogelnik, MD, PhD\n\nRecipient Title\n\nFounder & Chief Executive Officer\n\nProDx Health\n\n1190 O'Brien Dr\n\nMenlo Park, CA 94025\n\nUnited States\n\nsupport@prodxhealth.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nFebruary 10, 2026\nCBER 26-720762\nDear Dr. Andreas Kogelnik:\nThe United States Food and Drug Administration (FDA or the Agency) has learned that your firm, ProDx Health, is offering for sale in the United States human immunodeficiency virus (HIV) serological diagnostic sample self-collection kits (hereinafter, your “sample self-collection kits”) without marketing authorization, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act).1 Under section 201(h)(1) of the FD&C Act, 21 U.S.C. 321(h)(1), your sample self-collection kits are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nFDA has reviewed your company’s website at https:\u002F\u002Fprodxhealth.com (last visited February 2026) and your firm’s February 3, 2026 response to previous FDA correspondence. Based on our review of these materials, your firm offers its sample self-collection kits for delivery to individuals and intends for these individuals to use the kits to self-collect serological samples and ship those samples to laboratories for HIV testing. FDA has determined that your sample self-collection kits are adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B) because they do not have an approved premarket approval application (PMA) in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g). Your sample self-collection kits are also misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o), because notification of the intent to introduce the device into commercial distribution has not been provided to the Agency, as required by section 510(k) of the FD&C Act, 21 U.S.C. 360(k).\nFDA has not authorized your firm’s sample self-collection kits for use in HIV serological diagnostic testing. Notably, this letter focuses on your sample self-collection kits and is not intended to be a comprehensive list of potential issues with your firm’s products.\nWithout appropriate testing, data review, and marketing authorization, there is a lack of assurance of the safety and effectiveness of your sample self-collection kits. Self-collection raises several issues of importance, including, for example, whether the user can safely and properly collect the specimen, if the sample has been properly shipped, and if there is adequate stability of the specimen given the time lapse between collection and testing and the potential impact of shipping conditions. We note that there are FDA-approved over-the-counter HIV self-tests that can help meet the needs of individuals who wish to test themselves at home or who are unable to access other testing options.\nThe violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. FDA requests that your firm immediately cease any activities that result in the misbranding or adulteration of your sample self-collection kits. Your firm should take prompt action to address the violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your firm’s sample self-collection kits are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration in your response to this letter.\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov.\nSincerely,\n\u002Fs\u002F\nMelissa J. Mendoza\nDirector\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n\n1The letter FDA issued you on January 8, 2026, erroneously referred to your device as a “dried blood\nspot (DBS) card” self-collection kit. We have removed that letter from our website and are issuing this\namended Warning Letter.","ProDx Health","prodx-health-720762-02102026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fprodx-health-720762-02102026","2026-10-26T08:09:44.671953+00:00","2026-02-10","720762","Andreas Kogelnik, MD, PhD","2026-08-19T05:07:15.753+00:00","CBER 26-720762",{"id":219,"raw":220,"subject":224,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":193,"fei_number":19,"letter_url":229,"updated_at":230,"action_type":22,"case_status":23,"posted_date":231,"marcs_cms_no":232,"product_type":233,"closeout_date":19,"issuing_office":187,"recipient_name":234,"body_fetched_at":235,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":236,"medical_device_id":19,"response_letter_date":19},779,[221,222,223,187,224,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-09T04:00:00Z\">07\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fscope-health-inc-695085-07092025\">Scope Health Inc\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tom Freyne\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Scope Health Inc\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>79 Madison Ave, Fl 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New York\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10016\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@optase.com\"> hello@optase.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 9, 2025\u003C\u002Fp>\u003Cp>RE: 695085\u003C\u002Fp>\u003Cp>Dear Mr. Freyne:\u003C\u002Fp>\u003Cp>This letter is to advise you that on August 28, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address optase.com where your ophthalmic drug products are available for purchase in the United States without a prescription.\u003C\u002Fp>\u003Cp>Based on our review, your MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d). In addition, your Dry Eye Intense Drops (multi-use bottle) product is misbranded under section 502(f)(2) of the FD&amp;C Act, 21 U.S.C. 352(f)(2), and your Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), and HYLO Night Eye Ointment products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples of claims from the products’ labeling, including on your website listed above, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>MGD Advanced Dry Eye Drops\u003C\u002Fu>\u003Cbr>“OPTASE® MGD Advanced Drops provide a preservative free combination of ingredients designed to relieve dry eye symptoms . . . An Advanced Lipid-based drop for Evaporative Dry Eye &amp; MGD Symptoms . . .” [from your product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fmgd-advanced-dry-eye\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Dry Eye Intense Drops (multi-use bottle and single dose)\u003C\u002Fu>\u003Cbr>“The special formulation of OPTASE® Intense provides comfort from moderate to severe dry eye including dry eye post operatively. . . .” [from your product websites at https:\u002F\u002Foptase.com\u002Fproduct\u002Fdry-eye-intense-drops\u002F and https:\u002F\u002Foptase.com\u002Fproduct\u002Fdryeye-intense-drops-sdu\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Allegro Eye Drops\u003C\u002Fu>\u003Cbr>“Optase® Allegro Eye Drops is a preservative free lubricant that acts as a first line of defense to stop environmental irritants in their tracks . . . by creating a more protective tear film and strengthening the ocular mucosa. This unique formulation . . . creates a water rich shield to protect epithelial cells from environmental irritants” [from the product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fallegro-eye-drops\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>HYLO Night Eye Ointment\u003C\u002Fu>\u003Cbr>“How It Works . . . OPTASE® HYLO Night™ relieves night-time symptoms of burning, sore, dry eyes by forming a comfortable long-lasting protective film on the eyes. . . .” [from your product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fhylo-night\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Tea Tree Oil Eyelid Wipes\u003C\u002Fu>\u003Cbr>“Cleaning your eyelids daily will help remove debris, bacteria and oils that can often lead to Blepharitis, MGD or Dry Eye symptoms. . . . FORMULATED WITH NATURAL INGREDIENTS FOR SENSITIVE SKIN . . . Anti-Inflammatory Tea Tree Leaf Oil . . .” [from your product website https:\u002F\u002Foptase.com\u002Fproduct\u002Ftea-tree-oil-wipes\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Tea Tree Oil Eyelid Gel\u003C\u002Fu>\u003Cbr>“OPTASE® Tea Tree Oil Gel . . . can be used as part of the recommended management regimen for Blepharitis . . . GENTLE FORMULA ENRICHED WITH NATURAL INGREDIENTS . . . Anti-Inflammatory Tea Tree Leaf Oil . . .” [from your product website https:\u002F\u002Foptase.com\u002Fproduct\u002Ftea-tree-oil-gel\u002F]\u003C\u002Fp>\u003Cp>\u003Cu>Multiple products\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“About Meibomian Gland Dysfunction (MGD) . . . MGD is a chronic condition which occurs when the glands in the eyelids don’t produce enough oil, or the oil that is produced is of poor quality. . . . How to manage MGD . . . Cleanse . . . maintain clean eyelids and lashes to ensure there is nothing that can block oils from reaching the surface of the eye. . . . Hydrate . . . If you suffer from severe MGD you may require an eye drop that can supplement the oily layer in your tear film to reduce tear evaporation. . . . Addressing the root cause of MGD . . . can also lead to a reduction of symptoms in related conditions such as Dry Eye Disease (DED) and Blepharitis. . . . Products To Relieve Symptoms . . . MGD Advanced Dry Eye Drops . . . Dry Eye Intense Drops . . . Single Dose Dry Eye Intense Drops . . . HYLO Night Eye Ointment” [from your website at https:\u002F\u002Foptase.com\u002Fabout-mgd\u002F]\u003C\u002Fp>\u003Cp>“About Blepharitis . . . What is Blepharitis . . . There are two main types of Blepharitis: . . . Anterior Blepharitis . . . This is where the inflammation affects the skin around the base of your eyelashes . . . Posterior Blepharitis . . . This is where the inflammation affects your eyelid glands. Meibomian Gland Dysfunction (MGD) can occur when the eyelid glands become clogged. . . . How to manage Blepharitis . . . Daily lid hygiene is key to the management of Blepharitis and other conditions of the eye such as Meibomian Gland Dysfunction (MGD) and Styes. . . . Products To Relieve Symptoms . . . Tea Tree Oil Eyelid Wipes . . . Tea Tree Oil Eyelid Gel . . . Protect Eyelid Cleansing Spray” [from your website at https:\u002F\u002Foptase.com\u002Fabout-blepharitis\u002F]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, your MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray products are intended for use as topical ophthalmic drug products. As described below, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. Your above-referenced topical ophthalmic drug products are not generally recognized as safe and effective (GRASE) for their above referenced uses\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from the FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the products identified above.\u003C\u002Fp>\u003Cp>In addition, under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application—commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M018, Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your nonprescription ophthalmic drug products MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, and HYLO Night Eye Ointment do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\u003C\u002Fp>\u003Cp>\u003Cstrong>Ophthalmic Demulcent Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), and Allegro Eye Drops are demulcent products formulated with several active ingredients that are not permitted for OTC monograph ophthalmic demulcent drug products. Specifically, according to your products’ labeling, your MGD Advanced Dry Eye Drops product is formulated with the active ingredients glycerin, sacha inchi seed oil, trehalose, and sodium hyaluronate. Your Dry Eye Intense Drops products are formulated with glycerin and sodium hyaluronate and your Allegro Eye Drops product is formulated with hydroxyethyl cellulose and Ectoin®.\u003C\u002Fp>\u003Cp>However, sacha inchi seed oil, trehalose, sodium hyaluronate, and Ectoin® are not active ingredients permitted for ophthalmic demulcent drug products under M018.12. We note that, although you identify these ingredients as inactive ingredients on the product label, statements on your website show that they are active ingredients in their respective products because they are intended to furnish pharmacological activity for the treatment of a disease or condition.\u003Cem>\u003Cstrong>\u003Csup>3 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Examples of these statements include, “Contains Sacha inchi seed oil, Trehalose and Hyaluronic Acid which combine to strengthen and replenish your tear film, and protect your eyes. . . .” (MGD Advanced Dry Eye Drops); “INACTIVE INGREDIENT: Sodium hyaluronate . . . Binds to eye surface with comfortable, soothing properties” (Dry Eye Intense Drops); and “This unique formulation includes . . . Ectoin® which creates a water rich shield to protect epithelial cells from environmental irritants . . .” (Allegro Eye Drops). Thus, these ingredients are active ingredients and, because they are not active ingredients permitted under M018.12, the MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, and Allegro Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent product as set forth in M018.\u003C\u002Fp>\u003Cp>\u003Cstrong>Ophthalmic Emollient Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your HYLO Night Eye Ointment product is an emollient product formulated with the active ingredient vitamin A. However, vitamin A is not an active ingredient that is permitted for ophthalmic emollient drug products under M018.14. We note that, although you identify this ingredient as an inactive ingredient on the product label, statements on your website show that it is an active ingredient in the product because it is intended to furnish pharmacological activity for the treatment of a disease or condition.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> For example, your product website states, “OPTASE® HYLO Night™ is a soft and consistent ointment, containing Vitamin A . . . to help improve the tear film and protect the surface of the eye.” Thus, this is an active ingredient that is not permitted under M018.14, therefore your HYLO Night Eye Ointment product does not conform with the conditions for lawful marketing of an OTC ophthalmic emollient product as set forth in M018.\u003C\u002Fp>\u003Cp>For the above reasons, your above-referenced products MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Further, your Dry Eye Intense Drops (multi-use bottle) product is misbranded under section 502(f)(2) of the FD&amp;C Act because its labeling does not “\u003Cem>[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users…\u003C\u002Fem>”. Here, the warning described in M018.60, “\u003Cem>If solution changes color or becomes cloudy, do not use\u003C\u002Fem>”, is required for ophthalmic demulcent drug products, such as your Dry Eye Intense Drops (multi-use bottle) product, to be legally marketed under section 505G of the FD&amp;C Act. This monograph warning also falls within the scope of the warnings described in section 502(f)(2) of the FD&amp;C Act. Thus, omission of this monograph warning from the product labeling renders the product misbranded under section 502(f)(2).\u003C\u002Fp>\u003Cp>Additionally, your Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, (multi-use bottle and single dose), and HYLO Night Eye Ointment products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section (as described above) and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695085” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your above-referenced topical ophthalmic drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs @ FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Id.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nTom Freyne\n\nRecipient Title\n\nCEO\n\nScope Health Inc\n\n79 Madison Ave, Fl 8\n\nNew York, NY 10016\n\nUnited States\n\nhello@optase.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nJuly 9, 2025\nRE: 695085\nDear Mr. Freyne:\nThis letter is to advise you that on August 28, 2024 the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including on your website at the internet address optase.com where your ophthalmic drug products are available for purchase in the United States without a prescription.\nBased on our review, your MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). In addition, your Dry Eye Intense Drops (multi-use bottle) product is misbranded under section 502(f)(2) of the FD&C Act, 21 U.S.C. 352(f)(2), and your Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), and HYLO Night Eye Ointment products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nMGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples of claims from the products’ labeling, including on your website listed above, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nMGD Advanced Dry Eye Drops\n“OPTASE® MGD Advanced Drops provide a preservative free combination of ingredients designed to relieve dry eye symptoms . . . An Advanced Lipid-based drop for Evaporative Dry Eye & MGD Symptoms . . .” [from your product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fmgd-advanced-dry-eye\u002F]\nDry Eye Intense Drops (multi-use bottle and single dose)\n“The special formulation of OPTASE® Intense provides comfort from moderate to severe dry eye including dry eye post operatively. . . .” [from your product websites at https:\u002F\u002Foptase.com\u002Fproduct\u002Fdry-eye-intense-drops\u002F and https:\u002F\u002Foptase.com\u002Fproduct\u002Fdryeye-intense-drops-sdu\u002F]\nAllegro Eye Drops\n“Optase® Allegro Eye Drops is a preservative free lubricant that acts as a first line of defense to stop environmental irritants in their tracks . . . by creating a more protective tear film and strengthening the ocular mucosa. This unique formulation . . . creates a water rich shield to protect epithelial cells from environmental irritants” [from the product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fallegro-eye-drops\u002F]\nHYLO Night Eye Ointment\n“How It Works . . . OPTASE® HYLO Night™ relieves night-time symptoms of burning, sore, dry eyes by forming a comfortable long-lasting protective film on the eyes. . . .” [from your product website at https:\u002F\u002Foptase.com\u002Fproduct\u002Fhylo-night\u002F]\nTea Tree Oil Eyelid Wipes\n“Cleaning your eyelids daily will help remove debris, bacteria and oils that can often lead to Blepharitis, MGD or Dry Eye symptoms. . . . FORMULATED WITH NATURAL INGREDIENTS FOR SENSITIVE SKIN . . . Anti-Inflammatory Tea Tree Leaf Oil . . .” [from your product website https:\u002F\u002Foptase.com\u002Fproduct\u002Ftea-tree-oil-wipes\u002F]\nTea Tree Oil Eyelid Gel\n“OPTASE® Tea Tree Oil Gel . . . can be used as part of the recommended management regimen for Blepharitis . . . GENTLE FORMULA ENRICHED WITH NATURAL INGREDIENTS . . . Anti-Inflammatory Tea Tree Leaf Oil . . .” [from your product website https:\u002F\u002Foptase.com\u002Fproduct\u002Ftea-tree-oil-gel\u002F]\nMultiple products\n“About Meibomian Gland Dysfunction (MGD) . . . MGD is a chronic condition which occurs when the glands in the eyelids don’t produce enough oil, or the oil that is produced is of poor quality. . . . How to manage MGD . . . Cleanse . . . maintain clean eyelids and lashes to ensure there is nothing that can block oils from reaching the surface of the eye. . . . Hydrate . . . If you suffer from severe MGD you may require an eye drop that can supplement the oily layer in your tear film to reduce tear evaporation. . . . Addressing the root cause of MGD . . . can also lead to a reduction of symptoms in related conditions such as Dry Eye Disease (DED) and Blepharitis. . . . Products To Relieve Symptoms . . . MGD Advanced Dry Eye Drops . . . Dry Eye Intense Drops . . . Single Dose Dry Eye Intense Drops . . . HYLO Night Eye Ointment” [from your website at https:\u002F\u002Foptase.com\u002Fabout-mgd\u002F]\n“About Blepharitis . . . What is Blepharitis . . . There are two main types of Blepharitis: . . . Anterior Blepharitis . . . This is where the inflammation affects the skin around the base of your eyelashes . . . Posterior Blepharitis . . . This is where the inflammation affects your eyelid glands. Meibomian Gland Dysfunction (MGD) can occur when the eyelid glands become clogged. . . . How to manage Blepharitis . . . Daily lid hygiene is key to the management of Blepharitis and other conditions of the eye such as Meibomian Gland Dysfunction (MGD) and Styes. . . . Products To Relieve Symptoms . . . Tea Tree Oil Eyelid Wipes . . . Tea Tree Oil Eyelid Gel . . . Protect Eyelid Cleansing Spray” [from your website at https:\u002F\u002Foptase.com\u002Fabout-blepharitis\u002F]\nUnapproved New Drug Violations\nBased on the above labeling evidence, your MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray products are intended for use as topical ophthalmic drug products. As described below, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. Your above-referenced topical ophthalmic drug products are not generally recognized as safe and effective (GRASE) for their above referenced uses1 and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). With certain exceptions not applicable here, a new drug may not be legally introduced or delivered for introduction into interstate commerce without an approved application from the FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the products identified above.\nIn addition, under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application—commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, Over-the-Counter Monograph M018, Ophthalmic Drug Products for Over-the-Counter Human Use (hereinafter M018).2 However, your nonprescription ophthalmic drug products MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, and HYLO Night Eye Ointment do not conform to the conditions specified in M018 for the reasons described below, and thus cannot be legally marketed under section 505G.\nOphthalmic Demulcent Products\nYour MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), and Allegro Eye Drops are demulcent products formulated with several active ingredients that are not permitted for OTC monograph ophthalmic demulcent drug products. Specifically, according to your products’ labeling, your MGD Advanced Dry Eye Drops product is formulated with the active ingredients glycerin, sacha inchi seed oil, trehalose, and sodium hyaluronate. Your Dry Eye Intense Drops products are formulated with glycerin and sodium hyaluronate and your Allegro Eye Drops product is formulated with hydroxyethyl cellulose and Ectoin®.\nHowever, sacha inchi seed oil, trehalose, sodium hyaluronate, and Ectoin® are not active ingredients permitted for ophthalmic demulcent drug products under M018.12. We note that, although you identify these ingredients as inactive ingredients on the product label, statements on your website show that they are active ingredients in their respective products because they are intended to furnish pharmacological activity for the treatment of a disease or condition.3 Examples of these statements include, “Contains Sacha inchi seed oil, Trehalose and Hyaluronic Acid which combine to strengthen and replenish your tear film, and protect your eyes. . . .” (MGD Advanced Dry Eye Drops); “INACTIVE INGREDIENT: Sodium hyaluronate . . . Binds to eye surface with comfortable, soothing properties” (Dry Eye Intense Drops); and “This unique formulation includes . . . Ectoin® which creates a water rich shield to protect epithelial cells from environmental irritants . . .” (Allegro Eye Drops). Thus, these ingredients are active ingredients and, because they are not active ingredients permitted under M018.12, the MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, and Allegro Eye Drops products do not conform with the conditions for lawful marketing of an OTC ophthalmic demulcent product as set forth in M018.\nOphthalmic Emollient Products\nYour HYLO Night Eye Ointment product is an emollient product formulated with the active ingredient vitamin A. However, vitamin A is not an active ingredient that is permitted for ophthalmic emollient drug products under M018.14. We note that, although you identify this ingredient as an inactive ingredient on the product label, statements on your website show that it is an active ingredient in the product because it is intended to furnish pharmacological activity for the treatment of a disease or condition.4 For example, your product website states, “OPTASE® HYLO Night™ is a soft and consistent ointment, containing Vitamin A . . . to help improve the tear film and protect the surface of the eye.” Thus, this is an active ingredient that is not permitted under M018.14, therefore your HYLO Night Eye Ointment product does not conform with the conditions for lawful marketing of an OTC ophthalmic emollient product as set forth in M018.\nFor the above reasons, your above-referenced products MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use bottle and single dose), Allegro Eye Drops, HYLO Night Eye Ointment, Tea Tree Oil Eyelid Wipes, Tea Tree Oil Eyelid Gel, and Protect Eyelid Cleansing Spray are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nFurther, your Dry Eye Intense Drops (multi-use bottle) product is misbranded under section 502(f)(2) of the FD&C Act because its labeling does not “[bear]…such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users…”. Here, the warning described in M018.60, “If solution changes color or becomes cloudy, do not use”, is required for ophthalmic demulcent drug products, such as your Dry Eye Intense Drops (multi-use bottle) product, to be legally marketed under section 505G of the FD&C Act. This monograph warning also falls within the scope of the warnings described in section 502(f)(2) of the FD&C Act. Thus, omission of this monograph warning from the product labeling renders the product misbranded under section 502(f)(2).\nAdditionally, your Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, (multi-use bottle and single dose), and HYLO Night Eye Ointment products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section (as described above) and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “695085” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_____________________________\n1 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your above-referenced topical ophthalmic drug products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling.\n2 M018 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000023, available at FDA’s website OTC Monographs @ FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n3 See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n4 Id.","Scope Health Inc","scope-health-inc-695085-07092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fscope-health-inc-695085-07092025","2026-10-26T08:09:54.666726+00:00","2025-07-15","695085","Drugs Over-the-Counter Drugs","Tom Freyne","2026-08-19T16:36:15.173+00:00","2025-07-09",{"id":238,"raw":239,"subject":164,"body_html":245,"body_text":246,"firm_name":247,"letter_id":248,"created_at":249,"fei_number":19,"letter_url":250,"updated_at":251,"action_type":22,"case_status":88,"posted_date":252,"marcs_cms_no":253,"product_type":175,"closeout_date":254,"issuing_office":243,"recipient_name":255,"body_fetched_at":256,"delivery_method":257,"recipient_title":19,"reference_number":19,"action_taken_date":258,"medical_device_id":19,"response_letter_date":19},2340,[240,241,242,243,164,13,244,13],"\u003Ctime datetime=\"2022-11-17T13:30:00Z\">11\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-14T05:00:00Z\">11\u002F14\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022\">Calroy Health Sciences, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-07192023\">\u003Ctime datetime=\"2023-07-21T04:00:00Z\">07\u002F21\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chen and Mr. Hoyt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Calroy Health Sciences, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14362 N Frank Lloyd Wright, Suite 1000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 14, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 636311\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen and Mr. Hoyt:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\u003C\u002Fp>\n\n\u003Cp>On your Arterosil product page at www.arterosil.com:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Under the “Patient Education” Tab\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\u003C\u002Fli>\n\t\u003Cli>&nbsp;\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; &nbsp;and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chen and Mr. Hoyt\n\nCalroy Health Sciences, LLC\n\n14362 N Frank Lloyd Wright, Suite 1000\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nNovember 14, 2022\n\nRE: 636311\n\nDear Mr. Chen and Mr. Hoyt:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.arterosil.com in October 2022 and has determined that you take orders there for your Arterosil product. The claims on your website establish that Arterosil is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that Arterosil is intended for use as a drug include the following:\n\nOn your Arterosil product page at www.arterosil.com:\n\n\"Arterosil® - the only glycocalyx regenerating product patented to stabilize and regress vulnerable plaque…\"\n\n“The primary contributors to breakdown of the endothelial glycocalyx are high blood glucose, oxidative stress and inflammation. Pathologies associated with impaired endothelial glycocalyx include: Coronary heart disease, Hyperglycemia, Diabetes, Renal diseases, Lacunar stroke, Severe trauma…”\n\n\"Leukocyte Adhesion Study….Finding: Arterosil prevents the increase of leukocyte adhesion and inhibits endothelium-mediated inflammation\"\n\nUnder the “Patient Education” Tab\n\n\"What you need to remember is that LDL can only cause problems if it lodges in the artery wall. A healthy glycocalyx can slow or stop that from happening.\"\n\n\"MRI Carotid Plaque Regression Study….Finding: Arterosil caused a significant reduction of lipid-rich necrotic core (LRNC) of carotid atherosclerotic plaque\"\n\n\"Plaque Reduction Retrospective Case Study….Finding: Arterosil caused a significant reduction of artherosclerotic [sic] plaque.\"\n\n\"Hypertension Study….Finding: Arterosil significantly lowered diastolic blood pressure\"\n\n\"Diabetic Neuropathy Study….Finding: Arterosil improved objective and subjective measures of neuropathy.\"\n\nYour Arterosil product is not generally recognized as safe and effective for the above referenced uses and, therefore, Arterosil is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Arterosil is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Arterosil fails to bear adequate directions for its intended use and, therefore, Arterosil is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nWithin fifteen working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address these matters. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to Dr. Aaron Dotson, Compliance Officer, United States Food and Drug Administration, Center for Food Safety and Applied Nutrition, 5001 Campus Drive, Office of Compliance (HFS-608), Division of Enforcement, College Park, Maryland 20740-3835 or via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition\n\nFood and Drug Administration","Calroy Health Sciences, LLC","calroy-health-sciences-llc-636311-11142022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcalroy-health-sciences-llc-636311-11142022","2026-10-26T08:08:10.528128+00:00","2022-11-17","636311","2023-07-21","Mr. Chen and Mr. Hoyt","2026-08-20T01:25:36.732+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","2022-11-14",{"id":260,"raw":261,"subject":188,"body_html":264,"body_text":265,"firm_name":266,"letter_id":267,"created_at":193,"fei_number":19,"letter_url":268,"updated_at":269,"action_type":22,"case_status":23,"posted_date":196,"marcs_cms_no":270,"product_type":67,"closeout_date":19,"issuing_office":187,"recipient_name":19,"body_fetched_at":271,"delivery_method":272,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},661,[262,185,263,187,188,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felite-health-center-715869-09092025\">Elite Health Center\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Elite Health Center\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>273 Pascack Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Washington Twp\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07676\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:eliteinfonj@elitehealthcenter.com\"> eliteinfonj@elitehealthcenter.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Elite Health Center:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Feliterapidfatloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claim concerning compounded semaglutide products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claim concerning compounded semaglutide products appears on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Compounded semaglutide was first introduced and patented in 2016, and FDA approved as a type 2 diabetes treatment in 2017. It wasn’t until 2021 that compounded semaglutide was approved as a treatment for obesity!”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claim identified in this letter puts you on notice of our concerns but does not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nElite Health Center\n\n273 Pascack Rd\n\nWashington Twp, NJ 07676\n\nUnited States\n\neliteinfonj@elitehealthcenter.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nElite Health Center:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Feliterapidfatloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.1 As described below, your claim concerning compounded semaglutide products is false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claim concerning compounded semaglutide products appears on your website:\n“Compounded semaglutide was first introduced and patented in 2016, and FDA approved as a type 2 diabetes treatment in 2017. It wasn’t until 2021 that compounded semaglutide was approved as a treatment for obesity!”\nCompounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, this claim is false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claim identified in this letter puts you on notice of our concerns but does not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n_______________________\n1 The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Elite Health Center","elite-health-center-715869-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felite-health-center-715869-09092025","2026-10-26T08:08:34.660515+00:00","715869","2026-08-19T16:20:59.709+00:00","Via Electronic Mail - Delivery and Read Receipt Requested",{"id":274,"raw":275,"subject":281,"body_html":282,"body_text":283,"firm_name":284,"letter_id":285,"created_at":43,"fei_number":19,"letter_url":286,"updated_at":287,"action_type":22,"case_status":88,"posted_date":288,"marcs_cms_no":289,"product_type":134,"closeout_date":290,"issuing_office":124,"recipient_name":291,"body_fetched_at":292,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":293,"medical_device_id":19,"response_letter_date":19},1018,[276,277,278,124,279,13,280,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-28T05:00:00Z\">01\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-01282025\">Elanco Animal Health\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-09112025\">\u003Ctime datetime=\"2025-09-19T04:00:00Z\">09\u002F19\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey Simmons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Elanco Animal Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 Innovation Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greenfield\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 28, 2025\u003C\u002Fp>\u003Cp>Re: NADA 141-585, Zenrelia™ (ilunocitinib tablets)\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #: 695170\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Mr. Simmons:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Zenrelia (ilunocitinib tablets) including your veterinarian product website,\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> the consumer directed website,\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> your Product Brochure and Itch Tracker,\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which is linked on both websites, and a slide deck titled “Reach for Zen: New Relief for Dogs with Atopic Dermatitis\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>” and noted false or misleading claims and representations about the safety and effectiveness of Zenrelia. These promotional communications misbrand Zenrelia within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). FD&amp;C Act section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; see also section 201(n) [21 USC 321(n)]. It is a prohibited act to distribute a misbranded product in interstate commerce. FD&amp;C Act section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because the misleading promotional communications create a misleading impression regarding the safety and effectiveness of Zenrelia, which is a recently-approved veterinary drug in the Janus Kinase (JAK) inhibitor drug class.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Zenrelia is indicated for “control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.”\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Zenrelia’s FDA-approved Prescribing Information (PI) contains a boxed and bolded warning of the risk of “fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine” in dogs receiving Zenrelia. Therefore, the boxed warning states to discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.\u003C\u002Fp>\u003Cp>The PI contains additional warning language including:\u003C\u002Fp>\u003Cp>“Dogs should be monitored for the development of infections because Zenrelia may increase susceptibility to opportunistic infections, including demodicosis, interdigital furunculosis, coccidiosis, and pneumonia, and exacerbation of subclinical or uncomplicated infections (see \u003Cstrong>Target Animal Safety\u003C\u002Fstrong> and \u003Cstrong>Adverse Reactions\u003C\u002Fstrong>).”\u003Cbr>…\u003Cbr>“Zenrelia may cause a progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count (see \u003Cstrong>Target Animal Safety\u003C\u002Fstrong>).”\u003Cbr>“New neoplastic conditions (benign and malignant) were observed in dogs treated with Zenrelia during clinical studies (see \u003Cstrong>Adverse Reactions\u003C\u002Fstrong>).”\u003C\u002Fp>\u003Cp>The PI contains additional adverse event, warning, precaution, and contraindication information.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&amp;C Act sections 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>\u003Cu>Omitted Information\u003C\u002Fu>\u003C\u002Fp>\u003Cp>The websites mentioned above and the Product Brochure and Itch tracker omit the phrase “from modified live virus vaccines” from the boxed warning found in the Important Safety Information (ISI) sections. The Vaccine Response Study in the Target Animal Safety section of the PI describes a dog that was administered Zenrelia that developed lethargy, depression, poor body condition, and weakness after receiving a modified live virus (MLV) vaccination and was subsequently euthanized. This dog was later diagnosed with adenoviral hepatitis and pancreatitis that “were concluded to be vaccine-induced, secondary to Zenrelia-induced immunosuppression.” Omitting the phrase “from modified live virus vaccines” in promotional material is misleading because the fatal vaccine-induced disease occurred after administration of a MLV DHPP vaccination,\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a core vaccination for all dogs.\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Therefore, the phrase “from modified live virus vaccines” provides material facts that may be relevant to prescribing veterinarians and dog owners. &nbsp; &nbsp;\u003C\u002Fp>\u003Cp>In the ISI section of the consumer-directed website and on page one of the Product Brochure and Itch Tracker, the specific time period to withhold Zenrelia before and after vaccination is omitted (i.e., at least 28 days to 3 months prior to vaccination and at least 28 days after vaccination) and replaced with the phrase “for a time period before and after vaccination.” The specific time frame is also omitted from a 30-second video found on the veterinarian product website.\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> &nbsp;The phrase “for a time period before and after vaccination” is misleading because it does not provide necessary information to the pet owner. &nbsp;\u003C\u002Fp>\u003Cp>The Safety section of the Zenrelia veterinarian website contains only the statements “Read the entire package insert before using this drug, including the Boxed Warning” and “In clinical trials, the most observed adverse events were vomiting, diarrhea, and lethargy.” There is no mention of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines. We acknowledge that clicking on the box titled “Explore Zenrelia’s safety data” directs the reader to another webpage where more safety information is presented. However, this Safety section is also missing information about the risk of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines, as well as safety information from the Warnings section of the PI like monitoring for the development of infections, the risk of decreased hematocrit, hemoglobin, and\u002For red blood cell count, and the risk of new neoplastic conditions.\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>&nbsp;\u003C\u002Fp>\u003Cp>\u003Cu>Misrepresented Study Results\u003C\u002Fu>&nbsp;\u003C\u002Fp>\u003Cp>The veterinarian product website makes misleading claims about the results of the Vaccine Response Study. In the “Vaccinations FAQs” section of the website, under the question “What is vaccine-induced disease?” the response in part states “After the label was finalized, PCR testing confirmed this dog had Infectious Canine Hepatitis due to infection with canine adenovirus type 1 (CAV-1), which is genetically distinct from the strain of CAV-2 used in the MLV. Furthermore, this dog developed clinical signs of hepatitis (hematemesis) prior to receiving its first MLV. CAV-1 is highly contagious and difficult to kill with routine disinfectants; it is unknown how this dog became exposed or if it was a carrier prior to entering the bio-secure facility used for this study.” This claim is repeated on page 33 of the “Reach for Zen” slide deck. This information is in direct conflict with the PI and Freedom of Information (FOI) summary for Zenrelia, which concluded that the dog in the study had vaccine-induced adenoviral hepatitis and pancreatitis secondary to Zenrelia-induced immunosuppression.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The Safety section of the Zenrelia veterinarian website also contains information about adverse reactions seen in the field studies conducted for approval,\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> accessible by clicking on the boxes titled “US atopic dermatitis study vs placebo” and “US allergic dermatitis study vs placebo”. However, the adverse reaction data found on the website is not consistent with the information found in the Zenrelia PI. For example, for the Control of Pruritus Associated with Allergic Dermatitis study, the PI states that diarrhea was reported in 26 (12.2%) dogs and urinary tract infections were reported in 13 (6.3%) Zenrelia treated dogs, while the Zenrelia website reports these numbers as 19 (9.2%) and 3 (1.5%), respectively. The adverse reaction data was reviewed and verified by the FDA as part of the approval process. The statements on the Zenrelia website are therefore false and misleading because they misrepresent the safety profile of Zenrelia.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Additional Comments\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We offer the following additional comments about the promotion of Zenrelia:&nbsp;\u003C\u002Fp>\u003Cul>\u003Cli>Your product websites and Product Brochure state that there are “visible improvements in allergic itch from day one.” Neither effectiveness study (i.e., Control of Atopic Dermatitis or Control of Pruritus Associated with Allergic Dermatitis) supporting FDA approval assessed the speed of action of Zenrelia. According to the FOI summary, in the Control of Atopic Dermatitis study, treatment success\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on Day 28 was identified as the primary effectiveness endpoint. Pruritus Visual Analog Scale (PVAS) scores were also assessed at other time points, but they were considered secondary endpoints. This study did demonstrate that the estimated mean PVAS scores were lower in the Zenrelia group compared to placebo on Day 1, however, this difference was relatively small, and it is unknown if it represented a clinically identifiable difference in pruritus in the treatment group compared to the placebo group. Therefore, it cannot be concluded that the difference in PVAS scores indicates that Zenrelia improved pruritus compared to placebo on Day 1. In the Control of Pruritus Associated with Allergic Dermatitis study, the primary effectiveness endpoint was treatment success\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on at least 5 of the first 7 days of treatment. In this study, PVAS scores were assessed on Days 1 through 7, but the estimated mean PVAS score in the Zenrelia group was not lower than the placebo group until after Day 1, beginning on Day 2. &nbsp;\u003C\u002Fli>\u003Cli>Your product Detailer\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> makes the claim “77% of Zenrelia-treated dogs returned to normal versus 53% of Apoquel treated dogs.” The head-to-head study comparing treatment with Zenrelia to treatment with Apoquel showed that Zenrelia had similar efficacy as Apoquel on day 28, which was the primary effectiveness endpoint. The claim in the Detailer is based on PVAS scores on Day 112 of the study, which was a secondary endpoint. When multiple endpoints are tested statistically, the Type I error rate (the probability of erroneously concluding an effect when the truth is that there is no effect) may be inflated. Therefore, the p-values associated with the analyses of the multiple secondary endpoints should not be interpreted as evidence of statistically significant differences. We acknowledge you note with an asterisk that “PVAS &lt;2; P\u003Cu>&lt;\u003C\u002Fu>0.05. Secondary end point P values are not adjusted for multiple testing; therefore, caution should be exercised in interpretation.” However, this information is located in much smaller font at the bottom of the page and its inclusion in the Detailer does not mitigate the misleading impression made by the claim, which is presented prominently in large font in the center of the page. See 21 CFR 202.1(e)(7)(viii).\u003C\u002Fli>\u003Cli>Your product Detailer claims that “Results of multiple other studies demonstrate very similar safety profiles between Zenrelia and Apoquel.” The Zenrelia PI has a boxed warning regarding the risk of fatal vaccine-induced disease from modified live vaccines and inadequate immune response to any vaccine as well as additional warning language regarding the risk of progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count, while the Apoquel PI does not. Therefore, the claim of “similar safety profiles between Zenrelia and Apoquel” may be misleading.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your websites, Product Brochure and Itch Tracker, and slide deck titled “Reach for Zen” misbrand Zenrelia within the meaning of the FD&amp;C Act. FD&amp;C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n));, and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Zenrelia that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Zenrelia. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 695170.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>_____________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fmy.elanco.com\u002Fus\u002Fcampaign\u002Fzenrelia (last accessed on 1.27.25)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fyourpetandyou.elanco.com\u002Fus\u002Four-products\u002Fzenrelia (last accessed on 1.27.25)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-0697\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1330 and submitted to the Drug Experience Report (DER) portal under cover of form 2301 on October 2, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved package insert (PI) for Zenrelia\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> The risk information reproduced in this letter is only for background information related to the letter’s subject matter and does not necessarily represent the risk information that should be included in any promotional communications.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> The DHPP vaccine contains canine distemper virus (CDV), canine adenovirus (CAV-2), canine parainfluenza (CPiV), and canine parvovirus (CPV).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> A Core Vaccination is recommended for all dogs irrespective of lifestyle, unless there is a specific medical reason not to vaccinate according to the American Animal Hospital Association.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-0930&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> We recognize some of this information is found in the ISI section at the bottom of the main veterinarian website and linked webpage. However, due to the location and small size of the text, this information is not comparably noticeable or conspicuous compared to the benefit information. See 21 CFR 202.1(e)(7)(viii). &nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> The two field studies conducted for approval were the field study for Control of Atopic Dermatitis and the field study for Control of Pruritus Associated with Allergic Dermatitis. &nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus or at least a 50% reduction from baseline in investigator assessed CADESI-4 (Canine Atopic Dermatitis Extent and Severity Index version 4) score for skin lesions.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus on at least 5 out of the first 7 days of treatment&nbsp;\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1164, submitted to the DER under cover of form 2301 on September 23, 2024.&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJeffrey Simmons\n\nRecipient Title\n\nPresident and CEO\n\nElanco Animal Health\n\n2500 Innovation Way\n\nGreenfield, IN 46140\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJanuary 28, 2025\nRe: NADA 141-585, Zenrelia™ (ilunocitinib tablets)\nCMS #: 695170\nWARNING LETTER\nDear Mr. Simmons:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Zenrelia (ilunocitinib tablets) including your veterinarian product website,1 the consumer directed website,2 your Product Brochure and Itch Tracker,3 which is linked on both websites, and a slide deck titled “Reach for Zen: New Relief for Dogs with Atopic Dermatitis4” and noted false or misleading claims and representations about the safety and effectiveness of Zenrelia. These promotional communications misbrand Zenrelia within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act). FD&C Act section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; see also section 201(n) [21 USC 321(n)]. It is a prohibited act to distribute a misbranded product in interstate commerce. FD&C Act section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because the misleading promotional communications create a misleading impression regarding the safety and effectiveness of Zenrelia, which is a recently-approved veterinary drug in the Janus Kinase (JAK) inhibitor drug class.\nBackground\nZenrelia is indicated for “control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.”5\nZenrelia’s FDA-approved Prescribing Information (PI) contains a boxed and bolded warning of the risk of “fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine” in dogs receiving Zenrelia. Therefore, the boxed warning states to discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination.\nThe PI contains additional warning language including:\n“Dogs should be monitored for the development of infections because Zenrelia may increase susceptibility to opportunistic infections, including demodicosis, interdigital furunculosis, coccidiosis, and pneumonia, and exacerbation of subclinical or uncomplicated infections (see Target Animal Safety and Adverse Reactions).”\n…\n“Zenrelia may cause a progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count (see Target Animal Safety).”\n“New neoplastic conditions (benign and malignant) were observed in dogs treated with Zenrelia during clinical studies (see Adverse Reactions).”\nThe PI contains additional adverse event, warning, precaution, and contraindication information.6\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&C Act sections 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nOmitted Information\nThe websites mentioned above and the Product Brochure and Itch tracker omit the phrase “from modified live virus vaccines” from the boxed warning found in the Important Safety Information (ISI) sections. The Vaccine Response Study in the Target Animal Safety section of the PI describes a dog that was administered Zenrelia that developed lethargy, depression, poor body condition, and weakness after receiving a modified live virus (MLV) vaccination and was subsequently euthanized. This dog was later diagnosed with adenoviral hepatitis and pancreatitis that “were concluded to be vaccine-induced, secondary to Zenrelia-induced immunosuppression.” Omitting the phrase “from modified live virus vaccines” in promotional material is misleading because the fatal vaccine-induced disease occurred after administration of a MLV DHPP vaccination,7 a core vaccination for all dogs.8\nTherefore, the phrase “from modified live virus vaccines” provides material facts that may be relevant to prescribing veterinarians and dog owners.\nIn the ISI section of the consumer-directed website and on page one of the Product Brochure and Itch Tracker, the specific time period to withhold Zenrelia before and after vaccination is omitted (i.e., at least 28 days to 3 months prior to vaccination and at least 28 days after vaccination) and replaced with the phrase “for a time period before and after vaccination.” The specific time frame is also omitted from a 30-second video found on the veterinarian product website.9 The phrase “for a time period before and after vaccination” is misleading because it does not provide necessary information to the pet owner.\nThe Safety section of the Zenrelia veterinarian website contains only the statements “Read the entire package insert before using this drug, including the Boxed Warning” and “In clinical trials, the most observed adverse events were vomiting, diarrhea, and lethargy.” There is no mention of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines. We acknowledge that clicking on the box titled “Explore Zenrelia’s safety data” directs the reader to another webpage where more safety information is presented. However, this Safety section is also missing information about the risk of fatal vaccine-induced disease from MLV vaccines or inadequate immune response to any vaccines, as well as safety information from the Warnings section of the PI like monitoring for the development of infections, the risk of decreased hematocrit, hemoglobin, and\u002For red blood cell count, and the risk of new neoplastic conditions.10\nMisrepresented Study Results\nThe veterinarian product website makes misleading claims about the results of the Vaccine Response Study. In the “Vaccinations FAQs” section of the website, under the question “What is vaccine-induced disease?” the response in part states “After the label was finalized, PCR testing confirmed this dog had Infectious Canine Hepatitis due to infection with canine adenovirus type 1 (CAV-1), which is genetically distinct from the strain of CAV-2 used in the MLV. Furthermore, this dog developed clinical signs of hepatitis (hematemesis) prior to receiving its first MLV. CAV-1 is highly contagious and difficult to kill with routine disinfectants; it is unknown how this dog became exposed or if it was a carrier prior to entering the bio-secure facility used for this study.” This claim is repeated on page 33 of the “Reach for Zen” slide deck. This information is in direct conflict with the PI and Freedom of Information (FOI) summary for Zenrelia, which concluded that the dog in the study had vaccine-induced adenoviral hepatitis and pancreatitis secondary to Zenrelia-induced immunosuppression.\n(b)(4)\nThe Safety section of the Zenrelia veterinarian website also contains information about adverse reactions seen in the field studies conducted for approval,11 accessible by clicking on the boxes titled “US atopic dermatitis study vs placebo” and “US allergic dermatitis study vs placebo”. However, the adverse reaction data found on the website is not consistent with the information found in the Zenrelia PI. For example, for the Control of Pruritus Associated with Allergic Dermatitis study, the PI states that diarrhea was reported in 26 (12.2%) dogs and urinary tract infections were reported in 13 (6.3%) Zenrelia treated dogs, while the Zenrelia website reports these numbers as 19 (9.2%) and 3 (1.5%), respectively. The adverse reaction data was reviewed and verified by the FDA as part of the approval process. The statements on the Zenrelia website are therefore false and misleading because they misrepresent the safety profile of Zenrelia.\nAdditional Comments\nWe offer the following additional comments about the promotion of Zenrelia:\nYour product websites and Product Brochure state that there are “visible improvements in allergic itch from day one.” Neither effectiveness study (i.e., Control of Atopic Dermatitis or Control of Pruritus Associated with Allergic Dermatitis) supporting FDA approval assessed the speed of action of Zenrelia. According to the FOI summary, in the Control of Atopic Dermatitis study, treatment success12 on Day 28 was identified as the primary effectiveness endpoint. Pruritus Visual Analog Scale (PVAS) scores were also assessed at other time points, but they were considered secondary endpoints. This study did demonstrate that the estimated mean PVAS scores were lower in the Zenrelia group compared to placebo on Day 1, however, this difference was relatively small, and it is unknown if it represented a clinically identifiable difference in pruritus in the treatment group compared to the placebo group. Therefore, it cannot be concluded that the difference in PVAS scores indicates that Zenrelia improved pruritus compared to placebo on Day 1. In the Control of Pruritus Associated with Allergic Dermatitis study, the primary effectiveness endpoint was treatment success13 on at least 5 of the first 7 days of treatment. In this study, PVAS scores were assessed on Days 1 through 7, but the estimated mean PVAS score in the Zenrelia group was not lower than the placebo group until after Day 1, beginning on Day 2.\nYour product Detailer14 makes the claim “77% of Zenrelia-treated dogs returned to normal versus 53% of Apoquel treated dogs.” The head-to-head study comparing treatment with Zenrelia to treatment with Apoquel showed that Zenrelia had similar efficacy as Apoquel on day 28, which was the primary effectiveness endpoint. The claim in the Detailer is based on PVAS scores on Day 112 of the study, which was a secondary endpoint. When multiple endpoints are tested statistically, the Type I error rate (the probability of erroneously concluding an effect when the truth is that there is no effect) may be inflated. Therefore, the p-values associated with the analyses of the multiple secondary endpoints should not be interpreted as evidence of statistically significant differences. We acknowledge you note with an asterisk that “PVAS \u003C2; P\u003C0.05. Secondary end point P values are not adjusted for multiple testing; therefore, caution should be exercised in interpretation.” However, this information is located in much smaller font at the bottom of the page and its inclusion in the Detailer does not mitigate the misleading impression made by the claim, which is presented prominently in large font in the center of the page. See 21 CFR 202.1(e)(7)(viii).\nYour product Detailer claims that “Results of multiple other studies demonstrate very similar safety profiles between Zenrelia and Apoquel.” The Zenrelia PI has a boxed warning regarding the risk of fatal vaccine-induced disease from modified live vaccines and inadequate immune response to any vaccine as well as additional warning language regarding the risk of progressive or persistently decreased hematocrit, hemoglobin, and\u002For red blood cell count without a corresponding increase in absolute reticulocyte count, while the Apoquel PI does not. Therefore, the claim of “similar safety profiles between Zenrelia and Apoquel” may be misleading.\nConclusion and Requested Response\nFor the reasons discussed above, your websites, Product Brochure and Itch Tracker, and slide deck titled “Reach for Zen” misbrand Zenrelia within the meaning of the FD&C Act. FD&C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n));, and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Zenrelia that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Zenrelia. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 695170.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\n_____________\n1 https:\u002F\u002Fmy.elanco.com\u002Fus\u002Fcampaign\u002Fzenrelia (last accessed on 1.27.25)\n2 https:\u002F\u002Fyourpetandyou.elanco.com\u002Fus\u002Four-products\u002Fzenrelia (last accessed on 1.27.25)\n3 Identified by Elanco as PM-US-24-0697\n4 Identified by Elanco as PM-US-24-1330 and submitted to the Drug Experience Report (DER) portal under cover of form 2301 on October 2, 2024.\n5 FDA-approved package insert (PI) for Zenrelia\n6 The risk information reproduced in this letter is only for background information related to the letter’s subject matter and does not necessarily represent the risk information that should be included in any promotional communications.\n7 The DHPP vaccine contains canine distemper virus (CDV), canine adenovirus (CAV-2), canine parainfluenza (CPiV), and canine parvovirus (CPV).\n8 A Core Vaccination is recommended for all dogs irrespective of lifestyle, unless there is a specific medical reason not to vaccinate according to the American Animal Hospital Association.\n9 Identified by Elanco as PM-US-24-0930\n10 We recognize some of this information is found in the ISI section at the bottom of the main veterinarian website and linked webpage. However, due to the location and small size of the text, this information is not comparably noticeable or conspicuous compared to the benefit information. See 21 CFR 202.1(e)(7)(viii).\n11 The two field studies conducted for approval were the field study for Control of Atopic Dermatitis and the field study for Control of Pruritus Associated with Allergic Dermatitis.\n12 Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus or at least a 50% reduction from baseline in investigator assessed CADESI-4 (Canine Atopic Dermatitis Extent and Severity Index version 4) score for skin lesions.\n13 Treatment success for each dog was defined as at least a 50% reduction from baseline (Day 0) in owner-assessed PVAS score for pruritus on at least 5 out of the first 7 days of treatment\n14 Identified by Elanco as PM-US-24-1164, submitted to the DER under cover of form 2301 on September 23, 2024.","Elanco Animal Health","elanco-animal-health-695170-01282025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-695170-01282025","2026-10-26T08:08:32.23868+00:00","2025-03-11","695170","2025-09-19","Jeffrey Simmons","2026-08-19T16:58:17.985+00:00","2025-01-28",{"id":295,"raw":296,"subject":302,"body_html":303,"body_text":304,"firm_name":305,"letter_id":306,"created_at":85,"fei_number":19,"letter_url":307,"updated_at":308,"action_type":22,"case_status":23,"posted_date":92,"marcs_cms_no":309,"product_type":310,"closeout_date":19,"issuing_office":300,"recipient_name":311,"body_fetched_at":312,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":313,"medical_device_id":19,"response_letter_date":19},72,[297,298,299,300,301,13,13,13],"\u003Ctime datetime=\"2026-06-23T04:00:00Z\">06\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-05T04:00:00Z\">06\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fimu-tek-animal-health-incorporated-724610-06052026\">Imu-Tek Animal Health, Incorporated \u003C\u002Fa>","Human Foods Program","Dietary Supplement\u002FNew Drug\u002FMisbranded\u003Cbr \u002F>\r\n","Dietary Supplement\u002FNew Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Henry S. Dyjak, President\u002FCo-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Susan A. Dyjak, Vice President\u002FCo-Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Imu-Tek Animal Health, Incorporated \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3541 E. Vine Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Collins\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80524\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Henryd@Imutek.com\"> Henryd@Imutek.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 5, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 724610\u003C\u002Fp>\u003Cp>Dear Mr. and Mrs. Dyjak:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 3541 E. Vine Dr., Fort Collins, CO 80524 from October 6 through October 14, 2025. Based on inspectional findings and our review of your website, www.Imutek.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection on October 14, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated October 29, 2025.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>FDA reviewed your website at the Internet address www.imutek.com in April 2026 and has determined that you take orders there for the products Colostrom-5 Capsules and Colostrom-5 Powder. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\u003Cp>An example that provides evidence that your products are intended for use as drugs include:\u003C\u002Fp>\u003Cul>\u003Cli>“ImuTek Colostrum-5 Capsules and Powder. . . . has been shown to kill bacteria and viral invaders. It can also help correct bowel dysfunction by stimulating tissue repair.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drugs\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\u003Cp>Your products Colostrom-5 Capsules and Colostrom-5 Powder are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Colostrom-5 Capsules and Colostrom-5 Powder fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Adulterated Dietary Supplements\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>The inspection of your facility from October 6 through October 14, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Thus, in addition to being unapproved new drugs and misbranded drugs, your Colostrum-5 Capsules and Colostrum-5 Powder are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\u003C\u002Fp>\u003Cp>Your significant violations of the CGMP requirements are as follows:\u003C\u002Fp>\u003Cp>1. Your quality control personnel failed to reject a component or dietary supplement or approve a treatment, in-process adjustment, or reprocessing when a deviation or unanticipated occurrence took place during the production and in-process control system that resulted in, or could lead to adulteration of, a component or dietary supplement, as required by 21 CFR 111.113(b)(1). Specifically, your pasteurization procedure for colostrum used in your Colostrum-5 Capsules and Colostrum-5 Powder specifies a time\u002Ftemperature requirement of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes. However, review of multiple Batch Production Records (BPRs) revealed deviations from this procedure. For example, BPR for batch \u003Cstrong>(b)(4)\u003C\u002Fstrong> documented pasteurization temperatures ranging from \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F to \u003Cstrong>(b)(4)\u003C\u002Fstrong>°F, with unspecified hold times. Despite the deviation, you used the colostrum in your Colostrum-5 Capsules and Colostrum-5 Powder without approving a treatment, in-process adjustment, or reprocessing.\u003C\u002Fp>\u003Cp>In your response dated October 29, 2025, you stated that the pasteurization \u003Cstrong>(b)(4) \u003C\u002Fstrong>records the proper temperature of the actual pasteurization process. We are unable to evaluate the sufficiency of your correction action because your response does not, for example, explain the basis on which you did not reject product that deviated from your time\u002Ftemperature requirement for colostrum or the basis on which such deviation was accepted.\u003C\u002Fp>\u003Cp>2. You failed to establish, for each component that you use in the manufacture of a dietary supplement, identity specifications; component specifications that are necessary to ensure that specifications for purity, strength, and composition of the dietary supplement using the components are met; and component specifications regarding limits on those type of contamination that may adulterate or may lead to adulteration of the finished batch of dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). Specifically, you stated that the firm has not established any raw material specifications for any of the components used in the dietary supplements you produce.\u003C\u002Fp>\u003Cp>In your response dated October 29, 2025, you provided a list of tests that your firm performs and stated that you are in the process of creating a composition baseline with \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are unable to evaluate the sufficiency of your corrective actions because you did not provide documentation of established component specifications.\u003C\u002Fp>\u003Cp>In addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\u003Cp>3. You did not establish product specifications for the identity, purity, strength, composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, during the inspection you stated that you have not established finished product specifications for any of your dietary supplements.\u003C\u002Fp>\u003Cp>In your response dated October 29, 2025, you stated that the “range or limits were not evident on the testing form. However, the limits are recorded in our file of dietary supplement requirements,” and your new format will be submitted when finished. We are unable to evaluate the sufficiency of your corrective action because you have not provided specifications for your finished products that demonstrate the requirements in 21 CFR 111.70(e) have been met.\u003C\u002Fp>\u003Cp>In addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\u003C\u002Fp>\u003Cp>4. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, during the inspection the investigator requested your MMRs for Colostrum-5 Capsules and Colostrum-5 Powder, and you stated that you did not have an MMR.\u003C\u002Fp>\u003Cp>You must have a written MMR for each dietary supplement you manufacture that includes the following:\u003C\u002Fp>\u003Cul>\u003Cli>The name of the dietary supplement to be manufactured and the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)];\u003C\u002Fli>\u003Cli>A complete list of components to be used [21 CFR 111.210(b)];\u003C\u002Fli>\u003Cli>An accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\u003C\u002Fli>\u003Cli>The identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\u003C\u002Fli>\u003Cli>A statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\u003C\u002Fli>\u003Cli>A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\u003C\u002Fli>\u003Cli>A description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)];\u003C\u002Fli>\u003Cli>Written instructions, including the following:\u003Cbr>o Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)];\u003Cbr>o Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\u003Cbr>o Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)];\u003Cbr> Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\u003Cbr> For manual operations, such specific actions must include:\u003C\u002Fli>\u003Cli>One person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\u003C\u002Fli>\u003Cli>One person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)];\u003Cbr>o Special notations and precautions to be followed [21 CFR 111.210(h)(4)];\u003Cbr>o Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>We have reviewed your response to the FDA Form 483, dated October 29, 2025, which states that your “capsule” bottling form “should cover the issues” relating to the requirement to establish an MMR. We are unable to evaluate the sufficiency of your corrective action because the documentation you provided does not contain all required information required in an MMR.\u003C\u002Fp>\u003Cp>5. You failed to include necessary information in the batch production records (BPRs), as required in 21 CFR 111.260. Specifically, your “Colostrum \u003Cstrong>(b)(4)\u003C\u002Fstrong> Reports,” which you provided as your BPRs for your Colostrum-5 Capsules and your Colostrum-5 Powder, are missing the following required information:\u003C\u002Fp>\u003Cul>\u003Cli>The unique identifier that you assigned to each component (or, when applicable, to a product that you receive from a supplier for packaging or labeling as a dietary supplement), packaging, and label used [21 CFR 111.260(d)];\u003C\u002Fli>\u003Cli>The identity and weight or measure of each component used [21 CFR 111.260(e)]. For example, your BPR indicates that silica is a component in the final capsule product, but the BPR does not document how much silica was added.\u003C\u002Fli>\u003Cli>The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003C\u002Fli>\u003Cli>Documentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)];\u003C\u002Fli>\u003Cli>Documentation, at the time of performance, of packaging and labeling operations, including the unique identifier that you assigned to packaging and labels used; an actual representative label, or cross-reference to a physical location of the actual or representative label specified in the MMR; and the results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)];\u003C\u002Fli>\u003Cli>Documentation at the time of performance that quality control personnel approved or rejected the batch for distribution [21 CFR 111.260(l)(3)].\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response dated October 29, 2025, you provided a blank excel template for your Colostrum-5 Capsules that includes dates\u002Ftimes for mixing, a calculation for final product yields, and a review and approval section. We are unable to evaluate the sufficiency of your corrective action because the documentation you provided does not include all information required by 21 CFR 111.260.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written reply should be directed to Lauren Crivellone, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS # 724610 on any submissions and within the subject line of any emails to us. If you have any questions, you may email Ms. Crivellone at HFP-OCE-DietarySupplements@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Director, Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nHenry S. Dyjak, President\u002FCo-Owner\n\nRecipient Title\n\nSusan A. Dyjak, Vice President\u002FCo-Owner\n\nImu-Tek Animal Health, Incorporated\n\n3541 E. Vine Dr.\n\nFort Collins, CO 80524\n\nUnited States\n\nHenryd@Imutek.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nJune 5, 2026\nWARNING LETTER\nCMS # 724610\nDear Mr. and Mrs. Dyjak:\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 3541 E. Vine Dr., Fort Collins, CO 80524 from October 6 through October 14, 2025. Based on inspectional findings and our review of your website, www.Imutek.com, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov.\nAt the conclusion of the inspection on October 14, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your response dated October 29, 2025.\nUnapproved New Drugs\nFDA reviewed your website at the Internet address www.imutek.com in April 2026 and has determined that you take orders there for the products Colostrom-5 Capsules and Colostrom-5 Powder. The claims on your website establish that these products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\nAn example that provides evidence that your products are intended for use as drugs include:\n“ImuTek Colostrum-5 Capsules and Powder. . . . has been shown to kill bacteria and viral invaders. It can also help correct bowel dysfunction by stimulating tissue repair.”\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\nMisbranded Drugs\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\nYour products Colostrom-5 Capsules and Colostrom-5 Powder are intended for treatment or prevention of one or more diseases that are not amenable to self-diagnosis, treatment, or prevention without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Colostrom-5 Capsules and Colostrom-5 Powder fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\nAdulterated Dietary Supplements\nThe inspection of your facility from October 6 through October 14, 2025, identified serious violations of the FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements, under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). Thus, in addition to being unapproved new drugs and misbranded drugs, your Colostrum-5 Capsules and Colostrum-5 Powder are also adulterated dietary supplements under section 402(g)(1) of the Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements.\nYour significant violations of the CGMP requirements are as follows:\n1. Your quality control personnel failed to reject a component or dietary supplement or approve a treatment, in-process adjustment, or reprocessing when a deviation or unanticipated occurrence took place during the production and in-process control system that resulted in, or could lead to adulteration of, a component or dietary supplement, as required by 21 CFR 111.113(b)(1). Specifically, your pasteurization procedure for colostrum used in your Colostrum-5 Capsules and Colostrum-5 Powder specifies a time\u002Ftemperature requirement of (b)(4)°F for (b)(4) minutes. However, review of multiple Batch Production Records (BPRs) revealed deviations from this procedure. For example, BPR for batch (b)(4) documented pasteurization temperatures ranging from (b)(4)°F to (b)(4)°F, with unspecified hold times. Despite the deviation, you used the colostrum in your Colostrum-5 Capsules and Colostrum-5 Powder without approving a treatment, in-process adjustment, or reprocessing.\nIn your response dated October 29, 2025, you stated that the pasteurization (b)(4) records the proper temperature of the actual pasteurization process. We are unable to evaluate the sufficiency of your correction action because your response does not, for example, explain the basis on which you did not reject product that deviated from your time\u002Ftemperature requirement for colostrum or the basis on which such deviation was accepted.\n2. You failed to establish, for each component that you use in the manufacture of a dietary supplement, identity specifications; component specifications that are necessary to ensure that specifications for purity, strength, and composition of the dietary supplement using the components are met; and component specifications regarding limits on those type of contamination that may adulterate or may lead to adulteration of the finished batch of dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(b). Specifically, you stated that the firm has not established any raw material specifications for any of the components used in the dietary supplements you produce.\nIn your response dated October 29, 2025, you provided a list of tests that your firm performs and stated that you are in the process of creating a composition baseline with (b)(4). We are unable to evaluate the sufficiency of your corrective actions because you did not provide documentation of established component specifications.\nIn addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n3. You did not establish product specifications for the identity, purity, strength, composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, during the inspection you stated that you have not established finished product specifications for any of your dietary supplements.\nIn your response dated October 29, 2025, you stated that the “range or limits were not evident on the testing form. However, the limits are recorded in our file of dietary supplement requirements,” and your new format will be submitted when finished. We are unable to evaluate the sufficiency of your corrective action because you have not provided specifications for your finished products that demonstrate the requirements in 21 CFR 111.70(e) have been met.\nIn addition to establishing the required specifications, your firm must determine whether such specifications are met, in accordance with 21 CFR 111.73 and 111.75.\n4. You failed to prepare and follow a written master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Specifically, during the inspection the investigator requested your MMRs for Colostrum-5 Capsules and Colostrum-5 Powder, and you stated that you did not have an MMR.\nYou must have a written MMR for each dietary supplement you manufacture that includes the following:\nThe name of the dietary supplement to be manufactured and the strength, concentration, weight, or measure of each dietary ingredient for each batch size [21 CFR 111.210(a)];\nA complete list of components to be used [21 CFR 111.210(b)];\nAn accurate statement of the weight or measure of each component to be used [21 CFR 111.210(c)];\nThe identity and weight or measure of each dietary ingredient that will be declared on the Supplement Facts label and the identity of each ingredient that will be declared on the ingredients list of the dietary supplement [21 CFR 111.210(d)];\nA statement of any intentional overage amount of a dietary ingredient [21 CFR 111.210(e)];\nA statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process where control is needed to ensure the quality of the dietary supplement, and the expected yield when you finish manufacturing the dietary supplement, including the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary and material review is conducted and disposition decision is made [21 CFR 111.210(f)];\nA description of packaging and a representative label, or a cross-reference to the physical location of the actual or representative label [21 CFR 111.210(g)];\nWritten instructions, including the following:\no Specifications for each point, step, or stage in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(1)];\no Procedures for sampling and a cross-reference to procedures for tests or examinations [21 CFR 111.210(h)(2)];\no Specific actions necessary to perform and verify points, steps, or stages in the manufacturing process where control is necessary to ensure the quality of the dietary supplement and that the dietary supplement is packaged and labeled as specified in the MMR [21 CFR 111.210(h)(3)];\n Such specific actions must include verifying the weight or measure of any component and verifying the addition of any component [21 CFR 111.210(h)(3)(i)]; and\n For manual operations, such specific actions must include:\nOne person weighing or measuring a component and another person verifying the weight or measure [21 CFR 111.210(h)(3)(ii)(A)]; and\nOne person adding the component and another person verifying the addition [21 CFR 111.210(h)(3)(ii)(B)];\no Special notations and precautions to be followed [21 CFR 111.210(h)(4)];\no Corrective action plans for use when a specification is not met [21 CFR 111.210(h)(5)].\nWe have reviewed your response to the FDA Form 483, dated October 29, 2025, which states that your “capsule” bottling form “should cover the issues” relating to the requirement to establish an MMR. We are unable to evaluate the sufficiency of your corrective action because the documentation you provided does not contain all required information required in an MMR.\n5. You failed to include necessary information in the batch production records (BPRs), as required in 21 CFR 111.260. Specifically, your “Colostrum (b)(4) Reports,” which you provided as your BPRs for your Colostrum-5 Capsules and your Colostrum-5 Powder, are missing the following required information:\nThe unique identifier that you assigned to each component (or, when applicable, to a product that you receive from a supplier for packaging or labeling as a dietary supplement), packaging, and label used [21 CFR 111.260(d)];\nThe identity and weight or measure of each component used [21 CFR 111.260(e)]. For example, your BPR indicates that silica is a component in the final capsule product, but the BPR does not document how much silica was added.\nThe results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\nDocumentation that the finished dietary supplement meets specifications established in accordance with 21 CFR 111.70(e) and (g) [21 CFR 111.260(i)];\nDocumentation, at the time of performance, of packaging and labeling operations, including the unique identifier that you assigned to packaging and labels used; an actual representative label, or cross-reference to a physical location of the actual or representative label specified in the MMR; and the results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)];\nDocumentation at the time of performance that quality control personnel approved or rejected the batch for distribution [21 CFR 111.260(l)(3)].\nIn your response dated October 29, 2025, you provided a blank excel template for your Colostrum-5 Capsules that includes dates\u002Ftimes for mixing, a calculation for final product yields, and a review and approval section. We are unable to evaluate the sufficiency of your corrective action because the documentation you provided does not include all information required by 21 CFR 111.260.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nYour written reply should be directed to Lauren Crivellone, United States Food and Drug Administration, Human Foods Program, Office of Enforcement, 5001 Campus Drive, College Park, Maryland 20740-3835 or via email at HFP-OCE-DietarySupplements@fda.hhs.gov. Please reference CMS # 724610 on any submissions and within the subject line of any emails to us. If you have any questions, you may email Ms. Crivellone at HFP-OCE-DietarySupplements@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nDirector, Office of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Imu-Tek Animal Health, Incorporated","imu-tek-animal-health-incorporated-724610-06052026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fimu-tek-animal-health-incorporated-724610-06052026","2026-10-26T08:08:58.088644+00:00","724610","DrugsFood & Beverages","Henry S. Dyjak, President\u002FCo-Owner","2026-08-19T04:33:34.116+00:00","2026-06-05",{"id":315,"raw":316,"subject":164,"body_html":322,"body_text":323,"firm_name":324,"letter_id":325,"created_at":149,"fei_number":19,"letter_url":326,"updated_at":327,"action_type":22,"case_status":88,"posted_date":328,"marcs_cms_no":329,"product_type":330,"closeout_date":331,"issuing_office":320,"recipient_name":332,"body_fetched_at":333,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":334,"medical_device_id":19,"response_letter_date":19},2837,[317,318,319,320,164,13,321,13],"\u003Ctime datetime=\"2022-03-01T14:20:00Z\">03\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-17T05:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-02172022\">Vital Health &amp; Wellness\u003C\u002Fa>","Office of Human and Animal Foods Operations-East V","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-04282023\">\u003Ctime datetime=\"2023-05-08T04:00:00Z\">05\u002F08\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher A. Williamson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vital Health &amp; Wellness\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 Industrial Park Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Trenton\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38382\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Foods Operations-East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 618743\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 17, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Williamson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your tea processing facility, located at 800 Industrial Park Dr., Trenton, TN 38382 on August 23 and 30, 2021. During the inspection, FDA investigators collected your label for the product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea. FDA also reviewed your website at www.vitalhealthandwellness.net in November 2021 and February 2022 and determined that you take orders there for your Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea. The claims on your website and product label establish that your Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>An example on your product label of some of the claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “MAY BE BENEFICIAL FOR:… ACID REFLUX…HIGH BLOOD PRESSURE”\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your website’s “Ingredients” page that provide evidence that your product is intended for use as a drug include (the “Ingredients” page identifies Holy Thistle, Persimmon leaves, Malva leaves, Marsh Mallow leaves, Blessed Thistle, Papaya, Ginger and Chamomile as ingredients in Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea):\u003C\u002Fp>\n\n\u003Cp>• Persimmon leaves\u003Cbr>\n&nbsp; o “ . . . Persimmon leaves have anti-hypertensive, anti-carcinogenic, and anti-mutagen properties.”\u003Cbr>\n&nbsp; o “The [persimmon] leaf … is anti hemorrhagic (stops bleeding), is an effective remedy for hemorrhoids, and strengthens weak blood vessels such as spider veins or varicose veins.”\u003Cbr>\n• Holy thistle\u003Cbr>\n&nbsp; o “Holy thistle has been used medicinally for over 2000 years, most commonly for the treatment of liver disorders such as jaundice, and gallbladder disorders; but also for lactation problems, disorders of the spleen, psoriasis, and mushroom poisoning.”\u003Cbr>\n&nbsp; o “[Holy thistle] has recently been used by HIV-positive patients to protect the liver from diseases such as hepatitis and damage from the drugs taken for HIV or AIDS. . . . Silymarin[, a flavonoid in holy thistle,] has also been shown to regenerate injured liver cells.”\u003Cbr>\n&nbsp; o “Holy Thistle products are popular in Europe and the United States for various types of liver disease, being able to counteract the harmful actions of alcohol on the liver (cirrhosis), and helping the liver return to a healthy state when an alcoholic stops drinking. Some clinical trials indicate that it may improve quality of life and even increase life expectancy in patients with cirrhosis of the liver.”\u003Cbr>\n&nbsp; o “ . . . [D]rinking a cup of Holy Thistle tea twice a day can cure chronic headaches. It is also used for…constipation relief. It is very effective for dropsy….”\u003Cbr>\n• Malva leaves\u003Cbr>\n&nbsp; o “Malva Leaf teas are used in the treatment of renal disorders… and diarrhea. Malva Leaf has been used to treat stomachache, gastroenteritis, irritable bowel, and conditions of the spleen.”\u003Cbr>\n• Marshmallow leaves\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow swells up and becomes slick when it is exposed to fluids. The resulting slippery material coats the linings of the mouth, throat, and stomach to relieve irritation and control coughing associated with respiratory conditions such as smoker’s cough.”\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow has been used to treat sore throats and to alleviate heartburn...”\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow is listed for gastroenteritis, peptic and duodenal ulcers, colitis, and enteritis.”\u003Cbr>\n• Blessed thistle\u003Cbr>\n&nbsp; o “It was cultivated in monastery gardens as a cure for smallpox . . ..”\u003Cbr>\n&nbsp; o “Blessed Thistle has been used for smallpox, malaria, fever, anorexia, dyspepsia, indigestion, constipation, and flatulence.”\u003Cbr>\n&nbsp; o “More recently it has shown to be useful for indigestion, heartburn . . . . Blessed Thistle helps increase appetite in people with digestion or eating disorders such as anorexia . . . .”\u003Cbr>\n&nbsp; o “In herbal medicine, Blessed Thistle is used for cancer, infections, inflammation, gallbladder disease, jaundice, liver disorders, cervical dysplasia, heart ailments, skin ulcers, yeast infections, and diarrhea.”\u003Cbr>\n• Papaya\u003Cbr>\n&nbsp; o “It is rich in Anti-oxidants, the B vitamins, folate and pantothenic acid; and the minerals potassium and magnesium, and fiber. Together, ‘these nutrients…provide protection against colon cancer.’”\u003Cbr>\n&nbsp; o “ . . . [P]apaya contains the digestive enzyme, papain, which is used…to treat…allergies.”\u003Cbr>\n&nbsp; o “Papaya may therefore be a healthy fruit choice for preventing such illnesses as recurrent ear infections, colds, and flu.”\u003Cbr>\n• Ginger\u003Cbr>\n&nbsp; o “For over two thousand years Chinese Medicine has recommended ginger to treat a number of health problems including … coughing, vomiting, diarrhea, and rheumatism.”\u003Cbr>\n&nbsp; o “Ginger is also used in the Ayurvedic and Tibetan systems of medicine for the treatment of inflammatory joint diseases such as arthritis, rheumatism . . . .”\u003Cbr>\n&nbsp; o “Ginger may also ease sore throats, headaches, ulcerative colitis, some types of arthritis pain, and fevers and aches caused by colds and flu.”\u003Cbr>\n• Chamomile\u003Cbr>\n&nbsp; o “This bittersweet herb acts medicinally as an anodyne, anti-inflammatory, antibacterial, anti-allergenic, and sedative.”\u003Cbr>\n&nbsp; o “Chamomile tea can be used to treat … gastrointestinal spasms, inflammatory disease of the gastrointestinal tract, and to treat coughs and colds, fevers and bronchitis.”\u003Cbr>\n&nbsp; o “Chamomile’s mildly sedating and muscle-relaxing effects can help those who suffer from insomnia . . . . ”\u003Cbr>\n&nbsp; o “Chamomile helps to relieve nausea, heartburn . . . . It may also be useful in the treatment of diverticular disorders and inflammatory bowel conditions such as Crohn’s disease.”\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your website’s “TEA AND CANCER PREVENTION – NATIONAL CANCER INSTITUTE” page that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “More than 50 epidemiologic studies of the association between tea consumption and cancer risk have been published since 2006. The results of these studies have often been inconsistent, but some have linked tea consumption to reduced risks of cancers of the colon, breast, ovary, prostate, and lung. Green tea contains substances called polyphenols, which scientists think contribute to its anti-cancer activity. Laboratory studies of one polyphenol, catechin epigallocatechin-3-gallate (EGCG), show that it may interfere with several of the processes involved in cell replication, causing tumor cell death (apoptosis). Aug 16, 2017”\u003C\u002Fp>\n\n\u003Cp>Your product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nChristopher A. Williamson\n\nRecipient Title\n\nOwner\n\nVital Health & Wellness\n\n800 Industrial Park Dr.\n\nTrenton, TN 38382\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Foods Operations-East V\n\nUnited States\n\nWARNING LETTER 618743\n\nFebruary 17, 2022\n\nDear Mr. Williamson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your tea processing facility, located at 800 Industrial Park Dr., Trenton, TN 38382 on August 23 and 30, 2021. During the inspection, FDA investigators collected your label for the product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea. FDA also reviewed your website at www.vitalhealthandwellness.net in November 2021 and February 2022 and determined that you take orders there for your Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea. The claims on your website and product label establish that your Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAn example on your product label of some of the claims that provide evidence that your product is intended for use as a drug include:\n\n• “MAY BE BENEFICIAL FOR:… ACID REFLUX…HIGH BLOOD PRESSURE”\n\nExamples of some of the claims on your website’s “Ingredients” page that provide evidence that your product is intended for use as a drug include (the “Ingredients” page identifies Holy Thistle, Persimmon leaves, Malva leaves, Marsh Mallow leaves, Blessed Thistle, Papaya, Ginger and Chamomile as ingredients in Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea):\n\n• Persimmon leaves\n\no “ . . . Persimmon leaves have anti-hypertensive, anti-carcinogenic, and anti-mutagen properties.”\n\no “The [persimmon] leaf … is anti hemorrhagic (stops bleeding), is an effective remedy for hemorrhoids, and strengthens weak blood vessels such as spider veins or varicose veins.”\n\n• Holy thistle\n\no “Holy thistle has been used medicinally for over 2000 years, most commonly for the treatment of liver disorders such as jaundice, and gallbladder disorders; but also for lactation problems, disorders of the spleen, psoriasis, and mushroom poisoning.”\n\no “[Holy thistle] has recently been used by HIV-positive patients to protect the liver from diseases such as hepatitis and damage from the drugs taken for HIV or AIDS. . . . Silymarin[, a flavonoid in holy thistle,] has also been shown to regenerate injured liver cells.”\n\no “Holy Thistle products are popular in Europe and the United States for various types of liver disease, being able to counteract the harmful actions of alcohol on the liver (cirrhosis), and helping the liver return to a healthy state when an alcoholic stops drinking. Some clinical trials indicate that it may improve quality of life and even increase life expectancy in patients with cirrhosis of the liver.”\n\no “ . . . [D]rinking a cup of Holy Thistle tea twice a day can cure chronic headaches. It is also used for…constipation relief. It is very effective for dropsy….”\n\n• Malva leaves\n\no “Malva Leaf teas are used in the treatment of renal disorders… and diarrhea. Malva Leaf has been used to treat stomachache, gastroenteritis, irritable bowel, and conditions of the spleen.”\n\n• Marshmallow leaves\n\no “ . . . Marsh Mallow swells up and becomes slick when it is exposed to fluids. The resulting slippery material coats the linings of the mouth, throat, and stomach to relieve irritation and control coughing associated with respiratory conditions such as smoker’s cough.”\n\no “ . . . Marsh Mallow has been used to treat sore throats and to alleviate heartburn...”\n\no “ . . . Marsh Mallow is listed for gastroenteritis, peptic and duodenal ulcers, colitis, and enteritis.”\n\n• Blessed thistle\n\no “It was cultivated in monastery gardens as a cure for smallpox . . ..”\n\no “Blessed Thistle has been used for smallpox, malaria, fever, anorexia, dyspepsia, indigestion, constipation, and flatulence.”\n\no “More recently it has shown to be useful for indigestion, heartburn . . . . Blessed Thistle helps increase appetite in people with digestion or eating disorders such as anorexia . . . .”\n\no “In herbal medicine, Blessed Thistle is used for cancer, infections, inflammation, gallbladder disease, jaundice, liver disorders, cervical dysplasia, heart ailments, skin ulcers, yeast infections, and diarrhea.”\n\n• Papaya\n\no “It is rich in Anti-oxidants, the B vitamins, folate and pantothenic acid; and the minerals potassium and magnesium, and fiber. Together, ‘these nutrients…provide protection against colon cancer.’”\n\no “ . . . [P]apaya contains the digestive enzyme, papain, which is used…to treat…allergies.”\n\no “Papaya may therefore be a healthy fruit choice for preventing such illnesses as recurrent ear infections, colds, and flu.”\n\n• Ginger\n\no “For over two thousand years Chinese Medicine has recommended ginger to treat a number of health problems including … coughing, vomiting, diarrhea, and rheumatism.”\n\no “Ginger is also used in the Ayurvedic and Tibetan systems of medicine for the treatment of inflammatory joint diseases such as arthritis, rheumatism . . . .”\n\no “Ginger may also ease sore throats, headaches, ulcerative colitis, some types of arthritis pain, and fevers and aches caused by colds and flu.”\n\n• Chamomile\n\no “This bittersweet herb acts medicinally as an anodyne, anti-inflammatory, antibacterial, anti-allergenic, and sedative.”\n\no “Chamomile tea can be used to treat … gastrointestinal spasms, inflammatory disease of the gastrointestinal tract, and to treat coughs and colds, fevers and bronchitis.”\n\no “Chamomile’s mildly sedating and muscle-relaxing effects can help those who suffer from insomnia . . . . ”\n\no “Chamomile helps to relieve nausea, heartburn . . . . It may also be useful in the treatment of diverticular disorders and inflammatory bowel conditions such as Crohn’s disease.”\n\nExamples of some of the claims on your website’s “TEA AND CANCER PREVENTION – NATIONAL CANCER INSTITUTE” page that provide evidence that your product is intended for use as a drug include:\n\n• “More than 50 epidemiologic studies of the association between tea consumption and cancer risk have been published since 2006. The results of these studies have often been inconsistent, but some have linked tea consumption to reduced risks of cancers of the colon, breast, ovary, prostate, and lung. Green tea contains substances called polyphenols, which scientists think contribute to its anti-cancer activity. Laboratory studies of one polyphenol, catechin epigallocatechin-3-gallate (EGCG), show that it may interfere with several of the processes involved in cell replication, causing tumor cell death (apoptosis). Aug 16, 2017”\n\nYour product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Vital Health & Wellness","vital-health-wellness-618743-02172022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-02172022","2026-10-26T08:10:28.399544+00:00","2022-03-01","618743","Food & Beverages","2023-05-08","Christopher A. Williamson","2026-08-20T02:08:32.8+00:00","2022-02-17",{"id":336,"raw":337,"subject":281,"body_html":343,"body_text":344,"firm_name":345,"letter_id":346,"created_at":85,"fei_number":19,"letter_url":347,"updated_at":348,"action_type":22,"case_status":88,"posted_date":349,"marcs_cms_no":350,"product_type":351,"closeout_date":352,"issuing_office":124,"recipient_name":291,"body_fetched_at":353,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":354,"medical_device_id":19,"response_letter_date":19},334,[338,339,340,124,341,13,342,13],"\u003Ctime datetime=\"2026-02-17T05:00:00Z\">02\u002F17\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-08T05:00:00Z\">01\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-01082026\">Elanco Animal Health USA\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-08052026\">\u003Ctime datetime=\"2026-08-06T04:00:00Z\">08\u002F06\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jeffrey Simmons\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Elanco Animal Health USA\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2500 Innovation Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Greenfield\u003C\u002Fspan>, \u003Cspan>IN\u003C\u002Fspan> \u003Cspan>46140\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 8, 2026\u003C\u002Fp>\u003Cp>Re: NADA 141-550 Pradalex™ (pradofloxacin injection)\u003Cbr>\u003Cstrong>CMS #: 710613\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear: Mr. Simmons:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Pradalex (pradofloxacin injection) including a print advertisement titled “Fast track recovery with Pradalex™,”\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a detail aid titled “The Right Solution at the Right Time,”\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a “Cattle technical manual”\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> linked on the Pradalex beef product website,\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> a promotional presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview,\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and a promotional video\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> featuring Elanco representatives discussing the presentation, and noted false or misleading claims and representations about the safety and effectiveness of this product. These promotional communications misbrand your product within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) section 502(a) [21 U.S.C. 352(a)], section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning because pradofloxacin is in the fluoroquinolone drug class and fluoroquinolones are considered critically important antimicrobials in human medicine.\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>According to the Indications section of the FDA-approved package insert:\u003C\u002Fp>\u003Cp>\u003Cstrong>In cattle:\u003C\u002Fstrong>\u003Cbr>Pradalex is indicated for the treatment of [Bovine Respiratory Disease] BRD associated with \u003Cem>Mannheimia haemolytica, Pasteurella multocida, Histophilus somni \u003C\u002Fem>and \u003Cem>Mycoplasma bovis\u003C\u002Fem> in cattle intended for slaughter (beef calves 2 months of age and older, growing beef steers, growing beef heifers, and beef bulls intended for slaughter), and in cattle intended for breeding less than 1 year of age (replacement beef and dairy heifers less than 1 year of age and beef and dairy bulls less than 1 year of age). Not for use in cattle intended for breeding 1 year of age and older (replacement beef and dairy heifers 1 year of age and older, beef and dairy bulls 1 year of age and older, and beef and dairy cows), beef calves less than 2 months of age, dairy calves, and veal calves.\u003C\u002Fp>\u003Cp>\u003Cstrong>In swine:\u003C\u002Fstrong>\u003Cbr>Pradalex is indicated for the treatment of [Swine Respiratory Disease] SRD associated with \u003Cem>Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae\u003C\u002Fem> in weaned swine intended for slaughter (nursery, growing, and finishing swine, boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter).\u003C\u002Fp>\u003Cp>Not for use in swine intended for breeding (boars intended for breeding, replacement gilts, and sows intended for breeding) and in nursing piglets.\u003C\u002Fp>\u003Cp>The package insert contains the following “CAUTION” statements: “Federal law prohibits the extra-label use of this drug in food-producing animals” and “To ensure responsible antimicrobial drug use, use of pradofloxacin should be limited to treatment of bovine respiratory disease (BRD) in cattle and treatment of swine respiratory disease (SRD) in swine only after consideration of other non-fluoroquinolone therapeutic options.”\u003C\u002Fp>\u003Cp>The Freedom of Information Summary for Pradalex explains that the caution statement about responsible antimicrobial drug use was added to “all labels, inserts and marketing materials” to reduce the risk to public health from development of fluoroquinolone resistance among foodborne \u003Cem>Campylobacter\u003C\u002Fem> and \u003Cem>Salmonella\u003C\u002Fem> originating from treated cattle and swine.\u003Cem>\u003Cstrong>\u003Csup>9 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Specifically, inappropriate use of fluoroquinolones such as pradofloxacin contributes to antimicrobial resistance among organisms of human health concern, such as foodborne \u003Cem>Campylobacter\u003C\u002Fem> and \u003Cem>Salmonella\u003C\u002Fem>. Thus, use of pradofloxacin in food producing animals should be reserved for the treatment of clinical conditions that have responded poorly to other classes of antimicrobials.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular (see FD&amp;C Act sections 502(a), (n) (21 U.S.C 352(a), (n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>\u003Cstrong>First Pull Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The detail aid titled “The Right Solution at the Right Time” contains a chart stating that the “Recommended Protocol” for Pradalex is “First-pull treatment.” Likewise, the Product Overview presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview” contains the following statement: “Pradalex is an ideal choice for first pull BRD and SRD treatment.” This claim is also repeated multiple times in the promotional video.\u003C\u002Fp>\u003Cp>“First pull” refers to the first time an animal is treated for a specific condition. However, the CAUTION statement on the package insert specifically states that pradofloxacin should only be used “after consideration of other non-fluoroquinolone therapeutic options.” As explained in the Human Food Safety section of the Freedom of Information Summary for Pradalex, “use of pradofloxacin in food producing animals should…be reserved for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials.” Therefore, the claim that Pradalex is “Recommended” for “First-pull treatment” or an “ideal choice for a first pull” is false or misleading and causes the product to be misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>All Relevant Pathogens Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, the Product Overview presentation and associated video contain the statements:\u003C\u002Fp>\u003Cp>“Effective for the treatment of \u003Cu>all relevant BRD pathogens\u003C\u002Fu>.” [emphasis original]\u003Cbr>\u003Cem>and\u003C\u002Fem>\u003Cbr>“Effective for the treatment of \u003Cu>all relevant SRD pathogens\u003C\u002Fu>.” [emphasis original].\u003C\u002Fp>\u003Cp>The “all relevant BRD pathogens” claim is also repeated in a Cattle Technical Manual that is linked on the Pradalex cattle website. However, pradofloxacin treatment has not been shown to be effective for some pathogens that are relevant for BRD and SRD and therefore those pathogens are not part of the approved indication, including \u003Cem>Bibersteinia trehalosi, \u003C\u002Fem>which is a bacterial pathogen that may play a primary role in BRD\u003Cem>\u003Cstrong>\u003Csup>10, 11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and \u003Cem>Actinobacillus pleuropneumoniae\u003C\u002Fem> (APP), which is considered a major pathogen in SRD. APP is described as a “primary bacterial pathogen” for SRD by a reference cited in the Product Overview presentation\u003Cem>\u003Cstrong>\u003Csup>12\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and is listed on a promotional flyer for SRD disseminated by Elanco.\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> This flyer even contains a table showing that pradofloxacin is not recommended for use for the treatment of APP. Therefore, stating that Pradalex is effective for “all relevant” pathogens for both BRD and SRD in the Product Overview presentation and video overstates the effectiveness of the drug and is a false or misleading claim.\u003C\u002Fp>\u003Cp>Further, these claims may promote extralabel use of Pradalex because it is only approved to treat BRD and SRD associated with certain pathogens, but these promotional communications suggest Pradalex is effective for all pathogens associated with BRD or SRD. As noted on the label, federal law prohibits the extra-label use of Pradalex in food producing animals. Advertising or promotion of extralabel uses in animals of approved new animal drugs is not permitted by the extralabel drug use regulations (see 21 CFR 530.4).\u003C\u002Fp>\u003Cp>\u003Cstrong>Comparative Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The print advertisement titled “Fast track recovery with Pradalex” contains the statement “Treat respiratory disease with 2x the power in less than half the time” with a picture of a cow on a racetrack and a pig in a race car. This statement is false or misleading because it implies that Pradalex is effective against “respiratory disease” generally in cows and pigs. Pradalex is approved for the treatment of BRD and SRD associated with specific pathogens. There are other respiratory diseases in cattle and swine. Furthermore, it appears that this statement is making a claim about treatment times (“Treat… in less than half the time”) based on an in vitro measurement of bacterial kill rates against bovine strains of \u003Cem>Mannheimia haemolytica\u003C\u002Fem> and \u003Cem>Pasteurella multocida\u003C\u002Fem>. This statement cites Elanco data on file and a scientific article of an in vitro kill experiment measuring the rate and extent of bacterial killing by pradofloxacin against two BRD pathogens in comparison with seven other antimicrobials.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Evidence of bacterial kill rates in a cell culture is not evidence of treatment times in cows and pigs. As noted in the scientific article itself, “In vitro measurements, as they are reported here, cannot be extrapolated to clinical outcomes…. Rapid reductions in viable cells may predict shorter courses of therapy; however, this would need confirmation in clinical trials investigating the length of therapy.”\u003Cem>\u003Cstrong>\u003Csup>15\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> In addition, it is unclear what “power” refers to in this statement. We also note that the study measured BRD pathogens, but the advertisement includes a picture of a pig.\u003C\u002Fp>\u003Cp>The Product Overview presentation and associated video also contain the following statements that are unclear and, therefore, may be misleading:\u003C\u002Fp>\u003Cp>“In cattle, Pradalex kills BRD bacteria with 3x the power in less than half the time.”\u003Cbr>and\u003Cbr>“Pradalex kills SRD bacteria with 2x the power in less than half the time.”\u003C\u002Fp>\u003Cp>These broad statements imply that the comparative “power” and speed of bacterial killing of Pradalex applies to all drugs approved for the same indications. However, for the BRD statement, the presentation and video do not indicate a direct comparison with any other antibiotic. For the SRD statement, the graph in the presentation and the explanation in the video only show a direct comparison between the plasma concentration of Pradalex and the plasma concentration of a single other drug, enrofloxacin. A similar statement on the product webpage for SRD\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, “Pradalex is an SRD antibiotic treatment that reaches twice the concentration in a third of the time…” does not indicate a direct comparison with any other antibiotic. In addition, the meaning of the term “power” is unclear and could be interpreted to refer more broadly to the effectiveness of Pradalex or more specifically to the plasma concentration of Pradalex.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your promotional materials misbrand Pradalex within the meaning of the FD&amp;C Act. FD&amp;C Act section 502(a), [21 U.S.C. 352(a)]; section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Pradalex that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Pradalex. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 5001 Campus Drive, CPK1, College Park, MD, 20740. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter #710613.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-2059 and submitted to the Drug Experience Reporting System (DERS) under cover of form 2301 on October 31, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-21-1022 and submitted to the DERS under cover of form 2301 on June 25, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-1012.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Pradalex (pradofloxacin injection) Beef Product Page last viewed on January 8, 2026.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-24-2153 and submitted to the DERS under cover of form 2301 on December 11, 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-0047 and submitted to the DERS under cover of form 2301 on January 29, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> World Health Organization. Critically Important Antimicrobials for Human Medicine: 6th Revision 2018. See Draft Guidance for Industry #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern. Food and Drug Administration, Center of Veterinary Medicine, January 2023.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> This section does not include all the safety and risk information in the package insert for Pradalex and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> U.S. Food and Drug Administration, Center for Veterinary Medicine, April 9, 2024, Freedom of Information Summary, NADA 141-550 Pradalex (pradofloxacin injection) https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadFoi\u002F15250 at 29.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> Holschbach, C. L., Aulik, N., Poulsen, K., &amp; Ollivett, T. L. (2020). Prevalence and temporal trends in antimicrobial resistance of bovine respiratory disease pathogen isolates submitted to the Wisconsin Veterinary Diagnostic Laboratory: 2008–2017. Journal of Dairy Science, 103(10), 9464–9472. https:\u002F\u002Fdoi.org\u002F10.3168\u002Fjds.2019-17570\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> Merck Veterinary Manual. (n.d.). Retrieved June 10, 2025, from https:\u002F\u002Fwww.merckvetmanual.com\u002Frespiratorysystem\u002Fbovine-respiratory-disease-complex\u002Foverview-of-bovine-respiratory-diseasecomplex#Etiology_v74932734\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Blondeau, J. M., &amp; Fitch, S. D. (2024). Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of Actinobacillus pleuropneumoniae and Pasteurella multocida. \u003Cem>Molecules (Basel, Switzerland)\u003C\u002Fem>, 29(22), Article 5448. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmolecules29225448\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Identified by Elanco as PM-US-25-0197 and submitted to the DERS under cover of form 2301 on March 21, 2025.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> Blondeau, J.M.; Fitch, S.D. Comparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens. Microorganisms 2024.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> Id. at 11.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> Pradalex (pradofloxacin injection) https:\u002F\u002Ffarmanimal.elanco.com\u002Fus\u002Fswine\u002Fproduct\u002Fpradalex last viewed January 8, 2026.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nJeffrey Simmons\n\nRecipient Title\n\nPresident and CEO\n\nElanco Animal Health USA\n\n2500 Innovation Way\n\nGreenfield, IN 46140\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nJanuary 8, 2026\nRe: NADA 141-550 Pradalex™ (pradofloxacin injection)\nCMS #: 710613\nWARNING LETTER\nDear: Mr. Simmons:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for Pradalex (pradofloxacin injection) including a print advertisement titled “Fast track recovery with Pradalex™,”1 a detail aid titled “The Right Solution at the Right Time,”2 a “Cattle technical manual”3 linked on the Pradalex beef product website,4 a promotional presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview,5 and a promotional video6 featuring Elanco representatives discussing the presentation, and noted false or misleading claims and representations about the safety and effectiveness of this product. These promotional communications misbrand your product within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 502(a) [21 U.S.C. 352(a)], section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning because pradofloxacin is in the fluoroquinolone drug class and fluoroquinolones are considered critically important antimicrobials in human medicine.7\nBackground8\nAccording to the Indications section of the FDA-approved package insert:\nIn cattle:\nPradalex is indicated for the treatment of [Bovine Respiratory Disease] BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in cattle intended for slaughter (beef calves 2 months of age and older, growing beef steers, growing beef heifers, and beef bulls intended for slaughter), and in cattle intended for breeding less than 1 year of age (replacement beef and dairy heifers less than 1 year of age and beef and dairy bulls less than 1 year of age). Not for use in cattle intended for breeding 1 year of age and older (replacement beef and dairy heifers 1 year of age and older, beef and dairy bulls 1 year of age and older, and beef and dairy cows), beef calves less than 2 months of age, dairy calves, and veal calves.\nIn swine:\nPradalex is indicated for the treatment of [Swine Respiratory Disease] SRD associated with Bordetella bronchiseptica, Glaesserella (Haemophilus) parasuis, Pasteurella multocida, Streptococcus suis, and Mycoplasma hyopneumoniae in weaned swine intended for slaughter (nursery, growing, and finishing swine, boars intended for slaughter, barrows, gilts intended for slaughter, and sows intended for slaughter).\nNot for use in swine intended for breeding (boars intended for breeding, replacement gilts, and sows intended for breeding) and in nursing piglets.\nThe package insert contains the following “CAUTION” statements: “Federal law prohibits the extra-label use of this drug in food-producing animals” and “To ensure responsible antimicrobial drug use, use of pradofloxacin should be limited to treatment of bovine respiratory disease (BRD) in cattle and treatment of swine respiratory disease (SRD) in swine only after consideration of other non-fluoroquinolone therapeutic options.”\nThe Freedom of Information Summary for Pradalex explains that the caution statement about responsible antimicrobial drug use was added to “all labels, inserts and marketing materials” to reduce the risk to public health from development of fluoroquinolone resistance among foodborne Campylobacter and Salmonella originating from treated cattle and swine.9 Specifically, inappropriate use of fluoroquinolones such as pradofloxacin contributes to antimicrobial resistance among organisms of human health concern, such as foodborne Campylobacter and Salmonella. Thus, use of pradofloxacin in food producing animals should be reserved for the treatment of clinical conditions that have responded poorly to other classes of antimicrobials.\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular (see FD&C Act sections 502(a), (n) (21 U.S.C 352(a), (n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nFirst Pull Claims\nThe detail aid titled “The Right Solution at the Right Time” contains a chart stating that the “Recommended Protocol” for Pradalex is “First-pull treatment.” Likewise, the Product Overview presentation titled “Pradalex (pradofloxacin injection) Cattle and Swine Product Overview” contains the following statement: “Pradalex is an ideal choice for first pull BRD and SRD treatment.” This claim is also repeated multiple times in the promotional video.\n“First pull” refers to the first time an animal is treated for a specific condition. However, the CAUTION statement on the package insert specifically states that pradofloxacin should only be used “after consideration of other non-fluoroquinolone therapeutic options.” As explained in the Human Food Safety section of the Freedom of Information Summary for Pradalex, “use of pradofloxacin in food producing animals should…be reserved for the treatment of clinical conditions which have responded poorly to other classes of antimicrobials.” Therefore, the claim that Pradalex is “Recommended” for “First-pull treatment” or an “ideal choice for a first pull” is false or misleading and causes the product to be misbranded.\nAll Relevant Pathogens Claims\nAdditionally, the Product Overview presentation and associated video contain the statements:\n“Effective for the treatment of all relevant BRD pathogens.” [emphasis original]\nand\n“Effective for the treatment of all relevant SRD pathogens.” [emphasis original].\nThe “all relevant BRD pathogens” claim is also repeated in a Cattle Technical Manual that is linked on the Pradalex cattle website. However, pradofloxacin treatment has not been shown to be effective for some pathogens that are relevant for BRD and SRD and therefore those pathogens are not part of the approved indication, including Bibersteinia trehalosi, which is a bacterial pathogen that may play a primary role in BRD10, 11 and Actinobacillus pleuropneumoniae (APP), which is considered a major pathogen in SRD. APP is described as a “primary bacterial pathogen” for SRD by a reference cited in the Product Overview presentation12 and is listed on a promotional flyer for SRD disseminated by Elanco.13 This flyer even contains a table showing that pradofloxacin is not recommended for use for the treatment of APP. Therefore, stating that Pradalex is effective for “all relevant” pathogens for both BRD and SRD in the Product Overview presentation and video overstates the effectiveness of the drug and is a false or misleading claim.\nFurther, these claims may promote extralabel use of Pradalex because it is only approved to treat BRD and SRD associated with certain pathogens, but these promotional communications suggest Pradalex is effective for all pathogens associated with BRD or SRD. As noted on the label, federal law prohibits the extra-label use of Pradalex in food producing animals. Advertising or promotion of extralabel uses in animals of approved new animal drugs is not permitted by the extralabel drug use regulations (see 21 CFR 530.4).\nComparative Claims\nThe print advertisement titled “Fast track recovery with Pradalex” contains the statement “Treat respiratory disease with 2x the power in less than half the time” with a picture of a cow on a racetrack and a pig in a race car. This statement is false or misleading because it implies that Pradalex is effective against “respiratory disease” generally in cows and pigs. Pradalex is approved for the treatment of BRD and SRD associated with specific pathogens. There are other respiratory diseases in cattle and swine. Furthermore, it appears that this statement is making a claim about treatment times (“Treat… in less than half the time”) based on an in vitro measurement of bacterial kill rates against bovine strains of Mannheimia haemolytica and Pasteurella multocida. This statement cites Elanco data on file and a scientific article of an in vitro kill experiment measuring the rate and extent of bacterial killing by pradofloxacin against two BRD pathogens in comparison with seven other antimicrobials.14 Evidence of bacterial kill rates in a cell culture is not evidence of treatment times in cows and pigs. As noted in the scientific article itself, “In vitro measurements, as they are reported here, cannot be extrapolated to clinical outcomes…. Rapid reductions in viable cells may predict shorter courses of therapy; however, this would need confirmation in clinical trials investigating the length of therapy.”15 In addition, it is unclear what “power” refers to in this statement. We also note that the study measured BRD pathogens, but the advertisement includes a picture of a pig.\nThe Product Overview presentation and associated video also contain the following statements that are unclear and, therefore, may be misleading:\n“In cattle, Pradalex kills BRD bacteria with 3x the power in less than half the time.”\nand\n“Pradalex kills SRD bacteria with 2x the power in less than half the time.”\nThese broad statements imply that the comparative “power” and speed of bacterial killing of Pradalex applies to all drugs approved for the same indications. However, for the BRD statement, the presentation and video do not indicate a direct comparison with any other antibiotic. For the SRD statement, the graph in the presentation and the explanation in the video only show a direct comparison between the plasma concentration of Pradalex and the plasma concentration of a single other drug, enrofloxacin. A similar statement on the product webpage for SRD16, “Pradalex is an SRD antibiotic treatment that reaches twice the concentration in a third of the time…” does not indicate a direct comparison with any other antibiotic. In addition, the meaning of the term “power” is unclear and could be interpreted to refer more broadly to the effectiveness of Pradalex or more specifically to the plasma concentration of Pradalex.\nConclusion and Requested Response\nFor the reasons discussed above, your promotional materials misbrand Pradalex within the meaning of the FD&C Act. FD&C Act section 502(a), [21 U.S.C. 352(a)]; section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). Introducing or delivering misbranded new animal drugs for introduction into interstate commerce violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Pradalex that contain representations like that described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Pradalex. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 5001 Campus Drive, CPK1, College Park, MD, 20740. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter #710613.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice Surveillance and Compliance\nCenter for Veterinary Medicine\n_____________________\n1 Identified by Elanco as PM-US-25-2059 and submitted to the Drug Experience Reporting System (DERS) under cover of form 2301 on October 31, 2025.\n2 Identified by Elanco as PM-US-21-1022 and submitted to the DERS under cover of form 2301 on June 25, 2025.\n3 Identified by Elanco as PM-US-24-1012.\n4 Pradalex (pradofloxacin injection) Beef Product Page last viewed on January 8, 2026.\n5 Identified by Elanco as PM-US-24-2153 and submitted to the DERS under cover of form 2301 on December 11, 2024.\n6 Identified by Elanco as PM-US-25-0047 and submitted to the DERS under cover of form 2301 on January 29, 2025.\n7 World Health Organization. Critically Important Antimicrobials for Human Medicine: 6th Revision 2018. See Draft Guidance for Industry #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to their Microbiological Effects on Bacteria of Human Health Concern. Food and Drug Administration, Center of Veterinary Medicine, January 2023.\n8 This section does not include all the safety and risk information in the package insert for Pradalex and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\n9 U.S. Food and Drug Administration, Center for Veterinary Medicine, April 9, 2024, Freedom of Information Summary, NADA 141-550 Pradalex (pradofloxacin injection) https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002Fdocument\u002FdownloadFoi\u002F15250 at 29.\n10 Holschbach, C. L., Aulik, N., Poulsen, K., & Ollivett, T. L. (2020). Prevalence and temporal trends in antimicrobial resistance of bovine respiratory disease pathogen isolates submitted to the Wisconsin Veterinary Diagnostic Laboratory: 2008–2017. Journal of Dairy Science, 103(10), 9464–9472. https:\u002F\u002Fdoi.org\u002F10.3168\u002Fjds.2019-17570\n11 Merck Veterinary Manual. (n.d.). Retrieved June 10, 2025, from https:\u002F\u002Fwww.merckvetmanual.com\u002Frespiratorysystem\u002Fbovine-respiratory-disease-complex\u002Foverview-of-bovine-respiratory-diseasecomplex#Etiology_v74932734\n12 Blondeau, J. M., & Fitch, S. D. (2024). Comparison of the Minimum Inhibitory and Mutant Prevention Drug Concentrations for Pradofloxacin and 7 Other Antimicrobial Agents Tested Against Swine Isolates of Actinobacillus pleuropneumoniae and Pasteurella multocida. Molecules (Basel, Switzerland), 29(22), Article 5448. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmolecules29225448\n13 Identified by Elanco as PM-US-25-0197 and submitted to the DERS under cover of form 2301 on March 21, 2025.\n14 Blondeau, J.M.; Fitch, S.D. Comparative In Vitro Killing by Pradofloxacin in Comparison to Ceftiofur, Enrofloxacin, Florfenicol, Marbofloxacin, Tildipirosin, Tilmicosin and Tulathromycin against Bovine Respiratory Bacterial Pathogens. Microorganisms 2024.\n15 Id. at 11.\n16 Pradalex (pradofloxacin injection) https:\u002F\u002Ffarmanimal.elanco.com\u002Fus\u002Fswine\u002Fproduct\u002Fpradalex last viewed January 8, 2026.","Elanco Animal Health USA","elanco-animal-health-usa-710613-01082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felanco-animal-health-usa-710613-01082026","2026-10-26T08:08:32.290643+00:00","2026-02-17","710613","Animal & Veterinary","2026-08-06","2026-08-19T04:57:49.046+00:00","2026-01-08",{"id":356,"raw":357,"subject":361,"body_html":362,"body_text":363,"firm_name":364,"letter_id":365,"created_at":43,"fei_number":19,"letter_url":366,"updated_at":367,"action_type":22,"case_status":23,"posted_date":368,"marcs_cms_no":369,"product_type":67,"closeout_date":19,"issuing_office":187,"recipient_name":370,"body_fetched_at":371,"delivery_method":179,"recipient_title":19,"reference_number":372,"action_taken_date":373,"medical_device_id":19,"response_letter_date":19},1053,[358,359,360,187,361,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-10T05:00:00Z\">02\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025\">Marshalls Traditional Healthcare CC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-43\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vick Maharaj\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marshalls Traditional Healthcare CC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>560 Main Reef Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germiston\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gauteng\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>1400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Africa\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-43\u003C\u002Fp>\u003Cp>February 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Maharaj:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures an over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and testing for objectionable microorganisms.\u003C\u002Fp>\u003Cp>In your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state that you will perform all appropriate USP &lt;61&gt; and &lt;62&gt; testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\u003C\u002Fp>\u003Cp>Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\u003C\u002Fp>\u003Cp>In your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of \u003Cstrong>(b)(4)\u003C\u002Fstrong> System\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a component to manufacture your OTC drug product. You failed to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is suitable for producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the formulation of your drug product. For example, you turned your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is adequately monitored to ensure it consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets appropriate chemical and microbial attributes.\u003C\u002Fp>\u003Cp>In your response, you state that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system will continuously \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response is inadequate. You did not address the adequacy of your overall \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> meets, at a minimum, the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an inadequately validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> system on the quality of drug products you manufacture.\u003C\u002Fp>\u003Cp>Pharmaceutical \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. Under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>Further, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-43\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vick Maharaj\n\nRecipient Title\n\nChief Executive Officer\n\nMarshalls Traditional Healthcare CC\n\n560 Main Reef Road\n\nGermiston\n\nGauteng\n\n1400\n\nSouth Africa\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-43\nFebruary 10, 2025\nDear Mr. Maharaj:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures an over-the-counter (OTC) (b)(4) drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, (b)(4) and testing for objectionable microorganisms.\nIn your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, (b)(4). You also state that you will perform all appropriate USP \u003C61> and \u003C62> testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\nWithout adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\nIn your response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\nInadequate Process Validation\nYou did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\nIn your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nInadequate Control of (b)(4) System\nYour firm uses (b)(4) as a component to manufacture your OTC drug product. You failed to ensure that your (b)(4) system is suitable for producing (b)(4) used in the formulation of your drug product. For example, you turned your (b)(4) system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your (b)(4) system is adequately monitored to ensure it consistently produces (b)(4) that meets appropriate chemical and microbial attributes.\nIn your response, you state that your (b)(4) system will continuously (b)(4). Your response is inadequate. You did not address the adequacy of your overall (b)(4) system design to ensure that your (b)(4) meets, at a minimum, the USP (b)(4) monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using (b)(4) from an inadequately validated (b)(4) system on the quality of drug products you manufacture.\nPharmaceutical (b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of (b)(4) for use in manufacturing operations.\nIn your response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\nA (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nYour total microbial count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\nDrug Production Suspended\nWe acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. Under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nFurther, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\nhttps:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Marshalls Traditional Healthcare CC","marshalls-traditional-healthcare-cc-697697-02102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025","2026-10-26T08:09:20.909625+00:00","2025-02-18","697697","Mr. Vick Maharaj","2026-08-19T17:01:31.89+00:00","320-25-43","2025-02-10",{"id":375,"raw":376,"subject":382,"body_html":383,"body_text":384,"firm_name":385,"letter_id":386,"created_at":18,"fei_number":19,"letter_url":387,"updated_at":388,"action_type":22,"case_status":23,"posted_date":389,"marcs_cms_no":390,"product_type":330,"closeout_date":19,"issuing_office":391,"recipient_name":392,"body_fetched_at":393,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":394,"medical_device_id":19,"response_letter_date":19},1538,[377,378,379,380,381,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-29T05:00:00Z\">11\u002F29\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fregal-health-food-international-inc-662089-11292023\">Regal Health Food International, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","Food Labeling\u002FMisbranded\u003Cbr \u002F>\r\n","Food Labeling\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Igor Piatigorsky\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Regal Health Food International, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2701 N. Normandy Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chicago\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60707-2227\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 662089\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 29, 2023\u003Cbr>\n\u003Cbr>\nDear Mr. Piatigorsky:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has determined that your recalled Regal Gourmet Snacks Milk Chocolate Raisins (16oz., UPC #028744201002) with best by date “04\u002F07\u002F24” are misbranded within the meaning of section 403(w) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(w)], in that the finished product label did not declare a major food allergen, peanuts. The introduction or delivery for introduction into interstate commerce of any food that is misbranded is prohibited by section 301(a) of the Act [21 U.S.C. § 331(a)]. You may find the Act through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>On June 6, 2023, your firm recalled your product labeled Regal Gourmet Snacks Milk Chocolate Raisins after being notified by your consignee of a consumer complaint regarding milk chocolate peanuts being found in containers labeled as milk chocolate raisins. Your firm indicated in documentation provided to the Human and Animal Food Operations (OHAFO) East Division 6 Recall Coordinator that milk chocolate peanuts were packed into tubs labeled “Milk Chocolate Raisins” due to an error in the packing process by \u003Cstrong>(b)(4)\u003C\u002Fstrong> packers. This documentation also described your proposed corrective actions to prevent reoccurrence including: retraining employees on packing procedures, additional labeling of work in progress products, additional product and label confirmation steps and using an \u003Cstrong>(b)(4)\u003C\u002Fstrong> line which will have less opportunities for this type of error. We will verify implementation of any corrective actions during FDA’s next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Peanuts are considered a “major food allergen” under section 201(qq) of the Act [21 U.S.C. § 321(qq)]. A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fli>\n\t\u003Cli>The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your recalled “Regal Gourmet Snacks Milk Chocolate Raisins”, which contained chocolate covered peanuts are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (peanuts).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Comments\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your facility is subject to the requirements of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP and PC rule) (21 CFR Part 117). As such, you are required to identify and implement preventive controls to provide assurances that any hazard requiring a preventive control (e.g., undeclared allergens) will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facilities will not be adulterated under section 402 or misbranded under section 403(w) of the Act (21 CFR 117.135(a)(1) and (c)(2)). The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (subparts A, C, D, E, F, and G) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all‐inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct all violations noted in this letter. Failure to promptly correct these violations may result in legal action without further notice, including seizure and\u002For injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to Lauren Sexton, Compliance Officer, via e-mail at Lauren.Sexton@fda.hhs.gov. If you have any questions about this letter, please contact Lauren Sexton at (313) 393-8179 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nDivision East 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nIgor Piatigorsky\n\nRecipient Title\n\nPresident\n\nRegal Health Food International, Inc.\n\n2701 N. Normandy Avenue\n\nChicago, IL 60707-2227\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS 662089\n\nNovember 29, 2023\n\nDear Mr. Piatigorsky:\n\nThe United States Food and Drug Administration (FDA) has determined that your recalled Regal Gourmet Snacks Milk Chocolate Raisins (16oz., UPC #028744201002) with best by date “04\u002F07\u002F24” are misbranded within the meaning of section 403(w) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 343(w)], in that the finished product label did not declare a major food allergen, peanuts. The introduction or delivery for introduction into interstate commerce of any food that is misbranded is prohibited by section 301(a) of the Act [21 U.S.C. § 331(a)]. You may find the Act through links in FDA's home page at http:\u002F\u002Fwww.fda.gov.\n\nOn June 6, 2023, your firm recalled your product labeled Regal Gourmet Snacks Milk Chocolate Raisins after being notified by your consignee of a consumer complaint regarding milk chocolate peanuts being found in containers labeled as milk chocolate raisins. Your firm indicated in documentation provided to the Human and Animal Food Operations (OHAFO) East Division 6 Recall Coordinator that milk chocolate peanuts were packed into tubs labeled “Milk Chocolate Raisins” due to an error in the packing process by (b)(4) packers. This documentation also described your proposed corrective actions to prevent reoccurrence including: retraining employees on packing procedures, additional labeling of work in progress products, additional product and label confirmation steps and using an (b)(4) line which will have less opportunities for this type of error. We will verify implementation of any corrective actions during FDA’s next inspection of your facility.\n\nMisbranding\n\nPeanuts are considered a “major food allergen” under section 201(qq) of the Act [21 U.S.C. § 321(qq)]. A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\nThe word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\nThe common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Whey (Milk)”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\nYour recalled “Regal Gourmet Snacks Milk Chocolate Raisins”, which contained chocolate covered peanuts are misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (peanuts).\n\nAdditional Comments\n\nYour facility is subject to the requirements of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP and PC rule) (21 CFR Part 117). As such, you are required to identify and implement preventive controls to provide assurances that any hazard requiring a preventive control (e.g., undeclared allergens) will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facilities will not be adulterated under section 402 or misbranded under section 403(w) of the Act (21 CFR 117.135(a)(1) and (c)(2)). The failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (subparts A, C, D, E, F, and G) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)].\n\nThe violations cited in this letter are not intended to be an all‐inclusive list of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct all violations noted in this letter. Failure to promptly correct these violations may result in legal action without further notice, including seizure and\u002For injunction. Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time within which you will do so.\n\nYour firm’s response should be sent to Lauren Sexton, Compliance Officer, via e-mail at Lauren.Sexton@fda.hhs.gov. If you have any questions about this letter, please contact Lauren Sexton at (313) 393-8179 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nDivision East 6","Regal Health Food International, Inc.","regal-health-food-international-inc-662089-11292023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fregal-health-food-international-inc-662089-11292023","2026-10-26T08:09:48.216279+00:00","2024-04-02","662089","Division of Human and Animal Food Operations East VI","Igor Piatigorsky","2026-08-20T00:12:38.132+00:00","2023-11-29",{"id":396,"raw":397,"subject":164,"body_html":402,"body_text":403,"firm_name":404,"letter_id":405,"created_at":406,"fei_number":19,"letter_url":407,"updated_at":408,"action_type":22,"case_status":23,"posted_date":409,"marcs_cms_no":410,"product_type":310,"closeout_date":19,"issuing_office":401,"recipient_name":411,"body_fetched_at":412,"delivery_method":413,"recipient_title":19,"reference_number":19,"action_taken_date":414,"medical_device_id":19,"response_letter_date":19},3561,[398,399,400,401,164,13,13,13],"\u003Ctime datetime=\"2021-02-02T14:20:00Z\">02\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-01-22T05:00:00Z\">01\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-global-health-group-llc-610283-01222021\">American Global Health Group, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations West VI","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jonathan Jewett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Global Health Group, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11808 Northup Way, Suite W105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bellevue\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98005\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations West VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 22, 2021\u003C\u002Fp>\n\n\u003Cp>In reply, refer to CMS 610283\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jewett:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.aloecure.com in December 2020 and January 2021, and has determined that you take orders there for your AloeCure brand products including: AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme. We also reviewed your Facebook social media page at www.facebook.com\u002Faloecure, which promotes your products and directs users to your website, www.aloecure.com, for purchase.\u003C\u002Fp>\n\n\u003Cp>The claims on your website and Facebook page establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims and Facebook page claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure VeraFlex\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure VeraFlex webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint):\u003C\u002Fp>\n\n\u003Cp>• “Featuring A Clinically Proven Ingredient to Improve . . . Mobility, and Reduce Joint Discomfort”.\u003Cbr>\n• “Increase mobility, reduce stiffness . . .”\u003Cbr>\n• “Our research shows that joint stiffness, soreness and discomfort is caused by inflammation that attacks healthy cartilage and protective tissue. According to leading medical scientists, this inflammation is caused by two inflammatory enzymes released by the body’s own immune system . . . Remarkably, the active ingredients in VeraFlex help to block the production of both these critical enzymes, resulting in a dramatic decrease in discomfort.”\u003Cbr>\n• “[A] recent study in the Journal of Nutrition and Metabolism shows the potential of these ingredients [in VeraFlex] to help the production of new liver, lung, and immune system cells that respond to fight infections”.\u003C\u002Fp>\n\n\u003Cp>On the Facebook page at www.facebook.com\u002Faloecure:\u003C\u002Fp>\n\n\u003Cp>• “AloeCure’s VeraFlex features active ingredients that show improvement in joint stiffness in as few as 3 days and improved joint function within 7 days . . . ”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Advanced Formula Capsule\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Advanced Formula Capsule webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule):\u003C\u002Fp>\n\n\u003Cp>• “[D]elivers a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn while reducing inflammatory response . . .”\u003Cbr>\n• “Scientifically proven natural acid buffer reduces stomach acid by up to 100x . . .”\u003C\u002Fp>\n\n\u003Cp>On the Facebook page at www.facebook.com\u002Faloecure:\u003C\u002Fp>\n\n\u003Cp>• “[D]eliver a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn”.\u003Cbr>\n• “[D]elivers fast acid buffering results with plenty of Acemannan, the primary active ingredient in aloe vera known for healing”.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Pure Aloe Vera Extract\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Pure Aloe Vera Extract webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice):\u003C\u002Fp>\n\n\u003Cp>• “Aloe Extract will coat your esophagus and calm your stomach. Once it contacts excess stomach acid, this soothing extract will neutralize it instantly”.\u003Cbr>\n• “Buffers Stomach Acid on Contact”.\u003Cbr>\n• “[A]cts as an acid buffer, improving pH regulation and overall digestive function enough to relieve discomfort . . . it's brimming with malic-calcium, a powerful acid blocker that quenches the awful burning sensation in your throat, esophagus, and stomach. It keeps the acid levels balanced to help flare ups from coming back . . . AloeCure also contains polysaccharides including the highest levels of acemannan, Aloe's famous healing property . . . delivers relief to cells scorched by excess acid and inflammation . . . Aloe is an immune system modulator which can improve and manage … inflammation.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AloeCure Probiotic &amp; Enzyme\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>On the AloeCure Probiotic &amp; Enzyme webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproduct\u002Fprobiotic-enzyme):\u003C\u002Fp>\n\n\u003Cp>• “Each AloeCure Probiotic + Enzyme capsule, provided by American Global Health Group, LLC, contains over two billion beneficial biorganisms . . . mixed in a base of digestive enzymes.”\u003Cbr>\n• “There are varying degrees of enzyme deficiencies. At the extreme end of the spectrum is the inherited condition of cystic fibrosis, in which the enzymes needed to digest proteins, carbohydrates, and fats are either missing or are present in reduced amounts. Other severe conditions that are associated with enzyme deficiencies include pancreatic insufficiency, Celiac disease, and Crohn’s disease”.\u003C\u002Fp>\n\n\u003Cp>On the same webpage, the following claims were made for Amylase, Protease, and Lipase, ingredients in AloeCure Probiotic &amp; Enzyme:\u003C\u002Fp>\n\n\u003Cp>• “A protease deficiency results in an alkaline excess in the blood . . . can cause anxiety and insomnia . . . [A] protease deficiency lays the foundation of arthritis, osteoporosis and other calcium deficient diseases”.\u003Cbr>\n• “When you are low in amylase you are a candidate for abscesses. Amylase is also involved in anti-inflammatory reactions. An Amylase deficiency can result in skin problems such as psoriasis, eczema, hives, allergic reactions, atopic dermatitis, and all types of herpes. Asthma and emphysema may also be exacerbated by an amylase deficiency”.\u003Cbr>\n• “Lipase deficient people have a tendency towards high cholesterol, high triglycerides, . . . and diabetes. Lipase deficient people also have decreased cell permeability, which can cause nutrient deficiencies within cells. Conditions such as vertigo or dizziness aggravated by movement can result from lipase deficiency.”\u003Cbr>\n\u003Cbr>\nAlso, your website at www.aloecure.com contains evidence of intended use in the form of personal testimonials recommending that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples of these personal testimonials include:\u003C\u002Fp>\n\n\u003Cp>AloeCure Pure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule\u002F and https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice\u002F)\u003C\u002Fp>\n\n\u003Cp>• “In 2007 I was introduced to AloeCure®. I've put AloeCure to the test and it works! AloeCure helps naturally balance the stomach pH levels, decrease the acidity feeling and prevent that burning sensation so many complain of due to stress, worry, or an unhealthy lifestyle. AloeCure is an all-natural solution that allows your body to heal itself.”\u003C\u002Fp>\n\n\u003Cp>AloeCure VeraFlex (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint\u002F)\u003C\u002Fp>\n\n\u003Cp>• “I know first-hand the devastation of chronic pain and that restoration IS possible. While in medical school I developed rheumatoid arthritis, causing me to be wheelchair bound, potentially derailing my medical career . . . VeraFlex users can generally expect more flexibility in three days . . . their joint pain alleviated in five days . . . and in just seven days, a tremendous improvement in overall joint function. In my opinion, AloeCure has created the best supplement for joint health on the market and I recommend it to anyone looking for better mobility, reduced pain . . .”\u003Cbr>\n• “I have used VeraFlex since October 2019 for chronic annoying sciatica type pain. I would be driving the car for 20 minutes and I have to shift my position because I really was getting sore in that area and ever since I started the VeraFlex I have not had that situation, it is totally resolved it and I take it once a day every day.”\u003Cbr>\n• “Eight years ago I had an operation which resulted in losing 3 inches on one of my legs and that resulted in Joint pain. And over a period of years the pain got worse. And since I've taken VeraFlex I've had no knee pain at all.”\u003C\u002Fp>\n\n\u003Cp>Additionally, the Blog tab of your website (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F) contains evidence of intended use that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples include the following blog posts:\u003C\u002Fp>\n\n\u003Cp>• The article titled “5 Foods That Neutralize Stomach Acid” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F5-foods-that-decrease-stomach-acid) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “For any who have suffered through a sleepless night due to excess stomach acid or indigestion, an acidic stomach can be a great cause of pain, distress, and discomfort . . . ALOE VERA . . . contains a natural stomach acid buffer called malic-calcium that neutralizes excess acid . . . It contains two active constituents - glycoproteins and polysaccharides. The former helps to reduce inflammation and hinder pain . . . Aloe Vera can soothe the esophagus track, too, and provide relief from irritation . . . Other studies indicate and suggest that Aloe Vera . . . contributes in helping to balance stomach acid.”\u003Cbr>\n• The article titled “Aloe Vera vs. Apple Cider Vinegar” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Faloe-vera-vs-apple-cider-vinegar) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “Aloe Vera supports digestive wellness due to its anti-inflammatory properties. For many people, digestive issues stem from the occurrence of inflammation within the digestive system, the gastrointestinal tract . . . Aloe Vera . . . can offer benefits for an inflamed GI tract.”\u003Cbr>\n• The article titled “The Endless Benefits of Aloe Vera Gel” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Fendless-benefits-aloe-vera) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, and states: “Below we share some of our favorite ways aloe vera juice benefits us inside and out . . . When our bodies have too much inflammation, it can cause a range of problems from asthma and eczema to arthritis and rheumatism. Aloe’s main property is to be soothing as well as moistening which helps to clear inflammation throughout the body. The enzymes present in the plant’s inner gel produce an anti-inflammatory effect on the body . . .”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products AloeCure Probiotic &amp; Enzyme Blend and AloeCure VeraFlex are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, AloeCure Probiotic &amp; Enzyme Blend and AloeCure VeraFlex fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct any violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at \u003Cspan>425-302-0413\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Miriam R. Burbach\u003Cbr>\nDistrict Director Program Division Director\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nOvernight Delivery\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJonathan Jewett\n\nRecipient Title\n\nChief Executive Officer\n\nAmerican Global Health Group, LLC\n\n11808 Northup Way, Suite W105\n\nBellevue, WA 98005\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations West VI\n\nUnited States\n\nJanuary 22, 2021\n\nIn reply, refer to CMS 610283\n\nWARNING LETTER\n\nDear Mr. Jewett:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.aloecure.com in December 2020 and January 2021, and has determined that you take orders there for your AloeCure brand products including: AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme. We also reviewed your Facebook social media page at www.facebook.com\u002Faloecure, which promotes your products and directs users to your website, www.aloecure.com, for purchase.\n\nThe claims on your website and Facebook page establish that the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims and Facebook page claims that provide evidence that your products are intended for use as drugs include:\n\nAloeCure VeraFlex\n\nOn the AloeCure VeraFlex webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint):\n\n• “Featuring A Clinically Proven Ingredient to Improve . . . Mobility, and Reduce Joint Discomfort”.\n\n• “Increase mobility, reduce stiffness . . .”\n\n• “Our research shows that joint stiffness, soreness and discomfort is caused by inflammation that attacks healthy cartilage and protective tissue. According to leading medical scientists, this inflammation is caused by two inflammatory enzymes released by the body’s own immune system . . . Remarkably, the active ingredients in VeraFlex help to block the production of both these critical enzymes, resulting in a dramatic decrease in discomfort.”\n\n• “[A] recent study in the Journal of Nutrition and Metabolism shows the potential of these ingredients [in VeraFlex] to help the production of new liver, lung, and immune system cells that respond to fight infections”.\n\nOn the Facebook page at www.facebook.com\u002Faloecure:\n\n• “AloeCure’s VeraFlex features active ingredients that show improvement in joint stiffness in as few as 3 days and improved joint function within 7 days . . . ”\n\nAloeCure Advanced Formula Capsule\n\nOn the AloeCure Advanced Formula Capsule webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule):\n\n• “[D]elivers a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn while reducing inflammatory response . . .”\n\n• “Scientifically proven natural acid buffer reduces stomach acid by up to 100x . . .”\n\nOn the Facebook page at www.facebook.com\u002Faloecure:\n\n• “[D]eliver a concentrated formula of Aloe Vera to help neutralize bouts of acid reflux and heartburn”.\n\n• “[D]elivers fast acid buffering results with plenty of Acemannan, the primary active ingredient in aloe vera known for healing”.\n\nAloeCure Pure Aloe Vera Extract\n\nOn the AloeCure Pure Aloe Vera Extract webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice):\n\n• “Aloe Extract will coat your esophagus and calm your stomach. Once it contacts excess stomach acid, this soothing extract will neutralize it instantly”.\n\n• “Buffers Stomach Acid on Contact”.\n\n• “[A]cts as an acid buffer, improving pH regulation and overall digestive function enough to relieve discomfort . . . it's brimming with malic-calcium, a powerful acid blocker that quenches the awful burning sensation in your throat, esophagus, and stomach. It keeps the acid levels balanced to help flare ups from coming back . . . AloeCure also contains polysaccharides including the highest levels of acemannan, Aloe's famous healing property . . . delivers relief to cells scorched by excess acid and inflammation . . . Aloe is an immune system modulator which can improve and manage … inflammation.”\n\nAloeCure Probiotic & Enzyme\n\nOn the AloeCure Probiotic & Enzyme webpage (https:\u002F\u002Fwww.aloecure.com\u002Fproduct\u002Fprobiotic-enzyme):\n\n• “Each AloeCure Probiotic + Enzyme capsule, provided by American Global Health Group, LLC, contains over two billion beneficial biorganisms . . . mixed in a base of digestive enzymes.”\n\n• “There are varying degrees of enzyme deficiencies. At the extreme end of the spectrum is the inherited condition of cystic fibrosis, in which the enzymes needed to digest proteins, carbohydrates, and fats are either missing or are present in reduced amounts. Other severe conditions that are associated with enzyme deficiencies include pancreatic insufficiency, Celiac disease, and Crohn’s disease”.\n\nOn the same webpage, the following claims were made for Amylase, Protease, and Lipase, ingredients in AloeCure Probiotic & Enzyme:\n\n• “A protease deficiency results in an alkaline excess in the blood . . . can cause anxiety and insomnia . . . [A] protease deficiency lays the foundation of arthritis, osteoporosis and other calcium deficient diseases”.\n\n• “When you are low in amylase you are a candidate for abscesses. Amylase is also involved in anti-inflammatory reactions. An Amylase deficiency can result in skin problems such as psoriasis, eczema, hives, allergic reactions, atopic dermatitis, and all types of herpes. Asthma and emphysema may also be exacerbated by an amylase deficiency”.\n\n• “Lipase deficient people have a tendency towards high cholesterol, high triglycerides, . . . and diabetes. Lipase deficient people also have decreased cell permeability, which can cause nutrient deficiencies within cells. Conditions such as vertigo or dizziness aggravated by movement can result from lipase deficiency.”\n\nAlso, your website at www.aloecure.com contains evidence of intended use in the form of personal testimonials recommending that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples of these personal testimonials include:\n\nAloeCure Pure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fadvanced-formula-capsule\u002F and https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fpure-aloe-extract-aloe-juice\u002F)\n\n• “In 2007 I was introduced to AloeCure®. I've put AloeCure to the test and it works! AloeCure helps naturally balance the stomach pH levels, decrease the acidity feeling and prevent that burning sensation so many complain of due to stress, worry, or an unhealthy lifestyle. AloeCure is an all-natural solution that allows your body to heal itself.”\n\nAloeCure VeraFlex (https:\u002F\u002Fwww.aloecure.com\u002Fproducts\u002Fveraflex-healthy-joint\u002F)\n\n• “I know first-hand the devastation of chronic pain and that restoration IS possible. While in medical school I developed rheumatoid arthritis, causing me to be wheelchair bound, potentially derailing my medical career . . . VeraFlex users can generally expect more flexibility in three days . . . their joint pain alleviated in five days . . . and in just seven days, a tremendous improvement in overall joint function. In my opinion, AloeCure has created the best supplement for joint health on the market and I recommend it to anyone looking for better mobility, reduced pain . . .”\n\n• “I have used VeraFlex since October 2019 for chronic annoying sciatica type pain. I would be driving the car for 20 minutes and I have to shift my position because I really was getting sore in that area and ever since I started the VeraFlex I have not had that situation, it is totally resolved it and I take it once a day every day.”\n\n• “Eight years ago I had an operation which resulted in losing 3 inches on one of my legs and that resulted in Joint pain. And over a period of years the pain got worse. And since I've taken VeraFlex I've had no knee pain at all.”\n\nAdditionally, the Blog tab of your website (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F) contains evidence of intended use that the AloeCure products can cure, mitigate, treat, or prevent disease. Examples include the following blog posts:\n\n• The article titled “5 Foods That Neutralize Stomach Acid” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002F5-foods-that-decrease-stomach-acid) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “For any who have suffered through a sleepless night due to excess stomach acid or indigestion, an acidic stomach can be a great cause of pain, distress, and discomfort . . . ALOE VERA . . . contains a natural stomach acid buffer called malic-calcium that neutralizes excess acid . . . It contains two active constituents - glycoproteins and polysaccharides. The former helps to reduce inflammation and hinder pain . . . Aloe Vera can soothe the esophagus track, too, and provide relief from irritation . . . Other studies indicate and suggest that Aloe Vera . . . contributes in helping to balance stomach acid.”\n\n• The article titled “Aloe Vera vs. Apple Cider Vinegar” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Faloe-vera-vs-apple-cider-vinegar) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, as well as a general link to facilitate the purchase of AloeCure VeraFlex, AloeCure Advanced Formula Capsule, AloeCure Pure Aloe Vera Extract, and AloeCure Probiotic + Enzyme, and states: “Aloe Vera supports digestive wellness due to its anti-inflammatory properties. For many people, digestive issues stem from the occurrence of inflammation within the digestive system, the gastrointestinal tract . . . Aloe Vera . . . can offer benefits for an inflamed GI tract.”\n\n• The article titled “The Endless Benefits of Aloe Vera Gel” (https:\u002F\u002Fblog.aloecure.com\u002Fblog\u002Fendless-benefits-aloe-vera) contains links to purchase AloeCure Advanced Formula Capsule and AloeCure Pure Aloe Vera Extract, and states: “Below we share some of our favorite ways aloe vera juice benefits us inside and out . . . When our bodies have too much inflammation, it can cause a range of problems from asthma and eczema to arthritis and rheumatism. Aloe’s main property is to be soothing as well as moistening which helps to clear inflammation throughout the body. The enzymes present in the plant’s inner gel produce an anti-inflammatory effect on the body . . .”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. § 331(d), § 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products AloeCure Probiotic & Enzyme Blend and AloeCure VeraFlex are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, AloeCure Probiotic & Enzyme Blend and AloeCure VeraFlex fail to bear adequate directions for their intended use, and therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that exist in connection with your products. You are responsible for investigating and determining the causes of any violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct any violations cited in this letter. Failure to adequately address this matter may lead to legal action, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Jinkee M. Vila-Binayug, Compliance Officer, 22215 26th Avenue SE, Suite 210, Bothell, Washington 98021-4421. If you have any questions regarding this letter, please contact Compliance Officer Vila-Binayug at 425-302-0413.\n\nSincerely,\n\n\u002FS\u002F\n\nMiriam R. Burbach\n\nDistrict Director Program Division Director","American Global Health Group, LLC","american-global-health-group-llc-610283-01222021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-global-health-group-llc-610283-01222021","2026-10-26T08:07:54.889582+00:00","2021-02-02","610283","Jonathan Jewett","2026-08-20T03:24:57.367+00:00","Overnight Delivery","2021-01-22",23,{"510k":417,"classification":418,"enforcement":419,"event":420,"event_backfill":421,"pma":422,"warning_letter":423},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]